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General Introduction  |  9
General Introduction 
An increasing number of fetal diseases are being detected prior to birth due to major 
improvements in prenatal ultrasound examinations and the wide implementation of 
screening programs.1 For various diseases, fetal therapy may be a life-saving option or 
an alternative to postnatal treatment, to prevent permanent organ damage including 
the developing fetal brain. 
A major breakthrough in fetal therapy was the introduction of intrauterine blood 
transfusion (IUT) for severe fetal anemia. This intervention was first described in the 
early 1960s by Sir William Liley in New Zealand.2 Since then, fetal therapy has gradually 
evolved and resulted in a dramatic increase in overall survival in several fetal diseases. 
Throughout the world, specialized fetal therapy centers were initiated and a new 
medical discipline commenced. In the Netherlands, fetal surgical interventions were 
concentrated in one center, The Leiden University Medical Center (LUMC). The LUMC is 
a tertiary medical center which serves as the national referral center for fetal therapy. 
Intrauterine transfusion in fetal anemia
The technique of the first IUT was based on intraperitoneal blood transfusion. In the 
next decades, the technique evolved to an intravascular approach. The first intravascular 
IUTs in the Netherlands were performed in 1986. Indications for IUT mainly include 
fetal anemia due to hemolytic disease caused by Rhesus or Kell alloimmunization. 
Alloimmune hemolytic disease results from maternal alloimmunization to red cell 
antigens, for which mother and fetus are incompatible. Maternal antibodies pass the 
placenta into the fetal circulation and cause destruction of fetal red cells. The resulting 
progressive hemolysis leads, if left untreated, to severe fetal anemia, fetal hydrops and 
perinatal death.3 Nowadays, perinatal survival rates after IUT for severe fetal anemia 
exceed 95% in experienced centers.4 Other, non-immune, indications for IUT include 
parvovirus B19 infection or chronic or acute fetal maternal hemorrhage (FMT). 
Approximately 30 fetuses are treated annually with IUT at our center. With an average 
of 3 transfusions per fetus, up to a 100 transfusions are performed per year.
Fetoscopic laser surgery in monochorionic twin pregnancies
The other major intervention in fetal therapy, besides IUT, is related to fetal interventions 
in complicated monochorionic (MC) twin pregnancies. MC twins share their placenta 
and their blood circulation is connected by vascular anastomoses at the placental 
surface. Placental vascular anastomoses allow acute or chronic inter-twin blood 
transfusions between the circulation of the two fetuses. Imbalanced inter-twin blood 








































10  |  Part I
In TTTS, imbalanced blood flow from one twin (the donor) to the other twin (the 
recipient), results in hypovolemia and oligohydramnios in the donor and hypervolemia 
and polyhydramnios in the recipient twin. The first treatment of choice in TTTS is 
fetoscopic laser coagulation of placental vascular anastomoses. In the Netherlands, the 
first fetoscopic laser surgery was performed at the LUMC in the year 2000. Nowadays, 
around 60 MC twin pregnancies are treated annually at our center with fetoscopic laser 
surgery, with an overall survival rate of 74%.5 In a recently described complication in 
MC twins named twin anemia-polycythemia sequence (TAPS), several interventions can 
be considered including IUT or fetoscopic laser surgery. The optimal treatment of TAPS 
remains to be determined. 
Fetoscopic surgical interventions in complicated MC twin pregnancies include, besides 
laser coagulation of placental vascular anastomoses, also selective feticide through 
umbilical cord coagulation or radiofrequency ablation (RFA). In specific complicated 
MC pregnancies, selective feticide via cord occlusion or RFA can be offered as an 
alternative management option. Indications include twin reversed arterial perfusion 
(TRAP) sequence, selective intrauterine growth restriction (sIUGR), monoamniotic 
twin pregnancies or severe discordant congenital anomalies. Perinatal survival rates 
following selective feticide vary between 65% and 92%, depending on indication and 
technique.6
Long-term neurodevelopmental outcome after fetal therapy
With an increasing number of children being born alive after fetal therapy, attention 
is shifting from short-term outcome and perinatal survival to long-term outcome and 
neurodevelopmental morbidity. However, data on long-term neurodevelopmental 
outcome after fetal therapy remain scarce. Long-term neurodevelopmental outcome 
studies are costly and difficult to perform and therefore hard to realize. In addition, 
follow-up studies after fetal therapy are hampered by the rarity of these fetal diseases. 
Nevertheless, long-term follow-up studies are of paramount importance to determine 
optimal fetal management. Follow-up studies may provide clinicians better insights 
into the long-term neurodevelopmental outcome and quality of survival in children 
after fetal therapy. Detailed and adequate information on long-term outcome is also 
required to improve the quality of antenatal parental counseling using evidence-based 
information. 
Long-term follow-up studies with emphasis on child motor, cognitive and socio-
emotional development are essential for conducting future randomized controlled 
trials in all fields of fetal therapy, in order to implement new or modified techniques. 
This requires cooperation between obstetricians, neonatologists, child psychologists 
and other experts in the field of early human development in order to look beyond 
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obtain reliable data with large enough case series with sufficient power. Large enough 
case series enable research on potential risk factors for adverse long-term outcome. It 
is important to continuously assess child development including formal psychological 
testing and standardized measures of well documented psychometric quality, with 
increasing reliability of results with increasing age of surviving children following fetal 
therapy.
The aim of this thesis is to improve our knowledge on the long-term neurodevelopmental 
outcome in children treated with fetal therapy and to identify potential risk factors for 
adverse long-term outcome.
Outline of this thesis
PART I:  General introduction
PART II:  Intrauterine transfusions for fetal anemia
 Chapter 1 - Review of the literature on the long-term neurodevelopmental 
 outcome in children treated with IUT for fetal anemia.
 Chapter 2 - Study on the health-related quality of life and behavioral 
 functioning in children treated with IUT for fetal hemolytic disease.
 Chapter 3 - Study on the neurodevelopmental outcome in children included 
 in a randomized controlled trial and treated with either neonatal intravenous 
 immunoglobulins or placebo in Rhesus hemolytic disease.
PART III:  Fetoscopic laser surgery in twin-twin transfusion syndrome
 Chapter 4 - Review of the literature on the long-term neurodevelopmental 
 outcome in MC twins after fetal therapy.
 Chapter 5 - Systematic review of the literature on cerebral injury and 
 neurodevelopmental impairment in children treated with either 
 amnioreduction or fetoscopic laser surgery for TTTS.
 Chapter 6 - Study on the long-term neurodevelopmental outcome in 
 survivors of TTTS treated with laser surgery in the first six years (2000- 
 2005) of the fetoscopic laser surgery program at the LUMC, compared to 
 more recent years (2008-2010). 
 Chapter 7 - Study on the long-term outcome in children included in the 
 Solomon randomized controlled trial and treated with either the Solomon or 
 standard laser surgery technique for TTTS.
 Chapter 8 - Study on the long-term neurodevelopmental outcome in TAPS 








































12  |  Part I
PART IV:  Specific complications in monochorionic pregnancies
 Chapter 9 - Systematic review on the neurological outcome in MC twins with 
 sIUGR.
 Chapter 10 - Study on the neurological outcome and incidence of severe 
 cerebral injury in survivors after single fetal demise of the MC co-twin.
 Chapter 11 - Study on the perinatal outcome of the surviving twin after 
 selective feticide of the MC co-twin.
 Chapter 12 - Study on the long-term neurodevelopmental and behavioral 
 outcome in children following selective feticide of the MC co-twin.
PART V:  Discussion and summary
 Chapter 13 - General discussion concerning the results of these studies.
 Chapter 14 - Future perspectives and proposals for future research on the 
 long-term neurodevelopmental outcome after fetal therapy.
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18  |  Chapter 1
Abstract
The long-term neurodevelopmental outcome of children born after intrauterine 
blood transfusion (IUT) for red cell alloimmunization is considered favorable. Severe 
hydrops has been identified as a strong predictor for neurodevelopmental impairment. 
However, the long-term outcome of survivors of IUT for congenital Parvovirus B19 
infection and fetomaternal hemorrhage is not well known. Limitations of the follow-up 
studies to date are small sample size, lack of controls, unclear criteria for impairment 
and lack of standardized developmental tests. Future research should take in to account 
more subtle impairments, since cognitive functioning < - 1 SD, behavioral and learning 
problems already have a significant impact on care requirements and future socio-
economic potential. A better understanding of the effect of IUT and fetal anemia on 
child development over time will allow more accurate parental counseling and targeted 
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Background
Fetal anemia can have either an immune or non-immune cause. Maternal red blood cell 
alloimmunization is the most common cause of immune fetal anemia. Alloimmunization 
results from prior contact with an antigen, for which mother and fetus are incompatible, 
either through fetomaternal transfusion or prior blood transfusion.1 This triggers the 
formation of immunoglobulin G antibodies that are able to cross the placenta into the 
fetal blood circulation, causing hemolysis. 
Non-immune fetal anemia has many causes including congenital Parvovirus B19 infection 
and fetomaternal hemorrhage (FMH). Fetal anemia due to congenital Parvovirus B19 
infection results from crossing of the placental barrier of the virus and inhibition of fetal 
erythropoiesis by infection of erythroid precursor cells.2 Fetal anemia in FMH results 
from the passage of (acute or chronic) fetal blood into the maternal circulation, due to 
placental abnormalities, maternal trauma or invasive obstetrical procedures.3;4 
When untreated, fetal anemia may result in cardiac failure, hydrops, hypovolemic 
shock, fetal or neonatal death, neurologic injury or cerebral palsy (CP).1;3 The mainstay 
to correct fetal anemia is intrauterine intravascular blood transfusion (IUT). IUT can be 
considered a safe procedure with a relatively low procedure-related complication rate 
and a low perinatal loss rate.5 Perinatal survival rates after IUT nowadays exceed 90%.5;6 
Although advances in techniques allow even moribund and severely anemic fetus to 
survive, severe anemia or a prolonged hydropic state may lead to neurodevelopmental 
impairment (NDI).7;8 Hence, the outcome of antenatal management must be assessed 
not only by survival but also by long-term neurodevelopmental outcome.9 
We performed a systematic review of the literature on the long-term neurodevelopmental 
outcome in children treated with IUT for fetal anemia, secondary to maternal 
alloimmunization, Parvovirus B19 infection and FMH. The prevalence and nature 
of favorable and adverse neurodevelopmental outcome in light of methodological 
strengths and weaknesses of studies will be highlighted. In addition, risk factors for NDI 
are discussed. The aim of the review was to identify important areas for future research.
Methods of the Review
A systematic literature search was utilized to retrieve the studies and articles for this 
review. An electronic MEDLINE literature search was performed using the following 
mesh terms: Fetal Erythroblastosis, Intrauterine, Time, Prognosis, Epidemiologic 
Studies, Human Development, Neurobehavioral Manifestations and Morbidity. The 
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articles and included the period from 1981 to January 2011, since intrauterine 
intravascular transfusions are performed since 1981. All reference lists of primary 
articles and reviews were examined to search for additional references. Then, a manual 
search of identified articles was conducted. If needed, authors were contacted for 
further information. The following inclusion criteria were applied: children treated 
with intrauterine intravascular transfusion for fetal anemia secondary to maternal 
alloimmunization, congenital Parvovirus B19 infection or fetomaternal hemorrhage, 
assessment of neurodevelopmental outcome and the conduct of statistical tests. The 
methodological quality of each selected study was assessed independently by two 
reviewers (JK and EL). The following exclusion criteria were applied: case reports, 
dissertations, qualitative studies, book chapters, guidelines and commentaries. 
Results
We found no other review article or meta-analysis focusing solely on the long-term 
neurodevelopmental outcome in children treated with IUT for anemia due to maternal 
red cell alloimmunization, congenital Parvovirus B19 infection and FMH. In over 30 
years, we identified only 11 studies that met our inclusion criteria (9 on maternal 
alloimmunization and 2 on congenital Parvovirus B19 infection). Beyond case reports, 
research on long-term neurodevelopmental outcome following FMH is limited to 3 small 
series (31, 26 and 15 children).10;11 Since no IUTs were performed to correct anemia, 
these series were not included for review. Our selected studies are summarized, in 
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Table 1 Long-term neurodevelopmental outcome in children treated with IUT for maternal red 
cell alloimmunization.
Author, year Outcome measure CP NDI Methodological comments
Doyle, 
199312









Cattel Test no (0/8) no (0/8) Insufficient information 




Van Wieghen, POPS, 
Gesell Schedules, Denver 
Screening Test
4% (3/69) 10.1% 
(7/69)







n.a. No controls, high lost to 
follow-up rate, no formal 
criteria NDI, insufficient power
Grab, 
199915








n.a No controls, insufficient 
information patients 




Differential Ability Scales, 











no (0/40) n.a No controls, no 
















Table 2 Long-term neurodevelopmental outcome in children treated with IUT for parvovirus B19 
infection.
Author, year Outcome measure CP NDI Methodological comments
Dembinski, 
200220
Griffiths Test, Snijders 
Oomen Intelligence Test, 
Kaufman Battery
no (0/20) no (0/20) No controls, high lost to follow 
up rate












CP is Cerebral Palsy; NDI is Neuro Developmental Impairment which is defined as CP, cognitive 
functioning or developmental delay (< 2SD), blindness or deafness; n.a. is not available; POPS is 
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Methodological Issues 
The overall quality of the 11 selected studies is suboptimal. All studies concern small 
single center follow-up studies, including between 8 and 69 children, except for a recent 
study including 291 children for follow-up.19 Only 4 studies included controls, to validate 
their outcome against healthy children, children with similar neonatal problems, or 
children diagnosed with fetal anemia who did not receive IUTs. Both interval and timing 
of follow-up range considerably between studies that is, from 1984-1990 to 1988-2008 
and the children are tested as young as one month old to 16 years of age. All studies are 
cross sectional in design and, therefore, do not allow for observation of development 
over time. In 3 follow-up studies the children were not individually investigated with 
formal psychological testing. Criteria for NDI were not consequently described and 
neither was the way impairment was ‘measured’. In general, the outcome measures 
were able to identify major neurological deficits, but the more subtle abnormalities like 
behavioral problems or learning difficulties, which have a significant impact on care 
requirements, were likely overlooked.21 Abovementioned methodological issues and 
heterogeneity make the selected studies difficult to compare and, as a consequence, 
knowledge on the neurodevelopmental outcome of these children remains limited. 
Knowledge on the long-term development of children after IUT over time is however 
necessary. The main findings of each follow-up study are listed below, in chronological 
order.
Neurodevelopmental Outcome after Maternal Red Cell Alloimmunization
The first report on long-term neurodevelopment was published in 1993 by Doyle et al.12 
With formal psychological testing and clearly described criteria for NDI, Doyle found 
no impairment at 2 years of age in 92% (3/38) of children transfused in utero. The 
transfusion group compared favorably with both high risk survivors of very low birth 
weight (VLBW) and low risk children of normal birth weight. However, the low risk 
group was not contemporaneous with the transfusion group. 
With little information on their patients and methods, Stewart et al. reported no 
difference in neurodevelopment at 18-24 months between 8 children with Rhesus 
disease treated with IUT and 8 children with Rhesus disease not treated with IUT.9 
Neither group was different in terms of neurodevelopmental outcome from the general 
population. Such a small sample size evidently lacks statistical power to find differences. 
Furthermore, age range of follow up was 18-24 months, which is often too early for 
accurate assessment of CP or severe developmental delay.
Janssens et al. found normal neurodevelopment in 89.9% (62/69) of children after IUT 
(range 6 months to 6 years of age).13 With well-defined criteria for NDI, the 69 children 
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age, 10.1% versus 18% respectively. In contrast to the findings by Doyle et al.12, the 
transfusion group compared less favorably with healthy controls, 10.1% versus 6% 
respectively. Unfortunately, no p-values were reported. The discrepancy between Doyle 
et al. and Janssens et al. is probably to the much larger sample size in the latter. 
Hudon et al. reported neurodevelopmental scores within average at 9-62 months in 33 
children, with no differences in children with or without a history of hydrops (P = .72).14 
One child presented with CP (1/22) and one child with bilateral deafness (1/21). One 
of the major limitations of this study was the relatively large loss-to follow-up (82.5%, 
33/40). This may have biased results, as chances for adverse outcome are generally 
higher in the group that is initially lost to follow up.22
Grab et al. found no moderate or severe neurologic impairment at 6 years of age in 
35 children, including 7 cases with fetal hydrops at initial transfusion.15 Fetuses with 
hydrops at initial transfusion tended to have a higher perinatal mortality and had a 
significant higher rate of preterm delivery (P = .03). At follow-up, survivors were not 
individually investigated nor tested for neurodevelopment. Conclusions were solely 
based on questionnaires that were completed by the child’s primary care providers, a 
method known for underreporting of affected children.17 
Farrant et al. performed a follow-up study in 36 children treated with IUT.16 One 
child was born prematurely following death of a co-twin from twin-twin-transfusion 
syndrome and had CP and developmental delay, with an abnormal cranial ultrasound. 
Although 2 other children had an abnormal cranial ultrasound, no other child had 
neurodevelopmental impairment. Again, no child was individually investigated and 
tested for neurodevelopment. Of note, little information on the patients and methods 
was reported e.g., the age of assessment of the children was not recorded.
In 16 children with a history of hydrops, Harper et al. reported major neurological 
morbidity in 12.5% (2/16) of children.17 The neuropsychological assessment 
represented a balance of tasks to identify general and, even, subtle neuropsychological 
deficits. Except for a measure of attention, neurologic and neuropsychological outcome 
was similar to their unaffected siblings. According to the authors the significant 
difference was not verified by clinical and classroom behavioral observations that were 
required for confirmation of the diagnosis of attention deficit hyperactivity disorder. Six 
of the sixteen survivors (37.5%) had a minor physical or neurologic finding. However, 
like previous studies, this study was underpowered. 
Weisz et al. concluded that 85% of 40 children treated with IUT for fetal anemia reached 
satisfactory motor milestones according to age.18 Abnormal motor development by the 
age of 1 year was observed in 15% (6/40) and abnormal cognitive development in 
children aged ≥ 1 year in 13.5% (5/37), with no differences in children with a history 
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considered ‘abnormal’ and, like Grab15 and Farrant16, obtained their data not from the 
children individually with formal psychological testing but from their parents using a 
computerized questionnaire. 
Recently, Lindenburg et al. performed a large long-term follow up study of 291 children 
treated with IUT secondary to maternal alloimmunization between 1992 and 2008.19 
The primary objective was to assess the incidence of NDI, a composite outcome defined 
as the presence of at least one of the following: abnormal neurological outcome (CP), 
cognitive developmental test score < -2 SD, bilateral blindness or bilateral deafness 
requiring amplification. All children were tested at a median age of 8.2 years. Severe 
developmental delay was detected in 3.1% (9/291) of children, with a 4.8% incidence 
of NDI (14/291). Despite the notable large sample size, it concerns a single centre study 
with a considerable large follow-up interval. Moderate developmental delay (< -1 SD) 
was detected in 14.4% (42/291) of children.
Overall, when the results of the above mentioned follow-up studies are pooled together, 
the rate of CP and NDI is 2.4% (13/549) and 4.9% (27/549), respectively. 
Neurodevelopmental Outcome after Parvovirus B19 infection
Dembinski et al. found neurodevelopmental scores within 2 SD of a normal population 
in 20 children at 13 months to 9 years of age transfused for Parvovirus B19 induced 
anemia and fetal hydrops.20 Although children with neurodevelopmental scores of < -1 
SD fall within 2 SD of a normal population, these children are at risk for difficulties in 
school functioning. Nevertheless, the number and characteristics of these children were 
not further addressed. As only 20 out of 31 children (65%) were seen for testing, the 
study was limited by a high loss to follow-up rate.5 
Nagel and colleagues described 16 survivors at a median age of 4 years of which 5 
children (32%) demonstrated neurodevelopmental delay on formal psychological 
tests (mild delay n=3, severe delay n=2).8 Two children had minor congenital defects. 
Five children were <18 months at the time of testing and thus too young for reliable 
assessment. In this study, adverse outcome was not related to severity of anemia and 
acidemia, and the authors suggest congenital Parvovirus B19 infection itself might 
cause CNS damage.5 This hypothesis needs further study. Once more, low statistical 
power was the main limitation of this study. 
Overall, when the results of the 2 follow-up studies are pooled together, the rate of CP 
and NDI is 2.7 (1/36) and 5.5% (2/36), respectively.
Risk Factors for Neurodevelopmental Impairment
Lindenburg et al. showed severe hydrops to be a strong pre-operative predictor of 
NDI19, while the majority of studies could not confirm such a relationship.12-15 Other risk 
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education19, again in contrast to the majority of studies.8;12-15;20 According to Janssens et 
al. the probability that neurologic abnormalities would occur was significantly greater 
when perinatal asphyxia had been present (P < 0.05) and with a lower cord hemoglobin 
level at birth (P = .03).13 The discrepancy in outcome is due to the considerable 
difference in sample size between the studies. Sample sizes were often too small to 
detect a significant effect of risk factors on the outcome measures.
On the whole, risk factors were not clearly defined or registered in all studies and were 
recorded at different points in time, which make comparison difficult. Furthermore, 
the risk factors were studied in light of not so subtle outcome measures e.g., CP and 
cognitive functioning < -2 SD. Risk factors for an adverse outcome might become more 
apparent with more sensitive outcome measures such as cognitive functioning < -1 SD, 
which already has a large impact on care and educational requirements of children. 
Discussion
Despite the use of intrauterine transfusion for fetal anemia for 3 decades, knowledge on 
the long-term neurodevelopment of children treated with IUT is limited. The long-term 
neurodevelopmental outcome of children born after IUT for red cell alloimmunization 
is considered to be favorable. Severe hydrops has been identified as a strong predictor 
for NDI. However, the long-term outcome of survivors of IUT for congenital Parvovirus 
B19 infection and fetomaternal hemorrhage is not well known.
Few follow-up studies have been performed, commonly with sample sizes lacking the 
power to detect adverse neurological outcome. Since follow-up studies are restricted 
by the relative rarity of the disease and treatment, multicenter efforts are of utmost 
importance to increase sample size. However, with a large enough sample size any effect 
can be found statistically significant. Therefore, an equal emphasis should be placed 
on the clinical relevance of outcome: whether or not a child perceives impairment at 
an individual level and when to intervene as a clinician according to that individual 
perception. 
In order to facilitate communication, replication and collaboration between research 
groups it is necessary to be transparent, specific and uniform with respect to study 
design and outcome. Uniform ante-, peri- and neonatal characteristics should be 
recorded, at fixed time points. Imaging of the brain of the fetus as well as the neonate and 
child should be performed. It is important to continuously assess neurodevelopment of 
the children, at fixed points in time, with formal psychological testing and standardized 
measures of well documented psychometric quality, for instance at 4 years, 8 years, 12 
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Table 3 A proposition for future research: Assessment according to age in years. 
Fetus Neonate 2 5 8 10 12 14 16 years 
Brain development: cerebral imaging
Senses: hearing test, vision test
Cognitive functioning: Bayley scales/ Ages and Stages Questionnaire, Wechsler 
scales
Physical functioning: Touwen Neurological Examination, CP (Gross 
Motor Function Classification System)
School functioning: special education, number of grades below age- 
appropriate level
Neuropsychological functioning: learning, language, 
executive functioning, attention, visual spatial abilities, memory, 
fine motor development
Psychosocial functioning and behavior: internalizing and 
externalizing behavior, Quality of Life, Achenbach System, 
Vineland Adaptive Behavioral Scales
Developmental problems: Attention deficit, hyperactivity, 
autism spectrum
CP is Cerebral Palsy.
Wechsler scales are reliable and valid measures of cognitive functioning in (young) 
children.23;24 Beyond a full scale intelligence quotient, one can take into account the 
abilities that make up a full scale score, such as verbal skills, visual spatial skills and 
processing speed. For example, a certain child has an average full scale IQ score of 91, 
with a high-average verbal IQ score of 109, but a performance IQ score of 75. If we just 
look at the average full scale score, the child’s difficulties with visual spatial tasks will 
be overlooked. The child will not be scored as ‘impaired’ in the research to date, but in 
practice the child will encounter considerable difficulties at school or in daily life which 
are not recognized with the current criteria for an adverse outcome. 
To enable valid comparisons between follow-up studies, uniform criteria for an adverse 
outcome are indispensable. However, the outcome measures to date are not able 
to identify subtle abnormalities and should therefore be supplemented with a more 
sensitive definition of impairment: cognitive functioning test score < -1 SD, the presence 
of a learning problem, mild or moderate motor problems, symptoms of pervasive 
developmental disorder, attention deficit and/ or behavioral problems. These ‘subtle 
abnormalities’ already have a significant impact on care and educational requirements 
and affect the future socioeconomic potential of a child.21 Since subtle abnormalities 
might also include increased behavior or social emotional problems, questionnaires 
that cover psychosocial and behavioral functioning should be included to obtain a full 
image of the child at different ages and stages. Up till now, these measures are lacking in 
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A better understanding of the impact of IUT on child development over time, based on 
standardized outcome measures, will allow more accurate counseling of parents and 
targeted interventions to optimize development in these children when needed.
Key Guidelines:
•	 Long-term neurodevelopmental outcome after IUT for maternal red cell 
alloimmunization is considered favorable.
•	 Severe hydrops is a risk factor for an adverse outcome after IUT for maternal 
red cell alloimmunization, as well as neonatal morbidity, the number of IUTs 
received and parental education.
•	 Neurodevelopmental outcome after IUT in congenital Parvo B19 infection and 
FMT is not well known.
Research Directions:
•	 Long-term follow-up studies after IUT in congenital Parvo B19 infection and 
FMT are urgently needed.
•	 To enable valid comparisons between follow-up studies, uniform and well 
described criteria for an adverse outcome are indispensable.
•	 Future research should take in to account more subtle abnormalities, since 
cognitive functioning < -1SD, behavioral problems and learning difficulties 
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Abstract
Objective 
To assess health-related quality of life (HRQOL) and behavioral functioning in children 
and adolescents treated before birth with intrauterine transfusions for alloimmune 
anemia.
Study design 
Cross-sectional cohort study conducted at the Dutch referral center for the management 
of fetal alloimmune anemia. Follow-up data were obtained from 285 children at a mean 
age of 10.5 years (range, 3-21.5 years) with a response rate of 544/563 questionnaires 
(97%). Child-, adolescent- and parent-rated HRQOL was evaluated with the TNO AZL 
Child/Adult Quality of Life Questionnaire (TACQOL/TAAQOL). Parents reported on 
behavioral functioning with the Strengths and Difficulties Questionnaire (SDQ). Scores 
were compared to Dutch norm data. 
Results 
Significantly lower scores were reported by parents of children 6-11 years compared 
with Dutch norms on 3 scales: cognitive-, social functioning and positive emotions (P 
< .00, P = .02, P = .04). In children aged 8-11 the cognitive functioning scale score was 
significantly lower compared with Dutch norms (P = .01). The children aged 12-15 
reported higher scores on negative emotions (P = .02). When corrected for multiple 
testing, only the parent-rated cognitive functioning scale remained significant (P < .001). 
Regarding the HRQOL scores of adolescents ≥ 16 years, no differences were detected. 
Overall, behavioral difficulties were reported in 37/246 (15%) children 3-16 years, and 
were associated with maternal educational levels (P < .001). 
Conclusion 
Parents reported lower scores on cognitive functioning in their children aged 6-11 
years compared to norms. Behavioral difficulties were more prevalent than norms, and 
were associated with maternal educational level. Overall, in the majority of survivors 
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Introduction
Fetal and neonatal hemolytic disease results from maternal alloimmunization to red 
cell antigens, for which mother and fetus are incompatible. Maternal immunoglobulin 
G antibodies pass the placenta into the fetal circulation causing destruction of fetal red 
cells. The resulting progressive fetal anemia leads, if left untreated, to fetal hydrops and 
perinatal death. The mainstay to correct fetal anemia is intrauterine intravascular blood 
transfusion (IUT). IUT is considered a safe procedure with a relatively low procedure-
related complication rate and a low perinatal loss rate.1;2 In experienced centers, 
perinatal survival rates exceed 95%.3;4
As perinatal survival is improving, one of the concerns is that this could lead to an increase 
in children with long-term impairments. The incidence of long-term impairment in 
children treated with IUT ranges from 4.5 to 12%.5-12 Our previous study in the current 
cohort, including 291 children, found a 5% incidence of long-term neurodevelopmental 
impairment after IUT for alloimmune anemia.13 Nevertheless, even in children without 
obvious impairments, subtle problems may occur including health-related quality of life 
(HRQOL) issues or increased behavioral difficulties.14 
The aim of this study was to assess quality of life and behavioral functioning in children 
and adolescents treated before birth with IUT for severe alloimmune hemolytic disease, 
and to compare the outcomes with Dutch norm data. 
Methods
This cross-sectional cohort study was conducted at the Leiden University Medical 
Center (LUMC), the national referral center for the management and treatment of fetal 
alloimmune anemia. All children and adolescents who received IUT for alloimmune 
anemia between 1988 and 2008 at the LUMC, and participated in the LOTUS 
study were eligible.15 Our previous study in this cohort, focused on the long-term 
neurodevelopmental outcome.13 Patients with severe congenital anomalies unrelated 
to intrauterine anemia or treatment were excluded. Invitation letters were distributed 
by mail, and if families consented, questionnaires were sent out and collected during a 
follow-up visit at our outpatient clinic or by mail. The study was approved by the ethics 
committee of the LUMC and written informed consent was obtained. 
The following perinatal and neonatal data were collected retrospectively from the LUMC 
Rhesus database and medical records: hemoglobin level at IUT, severity of fetal anemia16, 
presence and severity of fetal hydrops17, number of IUTs, gestational age at birth, severe 
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the presence of 1 or more of the following: respiratory distress syndrome, necrotizing 
enterocolitis ≥ grade 2, sepsis, and/or severe cerebral injury. Perinatal asphyxia was 
defined as 3 or more of the following 5 criteria: non-reassuring cardiotocogram, 
umbilical cord arterial pH <7.10 and base excess ≥16 mmol/L or lactate >10 mmol/L, 
Apgar score <5 at 5 minutes after birth, failure of spontaneous breathing at 5 minutes 
after birth, and onset of multiple organ failure. 
Maternal education was recorded and divided into 3 levels: low (primary school), 
average (secondary school) and high (higher vocational school and university). Ethnicity 
was recorded as one or both parents with Dutch nationality or non-Dutch nationality. 
Long-term neurodevelopmental impairment was evaluated in our previous study in 
this cohort and defined as at least one of the following: cerebral palsy, severe motor and 
or cognitive delay (< -2SD), bilateral blindness and/or deafness.13
Measures
Two questionnaires were used to assess HRQOL: The Netherlands Organisation for 
Applied Scientific Research-Academisch Ziekenhuis Leiden (TNO-AZL) Child Quality 
of Life questionnaire (TACQOL) and the TNO-AZL Adult Quality of Life questionnaire 
(TAAQOL).18-21
TACQOL The TACQOL is a generic HRQOL instrument and consists of a parent form 
(PF) for parents of children aged 6-11 years and a child form (CF) for children aged 
8-15 years.18;19;19;22 HRQOL is defined as the combination of Health Status (HS) and 
the affective evaluation of problems in HS. The TACQOL contains 7 scales with 8 items 
each: physical complaints, motor functioning, autonomy, cognitive functioning, social/
peer functioning, positive- and negative emotional functioning. To each item-pair a 
score ranging from 0-4 is administered with scale scores ranging between 0-32. On 
the positive- and negative emotional functioning scales, a score ranging from 0-2 is 
administered with scale scores ranging from 0-16. Higher scores indicate better HRQOL. 
The psychometric properties are satisfactory and norm data from the general Dutch 
population are available.18;19;19;22
TAAQOL The TAAQOL addresses HRQOL in adolescents and adults aged ≥ 16 years 
and includes 45 items, divided into 12 scales: gross motor functioning, fine motor 
functioning, pain, sleeping, cognitive functioning, social functioning, daily activities, 
sexuality, vitality, positive, depressive and aggressive emotions.20;21 A single score is 
given for each item-pair (HS and the affective evaluation of problems in HS) and for 
each item in the vitality, positive, depressive and aggressive emotions scales. Scores 
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psychometric properties are satisfactory and TAAQOL norm data from the general 
Dutch population are available.20
Behavioral functioning Behavioral functioning was assessed with the Strengths and 
Difficulties Questionnaire Parent Form (SDQ-PF), a 25-item behavioral screening 
questionnaire to identify problems in children 3-16 years.23;24 The SDQ contains 25 items: 
20 items across 4 problem scales (emotional symptoms, conduct, hyperactivity and peer 
problems) and a 5-item pro-social behavior scale. For each item a score is administered 
from 0-2 (not true, somewhat true, and certainly true) with scale scores ranging 0-10. 
Higher scores indicate more problems, except for the pro-social behavior scale where 
higher scores indicate more strengths. Summing the scores from the 4 problem scales 
yields a total difficulties score ranging 0-40. The psychometric properties of the SDQ 
are acceptable.25 Dutch norm data are available for boys and girls separately (aged 8-16 
years) as well as preliminary cut-off values for the general Dutch population.24;26;27 A 
total difficulties score of ≥ 14 indicates behavioral difficulties, representing 10% of the 
general Dutch population.27
Statistical analyses
The Statistical Package for Social Sciences version 20.0 was used for statistical analyses 
(IBM, Armonk, NY, USA). Descriptive results for nominal variables are presented as 
number of cases and percentages. Data are reported as mean ± SD for continuous 
variables and median (range) for variables with a non-normal distribution. Differences 
between participants and non-participants were analyzed using independent t tests 
and Chi square tests. The TACQOL-CF was split in to 2 age groups, 8-11 and 12-15 years, 
since the scale structure and the reliability for the autonomy and social functioning 
scales proved to be less satisfactory for the children 12-15 years.19 The autonomy 
scale was deleted and the social functioning scale replaced with the peer functioning 
scale for this age group. To compare HRQOL and SDQ scores of children treated with 
IUT with mean Dutch norm data, independent t tests were used. Effect sizes of group 
differences (Cohen’s d) were computed by dividing the mean differences by the SD of 
the norm group. Effect sizes ≥ 0.80 were considered large.28 Due to multiple testing, 
Bonferroni correction was applied, and a P < 0.001 level was considered statistically 
significant. Total behavioral difficulties for the children aged 3-16 years (scores ≥ 14) 
were analyzed using a binomial test.
The following potential risk factors associated with HRQOL and total behavioral 
difficulties were studied in univariable linear regression models: severity of fetal anemia 
(Z-hemoglobin), fetal hydrops at IUT, number of IUTs, gestational age at birth, severe 
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A multivariable linear regression model included all variables that showed significant 
association with HRQOL and total behavioral difficulties in the univariable analysis. 
Results are expressed as regression coefficient B with 95% confidence interval (CI). 
Since the HRQOL questionnaires lack a total HRQOL score, risk factor analyses was 
planned only for the subscales that showed a significant difference (P < 0.001) between 
the IUT group and Dutch norm data.
Results
A flow diagram of study participants is shown in the Figure. 
 
Fetuses treated with IUT 
1998-2008: 
n=451 







Children < 3 years: n=24 
Congenital anomalies: 
n=5 
Fetal demise: n=31 
Neonatal death: n=11 




TACQOL-PF 6-11 yrs 
n=127 
TACQOL-CF 8-11 yrs 
n=80  
TACQOL-CF 12-15 yrs 
n=49  
TAAQOL 16-21 yrs 
n=44  
SDQ 3-16 yrs 
n=247  
Missing or incomplete 
questionnaires: n=16 
Figure Flow diagram of study participation.
TACQOL, TNO AZL Child Quality of Life questionnaire; PF, Parent Form; yrs, years; CF, Child 
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Between 1988 and 2008, 451 fetuses were treated with IUT for alloimmune anemia 
at our center. Of the 337 children participating in the initial LOTUS study, five (1%) 
children were diagnosed with severe congenital anomalies unrelated to intrauterine 
anemia or treatment, and were excluded from further analysis. Due to the age range of 
the questionnaires, 24 (7%) children under the age of 3 were excluded from the current 
study. Of 23 (7%) children no questionnaires were received. Follow-up data were 
obtained from 285/308 (93%) children and adolescents, with a total response rate of 
547/563 (97%) questionnaires consisting of 127 TACQOL Parent Forms age 6-11 (2 
missing), 80 TACQOL Child Forms age 8-11 (6 missing), 49 TACQOL Child Forms age 12-
15 (1 missing), 44 TAAQOL questionnaires age ≥ 16 (2 missing) and 247 SDQs age 3-16 
(5 missing). Detailed information on the baseline characteristics of the 285 participants 
is presented in Table 1. 




(n = 93) P
Gestational age at first IUT, mean ± SD (range), 
weeks
28 ± 5 (17-36) 27 ± 5 (16-35) .096
Hemoglobin at first IUT, mean ± SD (range), g/dL 3.4 ± 1.5 (0.7-8.2) 3.4 ± 1.5 (1.1-7.4) 1.00
Number of IUTs per fetus, mean ± SD (range) 3 ± 1 (1-6) 3 ± 1.5 (1-8) 1.00
Rhesus D alloimmunization, n (%) 233 (82) 82 (88) .199
Rhesus c, n (%) 16 (6) 1 (1) .084
Kell, n (%) 31 (11) 9 (10) .848
Other, n (%) 5 (2) 1 (1) 1.00
Hydrops, n (%) 77 (26) 30 (32) .354
Mild, n (%) 55 (19) 17 (18) .880
Severe, n (%) 22 (8) 13 (14) .097
Gestational age at birth, mean ± SD (range), weeks 36 ± 2 (28-39) 36 ± 2 (29-38) 1.00
≤ 32 weeks, n (%) 7 (3) 6 (7) .095
32-35 weeks, n (%) 49 (17) 15 (16) .875
≥ 35 weeks, n (%) 229 (80) 72 (77) .555
Male, n (%) 148 (52) 49 (53) .905
Exchange transfusions per neonate, median (IQR) 1 (0-2) 1 (0-2) .601
Top-up transfusions per neonate, median (IQR) 2 (1-3) 1 (1-2) .202
Severe neonatal morbidity, n/N (%) 26/285 (9) 1/23 (13) .465
Dutch ethnicity, n/N (%) 259/285 (91) 18/23 (79) .067
One parent Dutch, n/N (%) 8/285 (3) 1/23 (4) .507
Non-Dutch, n/N (%) 18/285 (6) 4/23 (17) .069
Maternal education
Low, n/N (%) 85/282 (30) 6/23 (26) .815
Average, n/N (%) 115/282 (41) 10/23 (44) .828
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No significant differences in antenatal and neonatal characteristics were found between 
the participants and the lost to follow-up group. Mean gestational age at first IUT of the 
study group was 28 ± 5 weeks (range: 17-36) and the mean number of IUTs per fetus 
3 ± 1 (range: 1-6). The majority was treated for Rhesus D alloimmunization (233/285, 
82%). Mean gestational age at birth was 36 ± 2 weeks (range: 28-39). The mean age 
of the children and adolescents at follow-up was 10.5 ± 4.7 years (range: 3.0-21.5). 
Neurodevelopmental impairment was evaluated in our previous study in this cohort 
and diagnosed in 14/285 (5%) of participants in the current study. 
Health-related Quality of Life (TACQOL and TAAQOL)
Table 2 shows the scale scores indicating HRQOL for the parent- and child forms. 
Significantly lower scores were reported by parents of children 6-11 years compared 
with the Dutch norm group on 3 scales: cognitive functioning, social functioning and 
positive emotions (P < .00, P = .02 and P = .04 respectively). In children aged 8-11 only 
the cognitive functioning scale score was significantly lower compared with the Dutch 
norm group (P = .01). The children aged 12-15 reported higher scores on the negative 
emotions scale compared to Dutch norms (P = .02). When corrected for multiple testing, 
only a difference with medium effect size was detected for the parent-rated cognitive 
functioning scale (P < .00). Table 3 shows the scale scores indicating HRQOL for the 
adolescent forms. No significant differences were detected between the adolescents ≥ 16 
years treated with IUT and Dutch norms. Excluding the cases with neurodevelopmental 
impairment from all HRQOL analyses did not alter the results. 
Potential risk factors were entered in a univariable regression analysis to assess the 
association with the parent-rated cognitive functioning scale (Table 4). No significant 
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(n = 179) d P
Gross motor functioning 95.2 (10.2) 92.8 (16.5) 0.15 .361
Fine motor functioning 98.6 (7.6) 97.1 (10.7) 0.14 .401
Cognition 78.7 (25.5) 84.2 (20.6) 0.27 .130
Sleep 76.6 (27.7) 76.3 (23.4) 0.01 .949
Pain 81.3 (25.1) 81.1 (20.4) 0.00 .961
Social contacts 89.3 (17.5) 89.8 (16.3) 0.03 .876
Daily activities 87.9 (20.1) 81.8 (22.9) 0.27 .104
Sexuality 92.1 (18.0) 92.1 (18.7) 0.00 .992
Vitality 67.3 (23.0) 65.1 (21.8) 0.10 .559
Positive emotions 74.4 (22.1) 73.4 (19.1) 0.05 .758
Depressive emotions 79.9 (23.0) 79.0 (17.9) 0.05 .774
Aggressive emotions 83.5 (23.8) 84.7 (17.8) 0.07 .701
Values are mean ± standard deviation (SD), effect size (d) and P.
TAAQOL, TNO AZL Adult Quality of Life Questionnaire.
Table 4. Analysis of potential risk factors associated with HRQOL cognitive functioning scale
Characteristics Univariate analysis
B (95% CI) P
Hydrops, severe 1.43 (-1.99 – 4.86) 0.409
Z-Hemoglobin (SDs) 0.33 (-0.12 – 0.77) 0.151
Number of IUTs -0.11 (-0.80 – 0.59) 0.760
GA at birth -0.16 (-0.70 – 0.39) 0.572
Perinatal asphyxia, yes 1.20 (-3.84 – 6.23) 0.638
Severe neonatal morbidity, yes 0.03 (-3.11 – 3.16) 0.988




-0.66 (-2.58 – 1.25)
1.67 (-0.17 – 3.51)







-1.43 (-4.33 – 1.47)
-2.94 (-7.95 – 2.07)




Values are regression coefficient B (95%CI) and P.
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Behavioral Functioning (SDQ)
Mean SDQ scores of the children treated with IUT compared to Dutch norms (8-16 
years), stratified for boys and girls, are presented in Table 5. No differences between 
boys treated with IUT compared to norms were detected. Parents of girls treated with 
IUT reported higher means on emotional symptoms, peer problems and total difficulties. 
After correction for multiple testing (P < .001), no differences were detected. Overall, for 
the children 3-16 years, 37/246 (15%) parents reported behavioral problems above the 
total difficulties cut-off point (≥ 14). This is significantly higher than the 10% reported 
in both literature and the general Dutch population (P < .001).27 The results were not 
affected after excluding the cases diagnosed with neurodevelopmental impairment.
Potential risk factors were entered in a univariable regression analysis to assess the 
association with total behavioral difficulties (Table 6). Low maternal education was 
associated with higher total difficulties scores (B 2.72, 95% CI 1.28 – 4.16, P < 0.000) 
and high maternal education was associated with lower total difficulties scores (B -2.73, 
95% CI -4.16 - -1.30, P < 0.000). 
Table 5 Behavioral functioning of boys and girls aged 8-16 years treated with IUT compared with 






SDQ-Parent Form (n = 69) (n = 146) d P (n = 74) (n = 154) d P
Total Difficulties 8.6 (6.3) 7.8 (5.5) 0.15 0.344 7.5 (5.3) 5.6 (4.8) 0.40 0.007*
Emotional 
symptoms
2.3 (2.3) 1.8 (1.9) 0.26 0.094 2.6 (2.5) 1.7 (1.8) 0.50 0.002*
Conduct problems 1.4 (1.6) 1.3 (1.6) 0.06 0.669 0.8 (1.2) 0.8 (1.2) 0.00 1.000
Hyperactivity 3.2 (2.6) 3.3 (2.9) 0.03 0.807 2.6 (2.4) 2.1 (2.3) 0.22 0.131
Peer problems 1.7 (2.0) 1.4 (1.7) 0.18 0.255 1.5 (1.8) 0.9 (1.4) 0.43 0.006*
Prosocial behavior 7.9 (2.3) 8.2 (1.6) 0.19 0.268 8.7 (1.7) 8.8 (1.4) 0.07 0.639
Values are mean ± standard deviation (SD), effect size (d) and P.
*Difference at P < .05; Difference at P < .001; Bonferroni correction for multiple testing applied.
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Table 6. Analysis of potential risk factors associated with behavioral difficulties
Characteristics Univariate analysis
B (95% CI) P
Hydrops, severe 0.25 (-2.28 – 2.78) 0.844
Z-Hemoglobin (SDs) 0.00 (-.01 – 0.02) 0.682
Number of IUTs -0.28 (-0.78 – 0.22) 0.268
GA at birth 0.19 (-0.24 – 0.62) 0.384
Perinatal asphyxia, yes 0.98 (-2.60 – 4.57) 0.591
Severe neonatal morbidity, yes 0.09 (-2.10 – 2.28) 0.937




2.72 (1.28 – 4.16)
0.05 (-1.34 – 1.43)







-0.92 (-3.28 – 1.43)
2.75 (-1.59 – 7.10)




Values are regression coefficient B (95%CI) and P.
*Difference at P < .001.
Discussion
This is the first study evaluating HRQOL and behavioral functioning in children and 
adolescents treated before birth with IUT for alloimmune anemia. The results of this 
study demonstrate that, differences were shown between the parent-rated IUT group 
and the norm population on cognitive, social and emotional domains. When corrected 
for multiple testing, only a difference was detected for the parent-rated cognitive 
functioning scale. Behavioral difficulties were more prevalent, and were associated 
with maternal educational levels. 
Interestingly, the children did not self-report more difficulties with cognitive function 
than norms. Discrepancies between parent- and child-reports have been documented 
frequently and do not imply that either reporter is inaccurate.30;31 Lack of agreement 
between parents and children on certain domains of HRQOL may result from different 
expectations, experiences and perceptions of the same situation.32 
Parents reported more behavioral difficulties compared to literature and norms.26;27;33 
More problems were reported if mothers had a low educational level. Socio-demographic 
factors, including socio-economic status and parental educational level, are well-known 
predictors of subsequent child outcomes including cognitive development, HRQOL and 
socio-emotional and behavioral functioning.34-36 Of the 37 children with behavioral 
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Excluding the children with neurodevelopmental impairment did not affect the results. 
It is important to mention that the Strengths and Difficulties Questionnaire (SDQ) is a 
screening questionnaire and an elevated score does not equate to the actual presence 
of a behavioral disorder. The SDQ primarily aims to draw the attention of professionals 
to the potential presence of behavioral problems. Furthermore, the SDQ is not yet 
validated for all age ranges in the Dutch population. Further study regarding potential 
behavioral disorders are required to investigate the clinical significance of this finding. 
Unfortunately, 21% (93/451) of the children were lost to follow-up, possibly because 
of the long time lapse since IUT treatment. However, comparison of the antenatal and 
perinatal characteristics showed no differences between the study group and lost to 
follow-up-group. Furthermore, it is likely that there are differences between our study 
group and the general Dutch population. Most importantly, the mean gestational age at 
birth was 36 weeks (late-preterm) in our study group versus 37-40 weeks of gestation 
in the general Dutch population. Studies have shown that children and adolescents born 
late preterm are at increased risk of cognitive, behavioral and emotional problems.37 
However, others suggest that children born mild to moderate premature do not 
experience an overall lower HRQOL.38 Neurodevelopmental impairment was evaluated 
in our previous study in this cohort and the vast majority (95%) of children treated with 
IUT had normal neurodevelopmental functioning.13 Several risk factors were found to 
be associated with neurodevelopmental impairment including fetal hydrops, number of 
IUTs, prematurity (<32 weeks), severe neonatal morbidity and parental education. In 
this study, only maternal educational level was associated with behavioral difficulties. 
Excluding the children with neurodevelopmental impairment did not alter our results. 
The pathophysiological mechanism causing long-term impairment in severely anemic 
and hydropic fetuses is not known. Hypoxic injury related to severe anemia or hydrops 
may result in cerebral injury which could lead to altered or impaired neurologic 
development. 
To conclude, the current study shows that the majority of parents and children 
perceived child HRQOL following IUT to be within the normal range. Only a difference 
on cognitive functioning was shown between the IUT group and the norm population. 
According to our screening questionnaire, parents reported more behavioral difficulties 
compared to norms associated with lower maternal educational levels. Decreased 
cognitive functioning may refer to learning difficulties, attention deficit problems 
and/or difficulties in the interaction with peers. Possible clinical and longer term 
implications of increased behavioral difficulties are problems in adult life related to 
adaptation issues. Both cognitive and behavioral difficulties are known to have an 
impact on future socioeconomic potential. This study is however the first on HRQOL 
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be interpreted with care. The clinical significance of our findings should be validated 
by further study, as assessment of HRQOL and socioeconomic status in adulthood will 
provide a clearer representation of the long-term functional outcomes following IUT. 
Future studies should include adequate controls matched for important perinatal (e.g. 
gestational age at birth) and demographic variables (e.g. socioeconomic status). We 
believe that long-term follow-up should be an integrated component of IUT treatment 
using standardized psychometric measures with the ability to address more subtle 
problems alongside obvious neurodevelopmental impairments. 
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Abstract
Objective
Prophylactic intravenous immunoglobulin (IVIg) does not reduce the need for exchange 
transfusion nor the rates of other adverse neonatal outcomes in neonates with Rhesus 
hemolytic disease of the fetus and newborn (Rhesus HDFN) according to our randomized 
controlled trial analysis. Our objective was to assess the long-term neurodevelopmental 
outcome in the children included in the trial and treated with either IVIg or placebo.
Methods
All families of children included in the trial were asked to participate in this follow-
up study. Long-term neurodevelopmental outcome in children at least two years of 
age was assessed using standardized tests. Primary outcome was the incidence of 
neurodevelopmental impairment defined as at least one of the following: cerebral 
palsy, severe cognitive and/or motor developmental delay (a test score <-2SD), bilateral 
deafness or blindness.
Results
Sixty-six of the 80 children (82.5%) who were recruited in the initial randomized 
controlled trial participated in the follow-up study. Children were assessed at a median 
age of 4 years (range: 2-7 years). The median cognitive score in the IVIg group was 96 
(range: 68-118) and 97 (range: 66-118) in the placebo group (P = 0.79). There was no 
difference in the rate of neurodevelopmental impairment between the IVIg and placebo 
groups (3% (1/34) versus 3% (1/32), P = 1.00).
Conclusions
Long-term neurodevelopmental outcome in children treated with intravenous 
immunoglobulin was not different from children treated with placebo. Standardized 
long-term follow-up studies with large enough case series and sufficient power are 
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Introduction
Rhesus hemolytic disease of the fetus and newborn (Rhesus HDFN) results from 
maternal red-cell alloimmunization against red blood cells antigens for which mother 
and fetus are incompatible. Rhesus HDFN can lead to perinatal death if fetal anemia is 
left untreated and can cause severe hyperbilirubinemia in neonatal survivors.1 
Conventional postnatal treatment consists mainly of intensive phototherapy (PT), 
exchange transfusions (ET) and top-up red blood cell transfusion. ET is necessary in 
Rhesus HDFN when intensive PT fails and serum bilirubin levels approach the threshold 
for ET. However, ET is an invasive procedure and is associated with several adverse 
events.2
Treatment with intravenous immunoglobulin (IVIg) combined with PT has been 
suggested as an alternative therapy to reduce the need for ET. In a recent randomized 
double-blind placebo-controlled trial we found that prophylactic treatment with IVIg 
did not reduce the need for ET in children with Rhesus HFDN.3 The effect of IVIg in 
children with Rhesus HDFN on the long-term neurodevelopmental outcome has not yet 
been studied.
The primary aim of this study was to evaluate the long-term neurodevelopmental 
outcome in all children with Rhesus HDFN included in the randomized controlled trial 
and treated with either IVIg or placebo. Our secondary aim was to assess the presence 
of allergies and susceptibility to ear-, nose- and throat infections. In a follow-up study 
in children after antenatal treatment for fetal/neonatal alloimmune thrombocytopenia 
(FNAIT), Radder et al found significantly less ear-, nose- and throat problems in 
those exposed to IVIg treatment compared to children not exposed to maternal IVIg 
treatment.4 
Patients and Methods
This follow-up study was performed at the Leiden University Medical Center, the 
Netherlands, national referral center for the management, intrauterine and perinatal 
treatment of Rhesus HDFN. Parents of all children with Rhesus HDFN included in the 
randomized controlled trial and treated with IVIg (n=41) or placebo (n=39) between 
2006 and 2010 were asked to participate in this follow-up study. The trial was initiated to 
investigate whether prophylactic use of IVIG reduces the need for exchange transfusions 
in neonates with Rhesus HDFN.3 After stratification for treatment with intra-uterine 
transfusion (IUT), neonates were randomized for IVIg or placebo. Informed consent was 
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children was previously reported in a large follow-up study after IUT (LOTUS study).1 
All families were asked to visit our outpatient department for neurodevelopmental 
examination. Families who were unable to travel to our outpatient department, were 
visited at home.
Primary outcome was a composite outcome termed neurodevelopmental impairment 
(NDI) defined as at least one of the following: cerebral palsy, severe cognitive delay 
(a test score <-2 Standard Deviation (SD)), severe motor delay (a test score <-2 SD), 
bilateral deafness requiring hearing amplification and/or bilateral blindness. Secondary 
outcome measures in the current study were the presence of allergies and susceptibility 
to ear-, nose- and throat infections. Parents were questioned about the presence of 
recurrent ear-, nose- and throat infections, hospitalization and required surgery.
Cognitive development in children aged 2 to 3 years was assessed according to the 
Dutch version of the Bayley Scales of Infant and Toddler Development, 2nd edition 
(BSID-II).5 BSID-II provides a mental development index (MDI) and a psychomotor 
development index (PDI). Children between 3 and 7 years of age were examined with 
the Dutch version of the Wechsler Preschool and Primary Scale of Intelligence, 3rd 
edition (WPPSI-III). WPPSI-III provides a full scale Intellectual Quotient (IQ) score and 
subsection scores for Verbal IQ and Performance IQ.6 BSID and WPPSI scores follow 
a normal distribution curve with a mean score of 100 and a standard deviation of 15. 
A score of 70-84 indicates mild delay (<-1 SD) and a score <70 indicates severe delay 
(<-2 SD). Parents of the children were still blinded at the time of assessment, and will 
be informed after the completion of this follow-up study. Socio-economic status of the 
parents was determined according to the Dutch Sociaal en Cultureel Planbureau, and 
was registered as high, average or low.7 
Statistical analysis
Categorical variables were compared using the chi-square test or Fisher’s exact test as 
appropriate. Student-t-test and Mann-Whitney test were used for continuous variables. 
A P value < 0.05 was considered statistically significant. Statistical analysis was 
performed using SPSS version 20.0 (SPSS Inc., Chicago, Il, USA). 
Results
All families of the 80 children included in the trial were approached to participate in 
this follow-up study. Fourteen children (18%) could not be assessed since parents 
declined consent or due to loss of contact information, of which 7/41 in the IVIg group 
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socio-economic status were found between the included and lost-to-follow-up group. 
Complete follow-up data were obtained from 66 (83%) children by a visit at our out-
patient department (n = 57) or a visit at home (n = 9). A flow diagram of study participants 
is shown in the Figure. The baseline characteristics of the IVIg and placebo groups were 
similar (Table 1). Detailed information on the long-term neurodevelopmental outcome 
of the children included for follow-up in both groups, overall and after stratification 
for treatment with or without IUT, is presented in Table 2. Median age at follow-up 
assessment was 4.0 (range: 2 - 7) years in the IVIg group and 4.1 (range: 2 - 7) years in 
the placebo group. The incidence of NDI in children treated with IVIg was 3% (1/34) 
compared to 3% (1/32) in the placebo group (P = 1.00). NDI in the two children was 
due to severe cognitive delay (cognitive score = 66 and 68). Median cognitive score in 
children in the IVIg group was 96 (range: 68 - 118) compared to 97 (range: 66 - 118) 
in the placebo group (P = 0.79). Mild cognitive delay (< -1 SD) was detected in 18% 
(6/34) and 16% (5/32) in the IVIg group and placebo group, respectively (P = 0.83). 
None of the children had cerebral palsy, bilateral blindness or deafness. Similar results 
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(N = 39) P
Gestational age at birth, mean ± SD, weeks 36.7 ± 1.0 36.5 ± 0.6 0.23
Birth weight, mean ± SD, grams 2994 ± 485 2953 ± 424 0.68
Male, n (%) 29 (71) 25 (64) 0.53
Neonates treated with intrauterine transfusions, n (%) 27 (66) 26 (67) 0.94
Number of IUTs per neonate, median (range) 2 (0-4) 3 (0-6) 0.48
Neonates treated with exchange transfusions, n (%) 7 (17.1) 6 (15.4) 0.84
Phototherapy, mean ± SD, days 4.7 (1.8) 5.1 (2.1) 0.34
No differences in the occurrence of allergies and ear-, nose- and throat infections 
between the IVIg and placebo groups was detected. The incidence of allergies in children 
treated with IVIg was 12 (4/34) compared to 19 (6/32) in those treated with placebo 
(P = 0.51). Recurrent ear-, nose-, and throat infections were present in 7/34 (21%) 
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Discussion
This is the first and largest randomized controlled study to date on long-term 
neurodevelopmental outcome in children with Rhesus HDFN treated postnatally with 
IVIg or placebo. We were able to follow-up 83% children who participated in the initial 
randomized controlled trial and found no difference in long-term neurodevelopmental 
outcome between children treated with either IVIg or placebo. The incidence of NDI 
was 3% in children treated with IVIg compared to 3% in children who received placebo. 
After stratification for treatment with or without IUT, similar results were obtained. 
Analysis from our initial randomized controlled trial showed that IVIg had no beneficial 
effect on the short-term outcome. In addition, this study suggests that IVIg does not 
have a beneficial effect on the long-term neurodevelopmental outcome.
The incidence of severe developmental delay in both groups (3% and 3%) seems in 
line with the incidence of severe delay in the general population (2.3%).8 None of 
the children had cerebral palsy, bilateral blindness or deafness. The incidence of NDI 
found in this study was slightly lower compared to a large follow-up study performed 
recently by our study group in 291 children with Rhesus HDFN (LOTUS study). In this 
large cohort, the incidence of NDI was 5%. However, all children included in the LOTUS 
study were treated with IUT for fetal anemia, and in 26% of cases fetal hydrops was 
present. As shown in the LOTUS study, fetal hydrops is an important risk factor for 
adverse neurodevelopmental outcome. In the cohort of children included in the current 
study, only 4 children had mild fetal hydrops and none of them developed severe 
developmental delay. 
Our findings also suggest that treatment with IVIg in the neonatal period does not 
seem to have harmful effects on the long-term outcome, which is in accordance with 
previous studies. In a randomized controlled trial of 82 infected neonates treated with 
IVIg prophylaxis in addition to antibiotics, von Muralt et al found no evidence of harmful 
effects on neurodevelopmental outcome.9 In another study, Ahmed et al (2011) used IVIg 
therapy during pregnancy in eight patients with pemphigus vulgaris. No developmental 
or behavioral abnormalities were detected in children born after a pregnancy treated 
with IVIg, with a mean follow-up period of 7 years.10 These studies, including ours, may 
however be too small to reliably determine the effect of IVIg on the long-term outcome.
The secondary objective of this study was to evaluate the incidence of allergies and ear-, 
nose- and throat infections in both groups. Comparison between both groups revealed 
no association between IVIg and allergies and ear-, nose- and throat infections. Not much 
is known on the association between IVIg in the perinatal period and the development 
of allergies and ear-, nose and throat problems at a later age. IgG appears to be involved 
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previous study in 48 children after antenatal treatment for fetal/neonatal alloimmune 
thrombocytopenia (FNAIT), Radder et al found significantly less ear-, nose- and throat 
problems in those exposed to IVIg treatment compared to children not exposed to 
maternal IVIg treatment.4 However, in our group, IVIg was given only once compared to 
repeated weekly administration of IVIg in the FNAIT group.
The most important limitation of our study is the relatively incomplete follow-up. 
We were not able to examine fourteen children (18%) due to loss of contact address 
or parents’ decline to participate. However, comparison of baseline characteristics 
between the study- and the lost-to-follow-up group showed no significant differences, 
assuming little bias. Lastly, our randomized controlled study was designed to detect a 
difference on the short-term outcome (namely the use of ET in the neonatal period) and 
was not designed to detect a difference on the long-term neurodevelopmental outcome. 
Our conclusions may thus be limited by the relatively small sample size and power.
Conclusion
We found no differences in long-term neurodevelopmental outcome in children with 
Rhesus HDFN treated with IVIg compared to placebo. Standardized long-term follow-
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Abstract
Monochorionic (MC) twins are at risk for several disorders, including twin-twin 
transfusion syndrome (TTTS), Twin Reverse Arterial Perfusion (TRAP) and selective 
intrauterine growth restriction (sIUGR). Several fetal interventions, such as serial 
amnioreduction (AR), fetoscopic laser coagulation of placental anastomoses (FLC) 
and selective feticide have led to improved perinatal morbidity and mortality rates. 
Nevertheless, the rate of cerebral lesions in monochorionic twins after fetal therapy 
appears to be high. Follow-up studies show a high incidence of cerebral palsy (CP) and 
neurodevelopmental impairment (NDI). We performed a systematic review on the 
long-term neurodevelopmental outcome in MC twins with TTTS following AR and FLC 
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Introduction
Due to placental vascular anastomoses, monochorionicity subjects twins to specific 
complications, in particular Twin-Twin Transfusion Syndrome (TTTS), selective 
Intrauterine Growth Restriction (sIUGR) and Twin Reverse Arterial Perfusion (TRAP). 
In addition, congenital anomalies are more common in monochorionic (MC) twins 
compared to dichorionic (DC) twins. Studies show a 3- to 4-fold higher risk of neurologic 
morbidities in MC twins compared to DC twins mainly due to a higher incidence of 
prematurity and very low birth weight1;2.
TTTS complicates approximately 10% of MC twin pregnancies and develops typically 
between 15 and 26 weeks of gestation3. It results from shunting of blood from one twin, 
the donor, to the other twin, the recipient, through placental vascular anastomoses. 
Serial amnioreduction (AR) and fetoscopic laser coagulation of placental anastomoses 
(FLC) are the two main treatment options in chronic TTTS. According to a Cochrane 
systematic review, FLC results in higher survival rates and better neonatal outcomes 
than AR4. With higher survival rates, an increasing number of follow-up studies in TTTS 
survivors are being published, shedding more light on neurodevelopmental outcome in 
the long-term.
In cases where severe complications lead to the impending death of one twin, selective 
feticide can be offered, to prevent exsanguination of the surviving twin into the dead 
twin5. Perinatal survival rates after selective feticide using cord occlusion techniques are 
reported to be high3, but information on the long-term neurodevelopmental outcome in 
survivors is limited.
The current systematic review focuses on the long-term neurodevelopmental outcome 
in MC twins with TTTS following AR and FLC and MC twins following selective feticide 
of the co-twin due to TTTS, TRAP, sIUGR and congenital anomalies.
Methods of the Review
A systematic literature search was utilized to retrieve the studies and articles for 
this review. An electronic MEDLINE, Embase and Cochrane Library literature search 
was performed using the following MESH terms: Monochorionic, amnioreduction, 
fetoscopic laser coagulation, selective feticide, cord occlusion, intrauterine, time, 
prognosis, epidemiologic studies, human development, neurobehavioral manifestations 
and morbidity. The computer aided search included the period from 1980 to April 
2011. All reference lists of primary articles and reviews were examined to search for 
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needed, authors were contacted for further information. Studies were included if the 
following criteria were present: the inclusion of MC twins treated for TTTS with AR 
and/or FLC, MC twins treated with selective feticide of the affected co-twin, long-term 
neurodevelopmental outcome, standardized measures and the conduct of statistical 
tests. The methodological quality of each selected study was assessed independently by 
two reviewers (JvK and EL). The following exclusion criteria were applied: case reports, 
reviews, dissertations, book chapters, guidelines and commentaries. 
Results
We found no review article or meta-analysis that focused specifically on the long-term 
neurodevelopmental outcome in children with TTTS treated with AR and/or FLC and 
neither on the long-term neurodevelopmental outcome after selective feticide of the 
affected co-twin. We identified 20 studies that met our inclusion criteria of which 8 on 
AR, 6 on FLC, 1 on AR and FLC, 2 reports on a RCT comparing AR with FLC6;7, and 3 on 
selective feticide. Our selected studies are summarized, in chronological order, in Tables 
1 (AR), 2 (FLC) and 3 (Feticide). Neurodevelopmental impairment (NDI) was determined 
on the basis of the presence of cerebral palsy (CP), cognitive/mental/developmental 
test scores < - 2SD, bilateral blindness, or deafness requiring amplification with hearing 
aids. 
Long-term outcome in TTTS treated with serial amnioreduction
Ten studies on TTTS following AR have been published to date (see Table 1). The 
reported incidence of CP after AR ranges from 13 to 23%, except for two studies, 
reporting a 5% (2/42) and 6% (3/52) incidence of CP8;9. These exceptions are probably 
due to underreporting, since the diagnosis of CP in these studies was solely based on 
clinical records in the first, while only children born very preterm underwent neurologic 
examination in the latter.
The incidence of NDI in TTTS after AR varies considerably, ranging from 6% to 26%8-
15. This large discrepancy is probably due to considerable differences in methodology 
between the studies and heterogeneity within the case series, such as TTTS stage at 
the time of intervention or gestational age at birth. In the majority of studies, case 
series were small, ranging from 20 to 52 children, and did not include appropriate 
comparison groups. As a consequence, studies were unable to assess whether NDI was 
due to confounders such as TTTS stage, prematurity or low birth weight8. Finally, not all 








































Long-term outcome in monochorionic twins after fetal therapy  |  63
According to Reisner et al. 21% (4/19) of the children had suspected CP at < 18 months 
and 15% (3/20) had confirmed CP at ≥ 18 months after AR for ‘stuck twin syndrome’15. 
However, Reisner et al. did not employ developmental tests and their outcome did not 
include NDI.
The long-term outcome according to Mari et al. included the diagnosis of CP and was 
reported in 5% (2/42) of children8. One other child was diagnosed with multicystic 
encephalomalacia, which is a significant risk factor for developing CP. No developmental 
tests were used. Among the cases in which both twins had clinically normal development, 
27% (9/34) required therapy because of mild speech and/or motor delay.
With formal psychological testing and a clear description of NDI, Cincotta et al. reported 
CP in 13% (3/23) and NDI in 22% (5/23) of survivors at the age of at least 2 years 
(2-4.5 years)13. Of note, all these children had abnormal brain scans. Periventricular 
leukomalacia and cerebral atrophy were seen in 17% of survivors, but in none of the 
gestation matched twin controls (P = .03). 
Both Haverkamp et al. and Frusca et al. classified the results of their neurological 
and psychomotor examinations into 3 groups that is, normal development, minor 
disabilities such as ‘clumsy’ coordination problems and mild mental retardation, and 
major impairment that is, CP and severe developmental delay11;12. Haverkamp et al. 
found minor NDI in 33% (13/40) and NDI in 23% (9/40), while Frusca et al. found 
minor NDI in 16% (5/31) and NDI in 26% (8/31) of TTTS survivors. 
At a mean age of 6.2 years at follow up, Lopriore et al. found an incidence of 26% (5/19) 
of CP10. Five children with CP needed special education or were ≥ 1 grades below 
the appropriate school level for their age and were therefore considered to have an 
abnormal mental development as well. In the group of children without CP or NDI, 22% 
(5/23) required speech therapy. 
Dickinson et al. reported CP in 6% (3/49) of TTTS survivors9. At a median age of five years, 
NDI was present in 14% (7/49). Minor NDI was not reported. The authors complemented 
their developmental test with questionnaires on behavioral problems. Although the 
mean intelligent quotient was 8 points lower compared to a contemporaneous regional 
cohort, there were no differences in behavioral scores. However, this reassuring finding 
relates only to pre-school children. The authors suggest that future research should 
include school-aged children. 
At 2 years, Lenclen et al. found minor and major NDI in 9.5% and 9.5% following AR 
(4/21), respectively14. Ages and Stages Questionnaires (ASQ) revealed lower scores in 
21 AR survivors compared to 88 FLC survivors and 201 DC twins (P = .01) and ASQ 
domains were more often abnormal (P = .005). 
Finally, Li et al. recently reported on the long-term outcome in 20 survivors treated 
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had major NDI and two children (10%) had minor NDI. The children with NDI were 
delivered before 29 weeks of gestation.
When the results of the follow-up studies are pooled together, the overall rate of CP 
and NDI in TTTS following AR is 14% (46/322) and 20.5% (32/156), respectively (see 
Table 1).
Long-term outcome in TTTS treated with fetoscopic laser surgery
Eight follow-up studies in TTTS after FLC have been published to date (see Table 2). The 
reported incidence of CP and NDI following FLC ranges from 3 to 12% and 8 to 18%, 
respectively17-22. 
In 1999, De Lia et al. report a 5.4% (5/93) incidence of severe handicaps in TTTS 
survivors after FLC19. Mean age at follow-up was however 14 months (range 1 to 34 
months), which is too early for accurate assessment of CP or developmental delay. In 
addition, no developmental tests were performed. 
Sutcliffe et al. found a 9% (6/66) incidence of CP in TTTS survivors treated with laser18. 
However, follow-up was incomplete and in 47% (31/66) of survivors neurological 
outcome was assessed using information from a general practitioner. In the group 
assessed by a pediatrician, 14% (5/36) had CP. Although the children assessed by a 
pediatrician were also tested with a standardized developmental test (Griffiths’ Scale), 
details on the number of children with severe developmental delay were not reported 
or scored as primary outcome. 
Two large follow-up studies from Germany, reported an incidence of major neurological 
impairment of 11% (10/89) and 6% (10/167)17;20. In both studies, the definition of 
neurological impairment did not include severe developmental delay. Hence, children 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Long-term outcome in monochorionic twins after fetal therapy  |  67
In a long-term follow-up study in 88 TTTS survivors treated with laser, Lenclen et al. 
report NDI in 11% (10/88) (CP: n=9; blindness: n=1)14. ASQ scores were similar in FLS 
and DC children. As suggested by the authors, since ASQ was used as a screening tool 
to determine developmental outcome instead of a standardized developmental test 
performed by psychologists, developmental delay might have been underestimated. 
Recently, 3 European fetal therapy centers (Barcelona, Leuven and Leiden) performed 
a multicenter follow-up study to investigate the risk factors for NDI in TTTS treated 
with FLC22. Long-term outcome data, including standardized developmental test results 
(Bayley scales), were collected in 278 TTTS survivors, the largest follow-up study in 
TTTS to date. CP was diagnosed in 6% of children (17/278; 95% CI 4%-10%). Severe 
mental developmental delay was diagnosed in 7% (19/278; 95% CI 4%-12%) and severe 
psychomotor developmental delay in 12% (34/278; 95% CI 9%-18%). Two children 
had bilateral blindness (1%) and two other had bilateral deafness (1%). Overall, the 
incidence of NDI was 18% (50/278; 95% CI 13%-24%). Minor NDI was not reported.
Gray et al. found a 4.4% (5/113) incidence of CP and NDI was diagnosed in 12.4% 
(14/113) of children23. Four children with CP also had severe cognitive impairment, 
whereas nine children without CP were diagnosed with severe cognitive impairment as 
well, according to Griffiths’ and Bayley scales
When the results of these follow-up studies are pooled together, the overall rate of CP 
and NDI in TTTS following FLC is 7.2 % (69/967) and 13.3% (83/624), respectively 
(see Table 2). One follow-up study from Lopriore et al.22 was excluded from this analysis 
because the included children were more fully described in the multicenter follow-up 
of this study21.
Amnioreduction versus Fetoscopic Laser Coagulation: the Eurofetus Trial
The first part of the largest RCT to date, the Eurofetus trial, comparing the perinatal 
outcome in TTTS following AR or FLC was published by Senat et al. in 2004 and 
showed a significant benefit in the FLC group6. Children in the FLC group were more 
likely to be free of major neurologic complications compared to children in the AR 
group at 6 months of age, 52% (75/144) versus 31% (44/140), respectively (P = .003). 
The definition of major neurologic complications included the presence of severe 
intraventricular hemorrhage (grade III or IV), severe cystic periventricular leukomalacia 
(grade III or IV), blindness and/or deafness. However, reliable assessment of neurologic 
abnormalities requires a longer follow-up period than 6 months. Recently, the authors 
published the long-term outcome in a subgroup of children included in the trial and 
found similar rates of CP between the AR and the FLC group that is, 15% (6/41) and 
13% (9/69), respectively (P = .12)7. Developmental outcome using ASQ at 24 months 
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age, the children in the FLC group had better ASQ scores compared to their peers in the 
AR group (261.3 ± 53.7 vs. 228.6 ± 79.1; P = .04). When assessed at 6 years of age with 
a more objective test (Wechsler Intelligence Scale for Children), again no difference was 
found between the groups (90.6 ± 19.9 vs. 91 ± 33.1; P = .27). These findings seem 
controversial considering the lower incidence of neurologic sequelae at 6 months of age 
in the FLC group and the outcomes of previous large case series (albeit not RCT)6;14;20. 
Several confounders may explain why FLC was not associated with a reduced risk of 
NDI compared to AR. First, although the mean total IQ was similar in both groups, the 
SD was much larger in the AR group (91 ± 33.1; a -1 SD score of 57.9). Presuming that 
IQ-scores are normally distributed, this suggests that a significant number of children in 
the AR group had severe developmental delay (IQ < 70; -2 SD). If this is the case, the rate 
of NDI could in fact be higher in the AR group. Unfortunately, a clear definition of NDI 
was not reported. Second, the most important reason for the absence of a difference in 
neurodevelopmental outcome is probably the extremely high rate of neonatal deaths 
(NND) in the AR group that is, 36% (26/73) of all live-born babies. Detailed information 
on the cause of death was not provided, but the high mortality rate was probably due to 
withdrawal of intensive-care-treatment in very preterm children with severe cerebral 
lesions. The missing information is crucial to put the results into perspective. As 
reported, 22% (20/93) of live-born children in the AR group had very severe cystic 
periventricular leukomalacia (grade III)6. A positive correlation between high NND rate 
and withdrawal of intensive-care-treatment in children with severe cerebral injury 
strongly influences the interpretation of the long-term outcome results. Had these 
severely damaged children survived, the rate of CP and/or NDI in the AR group would 
have been much higher.
Risk factors for Neurodevelopmental Impairment
Although several studies have found a trend towards an independent association 
between higher Quintero stage and NDI, statistical significance was not reached22. 
However, in a multivariate logistic regression model, both Gray et al. and Salomon et al. 
found more advanced Quintero stage to be a significant and independent risk factor for 
adverse outcome, (OR, 13.02; 95% CI, 1.92-88.33) and (OR, 3.23; 95% CI, 2.19-4.76; P < 
.001), respectively7;23. This may relate to the fact that in previous studies, stage IV TTTS 
represented a relatively small percentage of survivors, whereas these studies were able 
to include a relatively large percentage of severe cases7. 
Lopriore et al. found gestational age at birth independently associated with NDI (OR 
1.33 for each week, 95% CI: 1.05 to 1.67, P = .016)22. This association has been confirmed 
by Lenclen et al. and Li et al.14;16. The 2 large follow-up studies from Germany reported 
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between low gestational age at birth and NDI may not be surprising, as prematurity is 
a well-recognized major risk factor for adverse neurodevelopmental outcome24. Gray et 
al. could not confirm these results, however, on univariate analysis small for gestational 
age (SGA) twins were at increased odds for NDI23. When adjusting for Quintero stage, 
Salomon et al. could not confirm a relationship between advanced gestational age at FLC 
and neurodevelopmental outcome. This might be explained by a positive correlation 
between gestational age at intervention and Quintero stage22.
Whether survival and long-term neurodevelopmental outcome in stage I TTTS is 
better following FLC compared to conservative management with AR is not clear. In a 
retrospective study in stage I TTTS, Lopriore et al. found a higher incidence of NDI in the 
conservatively managed group compared to the group treated with FLC, 23% (7/30) 
versus 0% (0/21), respectively (P = .03), emphasizing the urgent need for a RCT in low 
stage TTTS25.
Finally, the majority of follow-up studies to date suggest that both donor and recipient 
twins are equally vulnerable to brain injury, since no difference in the rate of NDI 
between the donors en the recipients has been found7;9;10;12;17;18;20-23.
Long-term outcome in MC twins following selective feticide of the co-twin
Neurodevelopmental follow up of the surviving twin after selective feticide of the co-
twin is limited to only 3 small studies, with a range of included children from 6 to 6726-28. 
Details on the 3 follow-up studies are shown in Table 3. 
After bipolar cord coagulation for life-threatening malformation in one twin, TRAP 
sequence and severe TTTS with cerebral abnormalities, Robyr et al. found normal 
follow-up in all survivors but one with ‘some form of developmental delay’ at 1.4 years28. 
Follow-up was performed on a clinical basis at a very young age (0-42 months) and 
explicit criteria for NDI were lacking. According to the authors, the main contributors 
for poor outcome were performance of the procedure before 18 weeks of gestation and 
preterm rupture of the membranes (PROM) leading to preterm delivery. 
In the largest prospective study on cord coagulation to date, follow-up was available 
in 72 survivors, with 67 (93%) children at ≥ 1 year26. Cord coagulation was offered 
for TRAP, severe discordant anomaly, sIUGR and selected cases of TTTS. A pediatrician 
assessed fifty-five children at a median age of 1.3 years while in 12 children information 
was provided by the general practitioner. Mental and motor development was classified 
as normal, mild, moderate or severe delay with Bayley scales or Snijders-Oomen 
Intelligence test and Peabody test. Four children had mild cognitive and/or motor 
delay, and 1 was diagnosed with severe cognitive delay. All but one child with delay 
were born before 29 weeks. Three children were treated for TRAP after 23 weeks and 
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leukomalacia indicates a risk of 60-70% of CP, no CP was reported. The neonatal course 
of the children < 1 year of age was uneventful. According to the authors the assessment 
of developmental outcome would have been more accurate if all children had been 
evaluated at the treatment centers with the same assessment tools. 
In a small follow-up study by telephone in 6 cases at a mean age of 4 months (2.3-6.6 
months), Moise et al. reported that all survivors did well after radiofrequency ablation 
of the co-twin for major fetal anomalies27. However, 1 child was still in the NICU at the 
time of reporting, but had not developed major complications. 
NDI in the abovementioned case series was probably underreported, as case series were 
too small, developmental tests were not consequently employed and age at follow-up 
was too young to detect developmental delay which, in general, becomes more apparent 
at a later age. Developmental problems following selective feticide may arise from the 
underlying pathology, the type of procedure as well as from preterm delivery26. The 
series published to date are too small to assess the relative contribution of each of these 
factors.
Pooling the results of these follow-up studies, the overall rate of CP and NDI is 0% 
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Discussion and conclusions
According to current literature, the incidence of CP and NDI in TTTS treated with AR is 
high. The outcome of TTTS survivors treated with FLC appears to be more favorable. 
However, the Eurofetus RCT reported similar rates of impairment in children treated 
with AR or FLC. The results of this study were however limited and confounded by 
an extremely high rate of deaths in the neonates treated with AR, probably due to 
withdrawal of intensive care in neonates with severe cerebral injury. 
Recent findings suggest an important prognostic value of Quintero staging. Increased 
disease severity, that is higher Quintero stage, may not only be associated with 
increased perinatal mortality, but also with long-term morbidity7;22;29. Timely detection 
and treatment of TTTS are warranted to both increase survival and improve chances for 
a better long-term outcome. A controversial issue in TTTS remains however the optimal 
treatment for Quintero stage I TTTS. Multicenter RCTs with appropriate long-term 
follow-up are required to determine optimum management. Both donor and recipient 
in TTTS seem equally vulnerable to impairment. Finally, and not surprisingly, low 
gestational age at birth is a major risk factor for adverse neurodevelopmental outcome. 
Although long-term outcome following selective feticide is considered favorable, 
research is very limited and there is an urgent need for accurate and large long-term 
follow-up studies. 
Special care must be taken when comparing the results of the selected studies for 
review, as discrepancy may be due to different methodology, differences in neonatal 
death rates, considerable heterogeneity within the small case series and lack of uniform 
outcome criteria. All in all, regardless of antenatal treatment, all survivors are at risk for 
NDI and require long-term follow-up. 
Key Guidelines:
•	 Long-term neurodevelopmental outcome in TTTS following serial 
amnioreduction is considered worse when compared to laser surgery.
•	 The first RCT to date could not confirm a difference in long-term outcome after 
amnioreduction and laser surgery.
•	 Higher Quintero stage may not only be associated with perinatal mortality, but 
also with long-term neurodevelopmental impairment.
•	 The optimal management in stage I TTTS remains to be determined.
•	 Low gestational age at birth is a major risk factor for adverse outcome.
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Research Directions:
•	 Multicenter RCTs, including long-term follow-up, are required to determine the 
optimal management in stage 1 TTTS.
•	 Long-term follow-up after selective feticide is urgently needed.
•	 Uniform and clearly defined criteria for neurodevelopmental impairment, 
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Abstract 
Objective 
To estimate the odds of severe cerebral injury and long-term neurodevelopmental 
impairment in monochorionic twins treated with amnioreduction versus laser surgery 
for twin-twin transfusion syndrome. 
Methods
A systematic review and meta-analysis of studies on cerebral injury and long-term 
impairment after amnioreduction versus laser surgery were conducted. Odds ratios 
with their 95% confidence interval were computed. 
Results
Electronic and manual search identified 63 references. Five studies were included for 
analysis. We found an ample seven-fold higher risk of severe cerebral injury in live-born 
children treated with amnioreduction compared to laser (OR 7.69, 95% CI 2.78-20.0, 
P = .00). In children surviving the neonatal period, the odds were three-times higher 
following amnioreduction (OR 3.23, 95% CI 1.45-7.14, P = .00). Although not significant, 
monochorionic twins treated with amnioreduction had higher odds of periventricular 
leukomalacia and intraventricular hemorrhage (OR 2.08, 95% CI .86-5.00, P = .10 and 
OR 3.56, 95% CI .82-14.29, P = .09). Unfortunately, there were insufficient long-term 
outcome data available to assess the odds of neurodevelopmental impairment. 
Conclusion 
Amnioreduction is associated with an increased risk of severe cerebral injury compared 
to laser surgery in twin-twin transfusion syndrome. Our study highlights a crucial lack of 
studies focusing on long-term neurodevelopmental outcome. Follow-up into childhood 
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Introduction
Twin-twin transfusion syndrome (TTTS) is a severe complication of monochorionic 
(MC) twin pregnancies resulting from shunting of blood from one twin (the donor) 
to the other twin (the recipient) through placental vascular anastomoses. The donor 
twin becomes hypovolemic and anuric with oligohydramnios. The recipient twin 
becomes hypervolemic and polyuric with polyhydramnios. TTTS severity can be 
staged I to V according to Quintero’s classification system1. Serial amnioreduction of 
excessive amniotic fluid (AR) and fetoscopic laser coagulation of the placental vascular 
anastomoses (laser) are the two main treatment options in TTTS. There is extensive 
evidence that serial AR is associated with increased perinatal mortality when compared 
to laser surgery2. Reliable information on long-term impairment in survivors after both 
interventions is lacking3. 
The objective of the current systematic review and analysis was to estimate the odds 
of severe cerebral injury and long-term neurodevelopmental impairment in MC twins 
treated with serial AR compared to laser surgery for TTTS. 
Methods 
This systematic review was performed using PRISMA statement: preferred reporting 
items for systematic reviews and meta-analyses4. Inclusion criteria were formulated 
according to our pre-defined Patient-Intervention-Comparison-Outcome (PICO) 
question. The patients are live-born MC diamniotic twins with TTTS diagnosed using 
standard prenatal ultrasound criteria5. The intervention refers to serial AR and the 
comparison is fetoscopic laser coagulation of placental vascular anastomoses. The 
primary outcome entails severe cerebral injury and long-term neurodevelopmental 
impairment (NDI) with a follow-up period from pregnancy outcome to childhood: 
1. Severe cerebral injury was defined as intraventricular hemorrhage (IVH) ≥ grade 
III6, cystic periventricular leukomalacia (cPVL) ≥ grade II7, ventricular dilatation 
≥ 97th percentile8, porencephalic cysts, arterial or venous infarction detected on 
cerebral imaging i.e., cranial ultrasound, Computed Tomography scan or Magnetic 
Resonance Imaging. 
2. Neurodevelopmental impairment (NDI) was defined as cerebral palsy, bilateral 
blindness, bilateral deafness or cognitive developmental delay > 2 standard 
deviations (SD) below the population mean, diagnosed using standardized tests. 
Due to an anticipated lack of randomized controlled trials, we included both randomized 
and non-randomized studies. Studies that did not match our PICO question were 
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Data Sources
An electronic literature search was performed with PubMed, MEDLINE and ISI Web of 
Science (WoS) up to March 2012. Table 1 presents the search strategies for PubMed 
that were subsequently adapted for use in MEDLINE and ISI WoS. To identify articles 
not captured by the electronic searches, we hand-searched reference lists of relevant 
studies. 
Table 1. Search Strategies PubMed
Strategy Mesh and entry terms
#1 (“Fetofetal Transfusion”[Mesh] OR “Fetofetal Transfusion”[All Fields] OR “Twin 
Transfusion Syndrome”[All Fields] OR “Twin Transfusion Syndromes”[All Fields] OR 
“Twin Transfusion”[All Fields] OR “Twin Transfusions”[All Fields]) 
#2 (“Amniocentesis”[Mesh] OR “Amniocentesis”[All Fields] OR “Amniocenteses”[All 
Fields] OR “Amnioreduction”[All Fields] OR “Amniodrainage”[All Fields]) 
#3 (“Fetoscopy”[Mesh] OR “Fetoscopy”[All Fields] OR “Fetoscopic Surgeries”[All 
Fields] OR “Fetoscopic Surgical Procedures”[All Fields] OR “Intrauterine Laser 
Treatment”[All Fields] OR “Fetoscopic Laser Surgery”[All Fields] OR “In Utero 
Laser Ablation Therapy”[All Fields] OR “Laser Photocoagulation”[All Fields] OR 
“Laser Surgery”[All Fields] OR “Endoscopic Laser Surgery”[All Fields] OR “Laser 
Therapy”[All Fields]) 
#4 (“Infant”[Mesh] OR “Infant”[All Fields] OR “Infant Development”[All Fields] OR 
“Child”[All Fields] OR “Child development”[All Fields] OR “Neurologic Injury”[All 
Fields] OR “Cerebral Damage”[All Fields] OR “Neurodevelopmental Outcome”[All 
Fields] OR “Neurodevelopment”[All Fields] OR “Developmental Follow-Up”[All 
Fields]) 
#5 #1 AND #2 AND #3 AND #4 Results: 25
# = number.
Study Selection 
Eligibility and methodological quality of the studies were assessed independently by 
the corresponding (JK) and last author (EL). The following data were extracted and 
tabulated: first author, year of publication, study design, country of origin, selection and 
allocation of patients, data collection, comparability of patients and controls, potential 
confounders, operationalization of primary outcome and outcome measurement, 
efforts to minimize bias, the incidence of severe cerebral injury and NDI in patients and 
controls (2x2 tables) and the length and completeness of follow-up. In case of overlap or 
duplications in patients between studies, the study with the best overall study quality 
was included for review. A randomized controlled trial was, a priori, considered the 
best study design. Disagreements regarding eligibility, methodological quality and data 
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Statistical Analysis 
To summarize the results of the selected studies, an Excel spreadsheet was used. 
We performed statistical analysis using Stata (StataCorp LP, College Station, Texas). 
Categorical or dichotomous data were meta-analyzed with odds ratios (ORs) and their 
95% confidence intervals (CI), using 2x2 tables. We used the recommended method 
to add 0.5 where 2x2 tables contained cells with zero events, allowing continuity 
correction. Studies were a priori analyzed into two groups that is, studies including and 
studies excluding neonatal deaths in their outcome analysis. Heterogeneity between 
studies was examined with the inconsistency square (I2) statistics, with between-study 
heterogeneity at I2 ≥ 50% and P ≥ .05 9. In case of heterogeneity, a random effects model 
was used10. Otherwise, or in case of limited studies to reliably estimate between study 
variability, a fixed effect model was used. We performed meta-analyses and constructed 
forest plots to examine the effect of AR compared to laser surgery on severe cerebral 
injury with separate analyses for cPVL ≥ grade II and IVH ≥ grade III, and NDI with 
separate analyses for cerebral palsy, bilateral blindness, deafness and cognitive 
developmental delay. Publication bias was examined with the construction of a funnel 
plot and tested for asymmetry with the Egger test11.
Results
Study identification 
Combination of the 4 search strategies revealed 25 references in PubMed, 18 references 
in MEDLINE and 43 references in ISI WoS. A manual search revealed one additional study 
for consideration12. In total, after removal of duplicates, 63 references were screened. 
Figure 1 provides a flow diagram with the number of studies screened, assessed for 
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N=63 studies identified by 
electronic and manual search 
up to March 2012 
 





No MC twins with TTTS, 
letter, commentary, editorial, 




Exclusion n=16  
No amnioreduction, subgroup 
at > 27 weeks gestational age 
Comparison: Laser Surgery 
Inclusion n= 8  
 
Exclusion n=12  
No laser surgery, groups too 
small for comparison 
Outcome: Severe cerebral 
injury n=4 and NDI n=1 
 
Exclusion n=3  
No relevant outcomes, overlap 
between patients 
Figure 1. Flow diagram with the number of studies screened, assessed for eligibility and included 
for review with exclusion criteria according to our Patient- Intervention- Comparison- Outcome- 
question.
We found two other systematic reviews on AR versus laser surgery2;13. Roberts and 
colleagues (2008) analyzed one randomized controlled trial to compare AR with laser 
surgery on short-term perinatal outcome in their Cochrane meta-analysis2. We also 
accepted case-series for inclusion to obtain the full range of research to date. Rossi 
and D’Addario reported on mortality and cerebral anomalies representing the sum of a 
wide variety of cerebral injuries of varying degrees of severity, regardless of subsequent 
perinatal deaths or overlap in patients between studies, hence susceptible for bias13-15. 
We selected five studies, directly comparing AR with laser surgery on severe cerebral 
injury and NDI; three comparative studies plus two follow-up studies from the Eurofetus 
Trial15;16. Although well-designed and highly valuable, the two comparative studies 
published by Lenclen and colleagues were excluded from analysis, due to a considerable 
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Risk of bias and quality assessment using PRISMA statement
Since no randomization took place in the three comparative studies, performance- or 
selection bias could not be ruled out18-20. However, treatment allocation was unlikely 
correlated with TTTS severity in these studies since allocation to either AR or laser 
surgery was based on geographical location and treatment availability; consecutive 
patients were grouped according to treatment center and year of introduction of 
laser surgery in a center18. The RCT performed prospective power analysis and used 
computer generated central randomization sequences to maintain adequate allocation 
concealment15;16. Four studies employed a prospective design; of which one staged 
their AR group retrospectively15;16;19;20. All but one were multi-center studies20. All 
studies described techniques for both interventions in detail. Completeness of follow-
up ranged from 92 to 100%. Outcome assessment, including timing and frequency 
of postnatal brain imaging, was fully described in two of five studies and blinded in 
two15;16. Four studies accounted for TTTS stage in their comparison of AR to laser of 
which one stratified stage on outcome19. Two studies reported worse outcomes with 
increased TTTS stage in both groups; one study found increased TTS stage associated 
with poorer outcome in the AR group only19.
Results of individual studies 
Summary data for each intervention group are displayed in Table 2. Median gestational 
age at intervention was 20 to 22 weeks for both intervention groups and comparable 
in all but one study; 21.6 weeks at first AR versus 20.7 weeks at laser surgery19. This 
study reported an increased incidence of severe cerebral injury following AR which was 
related to increased TTTS stage. This effect was not observed in their laser group. All 
but one study staged TTTS, according to Quintero’s classification system1;18. TTTS stage 
at intervention was comparable between groups, with limited stage I cases in all studies. 
Gray and colleagues excluded stage I cases20. AR resulted in lower overall survival rates 
when compared to laser ranging from 39-59% compared to 54-77%, respectively. 
Treatment with AR resulted in higher neonatal mortality rates ranging from 14-55% 
compared to 6-15% when treated with laser. Median gestational age at birth was lower 
with AR, ranging from 28-31 weeks versus 32-34 weeks with laser. Accordingly, birth 
weight of donor and recipient twins was lower in the AR group ranging from 940-1612 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































86  |  Chapter 5
Synthesis of results 
A fixed effect model was used throughout because of the small number of included 
studies to reliably assess between study variability. To assess the odds of severe cerebral 
injury in children treated with either AR or laser, data were derived from four studies 
with 269 children in the AR group versus 357 children in the laser group15;18-20. The odds 
of severe cerebral injury in live-born children treated with AR were seven- to eight-
times higher when compared to children treated with laser (OR 7.69, 95% CI 2.78-20.0, 
P = .00; fig. 2). With subsequent neonatal deaths excluded from outcome analysis, the 
odds were three-times higher in the AR group compared to the laser group (OR 3.23, 
95% CI 1.45-7.14, P = .00; fig. 2). 
To assess the odds of cPVL ≥ II in live-born children, data were derived from two studies, 
one RCT and one comparative study, with 136 children in the AR and 144 children in the 
laser group 15;20. The OR demonstrated no significant difference in cPVL ≥ II in live-born 
children treated with either AR or laser (OR 2.08, 95% CI .86-5.00, P = .10; fig. 3). 
Two studies reported on the incidence of IVH ≥ III in live-born children15;20. Data were 
available from 136 children treated with AR versus 144 children treated with laser15. 
The OR demonstrated no significant difference in IVH ≥ III in live-born children treated 
with either AR or laser (OR 3.56, 95% CI .82-14.29, P=.09; fig. 4). Senat and colleagues 
identified eight (8/95) cases of IVH ≥ III in live-born children in their AR group versus 
two live-born children (2/93) in their laser group. Of these ten cases, only one child, 
treated with laser, was alive at six months of age15. According to Gray and colleagues, 
none of the live-born children developed IVH ≥ III in their first week of life20. 
There were insufficient long-term outcome data to assess the odds of NDI as a composite 
outcome. In their original article, Salomon and colleagues did not report individual 
observations of cognitive developmental delay as measured with the Ages and Stages 
Questionnaire (ASQ) and the Wechsler Intelligence Scale (WISC-IV)16. Salomon and 
colleagues did provide individual observations of CP, blindness or deafness. Data were 
available from 41 children treated with AR and 69 children treated with laser16. At 6-year 
follow-up, four children presented with CP, one child was blind and one child was deaf 
in the AR group (15%; 6/41) versus six children with CP, two children with blindness, 
and one child with deafness in the laser group (13%; 9/69). The absence of differences 
in long-term outcome was probably due to the significant higher neonatal death rate in 
the AR group that is, 55% (26/73) versus 15% (13/86) in the laser group. Kaplan-Meier 
curves showed that the probability of survival without major neurological impairment 
was lower with AR, adjusted for TTS stage (hazard ratio .61, 95% CI .41-.90, P = .01)16. 
Individual results of early brain imaging of these children were not reported.
Since the number of included studies was too small for a reliable assessment, 
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Figure 2 Fixed effect analysis of severe cerebral injury after amnioreduction versus laser surgery. 
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Figure 2. Fixed effect analysis of severe cerebral injury after amnioreduction versus laser surgery.
Figure 3 Fixed Effect Analysis of Cystic Periventricular Leukomalacia in Amnioreduction versus Laser Surgery. 
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Figure 4 Fixed Effect Analysis of Intraventricular Hemorrhage in Amnioreduction versus Laser Surgery. 
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Figure 4. Fixed Effect Analysis of Intraventricular Hemorrhage in Amnioreduction versus Laser 
Surgery.
Discussion
The objective of our systematic review and meta-analysis was to evaluate severe cerebral 
injury and long-term impairment in MC twins treated with AR compared to laser for 
TTTS. We found an ample seven-fold higher risk of severe cerebral injury in live-born 
children treated with AR compared to laser surgery. In children surviving the neonatal 
period, the odds were three-times higher following AR versus laser. Detailed analysis 
per type of severe cerebral injury demonstrated no significant difference between 
treatments regarding the incidence of cPVL ≥ II and IVH ≥ III. Importantly, there were 
not enough follow-up data to analyze long-term neurodevelopmental impairment in 
children treated with AR compared to laser surgery. 
Roberts and colleagues showed in their Cochrane review of only one trial that more 
children were alive without neurological abnormality at six months following laser 
surgery compared to AR (RR 1.66; 95% CI 1.17 to 2.35 adjusted for clustering, one 
trial)2. They reported no difference in the children alive at six months with neurological 
abnormality between interventions (RR 0.58; 95% CI 0.18 to 1.86 adjusted for 
clustering, one trial). The authors suggest that this might be secondary to plasticity 
of the developing brain or the demise of more severely affected fetuses. No data were 
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We aimed to present the full range of the research to date and included case-series as 
well, with a longer follow-up period.
Rossi and D’Addario showed in their meta-analysis of four studies comparing AR to laser 
that fetuses treated with AR were less likely to survive when compared to laser (overall 
survival: OR 2.04; 95% CI 1.52-2.76, P < .0001; neonatal death: OR .24, 95% CI .15-.40, 
P < .001)13. However, among these four studies, two studies have a considerable overlap 
in patients since both studies included participants of the Eurofetus RCT recruited and 
delivered in France15;21. Furthermore, their analysis of cerebral injury represented a 
sum of a wide variety of cerebral anomalies regardless of severity of the injury. Also, 
perinatal deaths were not taken into consideration in their outcome analysis. We 
excluded studies to avoid overlap between patients, specified cerebral injury according 
to type and severity and studies were a priori analyzed into two groups i.e., studies 
including and studies excluding neonatal deaths in outcome analysis.
We speculate that the increased risk of severe cerebral injury following AR is due to the 
higher rate of prematurity, which is a well-known risk factor for neonatal morbidity 
and mortality3. In addition, since AR is only a symptomatic intervention, fetuses remain 
exposed to TTTS for a longer period of time when compared to fetuses treated with laser 
coagulation of the placental anastomoses. The lack of difference in cPVL ≥ II and IVH ≥ 
III in live-born children between groups could be due to the small sample size since only 
two studies reported individual observations of these injuries in live-born children. The 
only RCT follow-up study concluded that there is no difference in neurodevelopmental 
impairment between interventions. However, these conclusions are likely biased by the 
significantly higher neonatal death rate in their AR group2;16.
The main limitation of the current systematic analysis is the small number of studies 
available for review and small sample size. Studies directly comparing AR to laser on 
outcome are scarce. The majority of the studies included in this systematic review 
employed a comparative design which is highly susceptible for bias. Among the studies, 
there were no stringent criteria regarding what constitutes severe cerebral injury. 
Although cranial ultrasound is useful for detecting neurologic morbidity, its sensitivity 
for subsequent neurodevelopmental impairment is not high3. In addition, a normal 
cranial ultrasound scan without cerebral injury does not necessarily equate with normal 
neurodevelopmental outcome20. This can only be ascertained by long-term follow-up to 
childhood in order to determine outcome in terms of CP, cognitive and socio-emotional 
development3;20. 
Our study highlights the crucial lack of studies focusing on cerebral injury and long-
term neurodevelopmental outcome in TTTS. Although serial AR and laser surgery have 
been introduced more than 2 decades ago, most studies in TTTS have focused mainly 
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of survivors is indispensable for determining best practice for clinicians as well as for 
counseling future parents using evidence-based information. This requires cooperation 
between obstetricians, pediatricians and other experts in the field of child cognitive 
and social-emotional development in order to look beyond perinatal survival as well as 
cooperation between international treatment centers to obtain reliable data with large 
enough case series with sufficient power. We suggest defining what is considered severe 
cerebral injury and neurodevelopmental impairment consistently, to provide individual 
information on all cases including early brain imaging in order to reliably estimate the 
effect on later development. It is important to continuously assess development of the 
children including formal psychological testing and standardized measures of well 
documented psychometric quality, with increasing reliability of results with increasing 
age. Table 3 represents a proposition for future research.
Conclusion 
Setting up a new RCT with long-term follow-up after AR versus laser surgery is not 
ethical, since higher overall survival rates and better perinatal outcomes have already 
been established with laser surgery. However, long-term follow-up with emphasis 
on child cognitive, socio-emotional development and quality of life is indispensible 
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Abstract
Objective 
To compare the incidence of neurodevelopmental impairment in surviving children 
from pregnancies with twin-twin transfusion syndrome treated with laser surgery 
between two time periods. 
Study design
We compared the neurodevelopmental outcome between the first consecutive cohort 
of twin-twin transfusion syndrome pregnancies treated with laser surgery from 2000 
to 2005, with a cohort treated between 2008 and 2010. Neurological, cognitive and 
motor development was evaluated using Bayley scales at 2 years of age corrected for 
prematurity. 
Results
A total of 229 twin pregnancies were treated with laser surgery, 113 in the first cohort 
and 106 in the recent cohort. Overall survival increased from 70% (158/226) to 80% 
(170/212) (P = .014). The incidence of neurodevelopmental impairment decreased 
from 18% (28/152) to 6% (10/155) (P < .01). In multivariate analysis, severe cerebral 
injury at birth was independently associated with neurodevelopmental impairment 
(OR 34.86, 95% CI 11.83-102.75, P < .01).
Conclusion 
Overall survival in twin-twin transfusion syndrome has improved over time, with a 
concomitant reduction in the incidence of neurodevelopmental impairment. Research 
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Introduction
Twin-twin transfusion syndrome (TTTS) is a major complication of monochorionic 
twin pregnancies and is the result of inter-twin blood transfusion through placental 
vascular anastomoses. Fetoscopic laser coagulation of the anastomoses is considered by 
many specialists the treatment of choice since it was first described two decades ago.1;2 
Despite improved short-term and long-term outcomes with increasing experience and 
advances in technique, TTTS treated with laser surgery is still associated with severe 
cerebral injury ranging from 3% to 16%3-6 and neurodevelopmental impairment ranging 
from 8% to 18%.7 Our objective was to compare the incidence of neurodevelopmental 
impairment in a cohort of TTTS pregnancies recently treated with laser surgery at our 
center between 2008 and 2010 with a previously published first cohort, treated at our 
center between 2000 and 2005.8
Materials and Methods
The Leiden University Medical Center serves as the national referral center for laser 
treatment in TTTS pregnancies in The Netherlands since 2000. Surviving children of all 
TTTS pregnancies treated with fetoscopic laser surgery were routinely assessed in our 
long-term outcome clinic since the start of our laser program, except, for organizational 
reasons, in the period between 2006 and 2007. We previously reported on the 
neurodevelopmental outcome at two years of age of our first cohort, treated between 
2000 and 2005. We evaluated neurodevelopmental outcome of all surviving children 
treated between 2008 and 2010, and compared the two groups.
TTTS was diagnosed by using standard prenatal ultrasound criteria9 and staged 
according to standard criteria.10 All fetoscopic laser procedures were performed by 
the same group of experienced operators during both study periods. Details on the 
laser technique used at our center and the short-term outcome results have previously 
been reported.11 During the second study period, the majority of TTTS cases were also 
included in a randomized controlled trial, the Solomon study (NTR1245) comparing 
laser coagulation of the entire vascular equator, the Solomon technique, with the 
standard selective laser technique. 
The following antenatal and neonatal data were recorded: gestational age at the 
time of laser treatment, stage of TTTS, occurrence of twin anemia-polycythemia 
sequence (TAPS) or recurrence of TTTS after laser, fetal demise, gestational age at 
delivery, birth weight, severe cerebral injury and neonatal death. TAPS was diagnosed 
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as intraventricular hemorrhage (IVH) ≥ grade III,13 cystic periventricular leukomalacia 
(cPVL) ≥ grade II,14 ventricular dilatation ≥ 97th percentile,15 porencephalic cysts, 
arterial or venous infarction detected on cerebral imaging. Socio-economic status (SES) 
of the parents was registered as high, average or low according to the Dutch Sociaal en 
Cultureel Planbureau.16 The follow-up visit was assessed at age 2 years (corrected for 
prematurity) and included a physical and neurologic examination and an assessment 
of cognitive and motor development using the Dutch version of the Bayley Scales of 
Infant and Toddler Development second edition (BSID-II) in the old cohort and third 
edition (BSID-III) in the new cohort by certified examiners.17;18 Both tests (BSID-II and 
BSID-III) provide a cognitive development and motor development score that follow a 
normal distribution with a mean of 100 and a standard deviation (SD) of 15. When each 
separate score was below 70, which is > 2 SD below the mean, this was indicative of a 
severe delay in either cognitive or motor development. A score below 85, > 1 SD below 
the mean, was indicative of at least mild to moderate delay. Cerebral palsy (CP) was 
defined according to the European CP Network and classified as diplegia, hemiplegia, 
quadriplegia, dyskinetic, or mixed.19 A composite outcome, termed neurodevelopmental 
impairment (NDI), was defined as any of the following: CP, cognitive development score 
of less than 70, motor development score of less than 70, bilateral blindness, or bilateral 
deafness requiring amplification. 
The primary aim of our study was to compare the incidence of NDI between both 
cohorts. The secondary aim was to determine risk factors associated with NDI. The 
institutional review board of the Leiden University Medical Center approved the study 
and all parents gave written informed consent for their children. 
Statistics
Data are reported as means with standard deviation (SD) or as medians with inter 
quartile range (IQR), as appropriate. Statistical analysis was performed using the 
t-test and Mann-Whitney test for continuous variables. Chi-square test and Fisher’s 
exact test were used for categorical variables, as appropriate. Analysis for risk factors 
possibly contributing to the neurodevelopmental impairment was conducted using 
univariate and multivariate regression methods. The following potential risk factors for 
neurodevelopmental impairment were studied in a univariate logistic regression model: 
gestational age at laser surgery, Quintero stage, fetal demise of one twin, gestational 
age at delivery, birth weight, treatment failure defined as post-laser TAPS or recurrent 
TTTS, and severe cerebral injury. The multivariate logistic regression model included 
all variables that showed significant association in the univariate analysis. Results are 
expressed as odds ratio (OR) with 95% confidence interval (CI). All analyses were 
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effect that observations within twins are not independent. A P-value of less than 0.05 
was considered significant. Statistical analysis was executed with computer software 
(SPSS 20.0, SPSS, Inc., Chicago, IL).
Results 
During the first study period between 2000 and 2005, 113 TTTS pregnancies were 
treated with fetoscopic laser surgery. During the second study period, between 2008 
and 2010, we treated 106 TTTS pregnancies. The incidence of intrauterine fetal demise 
was 26% (58/226) and 16% (33/212), respectively (P = .01) with significant more 
double fetal demises in the first cohort (17% versus 7%; P < .01). Although in both 
groups the majority of pregnancies were classified as Quintero stage II or III, the recent 
cohort comprised significantly more stage III diagnoses at therapy (P = .02). Median 
gestational age at birth and median birth weight in live-born neonates was higher in 
the first cohort, 34 versus 32 weeks (P < .01) and 1982.5 versus 1700 grams (P < .01), 
respectively. 
Severe cerebral injury was detected in 10% (16/168) of live-born neonates in the 
first cohort and 6% (11/179) in the recent cohort (P = .32). Neonatal death rate was 
similar, 6% (10/168) and 5% (9/179), respectively (P = .90). Overall survival to 30 days 
was significantly higher in the recent cohort, 70% (158/226) versus 80% (170/212) 
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Gestational age at laser - weeks 20.1 ± 3.1 20.1 ± 3.3 .93
Quintero stage
I – n (%)
II – n (%)
III – n (%)








































Gestational age at birth - weeks 34 (5) 32 (6) <.01
Birth weight - grams 1982.5 (1258) 1700 (870) <.01
Severe cerebral injury 16/168 (10) 11/179 (6) .32
Neonatal death 10/168 (6) 9/179 (5) .90
Overall perinatal survival 158/226 (70) 170/212 (80) .01
N, number; SES, socio economic status; TAPS, twin anemia-polycythemia sequence; 
Data are presented as mean ± standard deviation, median (IQR), n (%) or n/N (%).
In both cohorts, follow-up data were obtained from 97% (153/158 and 165/170) of 
surviving children. Seven children could not be assessed since the parents declined 
consent. Contact information was lost for two children. One child was excluded from 
the analysis due to infantile Tay-Sachs disease; the co-twin was a fetal demise. 
All children underwent physical and neurological examination but three children 
did not complete the motor scale of the BSID-III and eight children did not complete 
the cognitive and motor scale. No significant differences in antenatal and neonatal 
characteristics and SES were found between the included and lost-to-follow-up group. A 
flow chart showing the derivation of the study population is shown in Figure 1. Baseline 








































Neurodevelopment over time in twin-twin transfusion syndrome  |  101
2000-2005 
N = 226 Fetuses  
Live-born neonates 
n = 168  (74%) 
Survivors 
n = 158 (70%) 
Follow-up 
N = 153 (97%) 
Complete follow-up 
n = 152 (99%) 
Incomplete follow-up 
n = 1 (1%) 
Lost to follow-up  
n = 5 (3%) 
Neonatal death  
n = 10 (6%) 
Fetal demise 
n = 58 (26%) 
2008-2010 
N = 212 Fetuses 
Live-born neonates 
n = 179 (84%) 
Survivors 
n = 170 (80%) 
Follow-up 
N = 165 (97%) 
Complete follow-up 
n = 155 (94%) 
Incomplete follow-up 
n = 10 (6%) 
Lost to follow-up 
n = 5 (3%) 
Neonatal death 
n = 9 (5%) 
Fetal demise 
n = 33 (16%) 
Figure 1 Flow chart showing the derivation of the study population.

















Donor 79 (52) 84 (51) .88
Gestational age at laser (weeks) 20.4 ± 3.4 (15-28) 20.4 ± 3.4 (14-29) .86
Quintero stage - median (range)
I – n (%)
II – n (%)
III – n (%)
















Fetal demise co-twin 19 (12) 17 (10) .60
















Birth weight (grams) 2000 (1202.5) 1710 (851) <.01
Female 79 (52) 91 (55) .53
SES, socio-economic status.
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The incidence of NDI in children with complete follow-up was 18% (28/152) in the 
first cohort, versus 6% (10/155) in the recent cohort (P < .01). NDI was due to CP in 12 
cases in the first compared to 5 cases in the recent cohort (P = .07). CP was classified as 
quadriplegia (n = 5), diplegia (n = 2), and hemiplegia (n = 5) and as quadriplegia (n = 
2) and hemiplegia (n = 3) respectively. Severe cognitive developmental delay occurred 
in 14 cases in the first cohort compared to 5 cases in the recent cohort (P = .03). Severe 
motor development delay was detected in 20 cases in the first cohort compared to 5 
cases in the recent cohort (P < .01). Details on the combinations of abnormal findings 
detected in the children with NDI are presented in Table 3. In the first cohort, 36% 
(10/28) of children with NDI also had severe cerebral injury, versus 60% (6/10) in the 
recent cohort (P = .27). Mean BSID cognitive scores in the first cohort were seven points 
lower compared to the recent cohort, 94.6 ± 17.0 versus 102.0 ± 12.3, respectively (P 
< .01). Mean BSID motor scores in the first cohort were 12 points lower, 89.7 ± 17.7 
versus 101.8 ± 13.8, respectively (P < .01). 





CP 1 (1) 2 (1)
Cognitive development <2 SD 6 (4) 3 (2)
Motor development <2 SD 6 (4) 1 (1)
CP and cognitive and motor development <2 SD 4 (3) 1 (1)
CP and cognitive development <2 SD 1 (1) 0
CP and motor development <2 SD 5 (3) 2 (1)
CP and bilateral deafness 1 (1) 0
Cognitive and motor development <2 SD 3 (2) 1 (1)
Cognitive and motor development <2 SD and deafness 1 (1) 0
Neurodevelopmental impairmenta 28 (18) 10 (6)
N, number; CP, cerebral palsy; SD, standard deviation.
Data are expressed as n (%).
aNeurodevelopmental impairment included any of the following: Cerebral Palsy, cognitive 
development <2 SD, motor development <2 SD, bilateral deafness or blindness.
Univariate analysis of potential risk factors for NDI was performed for both cohorts 
(Table 4). Risk factors found to be associated with NDI were advanced gestational age 
at laser surgery (OR, 1.12 for each week; 95% CI, 1.01-1.25; P = .03), lower birth weight 
(OR, 1.08 for each 100-gr decrease; 95% CI, 1.01-1.15; P = .02) and severe cerebral 
injury at birth (OR, 40.00; 96% CI, 13.39-119.46; P < .01). We found a (small) positive 
correlation between gestational age at laser and Quintero stage (r = .11; P = .05) and a 
strong positive correlation between gestational age at birth and birth weight (r = .85; 
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We found no statistically significant difference in NDI between donors and recipients 
(P = .86), between males and females (P = .07) and between children with and without 
treatment failure (P = .21). All (7 of 7) children with recurrent TTTS had normal 
neurodevelopmental outcome, three (3 of 24) children with TAPS had NDI. 
Risk factors associated with NDI by univariate analyses were entered in a multivariate 
logistic regression model to measure the independent association with NDI (Table 4). 
We found that only severe neonatal cerebral injury was still significantly associated 
with NDI (OR, 34.86; 95% CI, 11.83-102.75; P < .01).
Comment
This is the first study evaluating changes in long-term neurodevelopmental outcome in 
TTTS survivors treated with laser surgery over time. Overall survival rate improved from 
70% to 80% with a significant reduction in (double) fetal demise. Increased survival was 
associated with a concomitant decrease in incidence of long-term neurodevelopmental 
impairment, from 18% in the first 6 years of our laser program (2000-2005) to 6% in 
the recent cohort (2008-2010). The incidence of NDI in our recent cohort is also lower 
compared to the 11% rate of NDI recently reported in a systematic review by Rossi, 
Vanderbilt & Chmait20 who used data from pregnancies treated between 1995 and 2006.
Our study shows that although TTTS remains one of the most lethal conditions in 
perinatal medicine, the outcome (in terms of its most important parameter, disease-
free survival) has significantly improved in the last decade.
Several factors may explain this improvement in disease-free survival, including 
improvements in fetal and prenatal care strategies (monitoring and management 
options), increased awareness and knowledge of potential (treatable) complications 
in TTTS, learning curve effect associated with a highly technical procedure such as 
laser surgery and the introduction of a new laser technique (Solomon technique) since 
2008.21 Since many of these changes occurred simultaneously, it is impossible to assess 
the contribution of each of these factors. Whether improvement in long-term outcome 
could be related to the Solomon laser technique, is currently being evaluated in a large 
long-term follow-up program. Long-term outcome results in the Solomon study are 
awaited in 2015. 
One limitation of our study that requires attention is the use of the BSID-III instead 
of the BSID-II in the analysis of the recent cohort. Several studies report a significant 
underestimation of developmental delay using the BSID-III compared to BSID-II 
assessment, with cognitive and motor score differences ranging from three up to 18 
points in favor of BSID-III assessment.22-26 In our study, mean BSID-III cognitive scores 
were seven points higher than mean BSID-II cognitive scores, in accordance with what 
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mean BSID-II motor scores. To account for possible underestimation of delay in the new 
cohort, we first applied a correction of 7 points on both scales. With this correction, the 
rate of NDI in the recent cohort did not change. Then, following the example of Vohr et 
al (2012),26 we applied a correction of 15 points on both scales, raising our threshold 
for cognitive and motor delay from a score of < 2 SD (test scores < 70) to a score of < 1 
SD (test scores < 85). With this correction, the rate of NDI increased from 6% (10/155) 
to 10% (15/155). Compared to 18% (28/152) of children with NDI in the first cohort 
using BSID-II assessment, the difference between the two cohorts remains significant 
(P = .03). 
Interestingly, the rate of impairment was lower in the recent cohort, despite the fact 
that the median gestational age at birth was significantly lower. The most plausible 
factor causing a decrease in gestational age at birth in the recent cohort is related 
to a gradual change of obstetrical management in monochorionic twin pregnancies 
over the last decade. Although the optimal timing of delivery in monochorionic twin 
pregnancies remains controversial, guidelines in The Netherlands nowadays advise to 
induce delivery between 36 and 37 weeks. As shown in this study, the percentage of 
monochorionic twin pregnancies delivering between 37 and 40 weeks was significantly 
higher in the first cohort. 
This also provides several clues to further understand which children may be at 
increased risk for adverse long-term outcome. In a univariate analysis including both 
cohorts we found that advanced gestational age at laser surgery, low birth weight 
and severe neonatal cerebral injury are potential risk factors for NDI. The association 
between low birth weight (which was strongly related with low gestational age at 
birth) and neurodevelopmental impairment is not surprising since low birth weight 
and low gestational age are well-recognized risk factors for long-term impairment.8;27;28 
The association between advanced gestational age at laser and neurodevelopmental 
outcome is more difficult to explain. A possible explanation could be that the fetal brain 
may be more susceptible for circulatory imbalance and development of TTTS at a more 
advanced age. Alternatively, we also found a positive correlation with advanced age 
at treatment for TTTS and Quintero stage. Previous studies have shown that higher 
Quintero stage may have an impact on long-term neurodevelopmental impairment.8 
However, we found an increased number of Quintero stage III cases in the recent cohort. 
We speculate that there has been a gradual change in our interpretation of Doppler 
waveform analysis, with in more recent years considering milder ductus venosus 
waveform changes as being abnormal. 
Multivariate logistic regression showed that severe neonatal cerebral injury detected 
at birth is an independent risk factor for long-term neurodevelopmental impairment. 
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cranial ultrasound scans should be routinely performed at birth.29 However, although 
the predictive value of cerebral imaging techniques is increasing, its predictive accuracy 
remains subject of debate.30 Presence of long-term impairment can only reliably be 
ascertained by accurate and standardized long-term follow-up until at least childhood.
One of the limitations of this study is the absence of a non-TTTS control group. Another 
potential limitation is related to the as yet unclear predictive value of the Bayley scales 
for future cognitive and motor development. In addition, some developmental problems 
become more apparent only at a later age, especially at school age. Therefore follow-up 
until at least school age is highly recommended. 
In conclusion, we found a significant increase in survival rate and a concomitant decrease 
in long-term neurodevelopmental impairment in TTTS after laser surgery from 2000-
2005 to 2008-2010, suggesting major improvement in overall outcome in TTTS. We were 
able to establish several risk factors for neurodevelopmental impairment, including 
advanced gestational age at laser, low birth weight and severe neonatal cerebral injury. 
Although the optimal management of TTTS remains a major challenge for obstetricians 
and neonatologists, our data can be used to counsel parents in a more optimistic way 
compared to a decade ago. 
Clinical Implications
•	 Overall survival in twin-twin transfusion syndrome has improved over 
time, with a concomitant reduction in the incidence of neurodevelopmental 
impairment. 
•	 Although the optimal management of TTTS remains a major challenge for 
obstetricians and neonatologists, our data can be used to counsel parents in a 
more optimistic way compared to a decade ago.
•	 Research focused on prevention of cerebral injury is needed to further improve 
outcomes of these complicated twin pregnancies.
•	 Presence of long-term impairment can only reliably be ascertained by accurate 
and standardized long-term follow-up until at least childhood.
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Abstract
Background
The preferred treatment for twin-twin transfusion syndrome (TTTS) is fetoscopic 
laser coagulation of inter-twin vascular anastomoses on the monochorionic placenta. 
Severe postoperative complications can occur when inter-twin vascular anastomoses 
remain patent including twin-anemia polycythemia sequence (TAPS) or recurrent 
TTTS. To minimize the occurrence of residual anastomoses, a modified laser surgery 
technique, the Solomon technique, was developed in which the entire vascular equator 
is coagulated. In the Solomon randomized controlled trial (NTR1245), the Solomon 
technique was associated with a significant reduction in TAPS and recurrence of 
TTTS when compared to the standard laser surgery technique. Although a significant 
improvement in perinatal outcome was shown after the Solomon technique, the clinical 
importance should also be ascertained with long-term follow-up of the surviving 
children.
Objective
To compare the long-term neurodevelopmental outcome in surviving children with 
TTTS included in the Solomon randomized trial and treated with either the Solomon 
technique or standard laser surgery technique. 
Study design
Routine standardized follow-up in survivors, at least 2 years after the estimated date 
of delivery, was performed at two of the five centers participating in the Solomon trial, 
Buzzi Hospital Milan (Italy) and Leiden University Medical Center (The Netherlands). 
The primary outcome of this follow-up study was survival without long-term 
neurodevelopmental impairment (NDI) at age 2 years. NDI was defined as: Cerebral 
Palsy, cognitive and/or motor development score of less than 85, bilateral blindness 
or deafness. Cognitive and motor development was evaluated using Bayley-III. All 
analyses per fetus, neonate or child were conducted using the generalized estimated 
equation module to account for the effect that observations between co-twins are not 
independent.
Results 
The primary outcome, survival without NDI, was detected in 95/141 (67%) in the 
Solomon group and in 99/146 (68%) in the standard group (P = .92). NDI in long-term 
survivors included for follow-up was detected in 12/107 (11%) in the Solomon and in 
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case (spastic unilateral) in the Solomon group and in 2 (2%) cases (spastic unilateral 
and spastic bilateral) in the standard group (P = .58). Cognitive development < 85 was 
detected in 2/105 (2%) children in the Solomon group and in 6/106 (6%) children in 
the standard group (P = .23). Motor development < 85 occurred in 8/103 (8%) children 
in the Solomon group and 3/104 (3%) in the standard group (P = .23). 
Conclusion
We found no difference in survival without NDI between the Solomon and standard 
laser technique. In view of the reduction of short-term complications and absence 
of increased adverse long-term effects, these data support the use of the Solomon 
technique in the treatment of TTTS.
Introduction
Twin-twin transfusion syndrome (TTTS) is a major complication of monochorionic twin 
pregnancies and is the result of unbalanced inter-twin blood flow through placental 
vascular anastomoses. The preferred treatment for TTTS is fetoscopic laser coagulation 
of the anastomoses, with an overall survival rate of up to 74%.1 Although the goal of 
fetoscopic laser surgery is to coagulate all anastomoses, in up to 33% of pregnancies 
some vascular connections remain patent.2;3 These residual anastomoses can cause 
severe complications such as twin-anemia polycythemia sequence (TAPS) or recurrent 
TTTS.1;4 To minimize the occurrence of residual anastomoses and their associated 
complications, a modified fetoscopic laser surgery technique was developed called 
the ‘Solomon technique’, in which a coagulation line is drawn along the entire vascular 
equator.1 In the Solomon randomized controlled trial, this technique was associated 
with a significant reduction in TAPS and recurrence of TTTS when compared to the 
standard laser surgery technique.1 Although a significant improvement in perinatal 
outcome was shown after the Solomon technique, the clinical importance should also 
be ascertained with long-term follow-up of the surviving children. The aim of this study 
was to compare the long-term neurodevelopmental outcome in surviving children 
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Materials and Methods
The Solomon trial was an open-label, international, multicenter, randomized controlled 
trial (NTR1245). The background of the trial, methods, baseline characteristics and 
perinatal outcome have been reported previously.1;5 The protocol of the trial can be 
found on http://www.studies-obsgyn.nl/solomon/page.asp?page_id=791. In brief, 
the trial included 274 women with MC twin pregnancies up to 26 weeks’ gestation 
complicated by TTTS. Women were randomly assigned to the Solomon technique or 
standard technique. All fetoscopic laser procedures were undertaken by experienced 
operators, each of whom had done at least 60 previous laser procedures and were 
competent to undertake the Solomon technique. Routine standardized follow-up in 
survivors at least 2 years of age was performed at two of the five centers participating 
in the Solomon trial, Buzzi Hospital Milan (Italy) and Leiden University Medical Center 
(The Netherlands). Of the 274 patients included in the Solomon trial, 156 (57%) were 
randomized in one of these two centers. The follow-up study was approved by the 
Institutional Review Board of both centers. All parents gave written informed consent 
for their children. 
The following antenatal and neonatal data were recorded: gestational age at laser 
surgery, Quintero stage, fetal demise, antenatal and/or postnatal TAPS, recurrence of 
TTTS, gestational age at birth, birth weight, severe neonatal morbidity, cerebral injury 
and neonatal death (death of a live-born baby within the first four weeks of life). The 
presence of TAPS was identified according to previously published antenatal and 
postnatal criteria.6 In brief, antenatal TAPS was diagnosed when Doppler ultrasound 
examination revealed an increase in peak systolic velocity in the middle cerebral artery 
of > 1.5 Multiples of the Median (MoM) in one fetus that coincided with a decreased 
velocity of < 1.0 MoM in the co-twin, in the absence of twin oligo-polyhydramnios 
sequence. Postnatal TAPS diagnosis is based on inter-twin hemoglobin (Hb) difference 
≥ 8.0 g/dL and at least one of the following criteria: reticulocyte count ratio > 1.7 or 
small anastomoses (< 1 mm) at the placental surface.6 
Severe neonatal morbidity was defined as: respiratory distress syndrome, chronic lung 
disease (defined as oxygen dependency at 36 weeks gestational age), patent ductus 
arteriosus needing medical therapy or surgical closure, necrotizing enterocolitis ≥ grade 
2, retinopathy of prematurity ≥ stage 3, ischemic limb injury, amniotic band syndrome, 
or severe cerebral injury. Severe cerebral injury includes: intraventricular hemorrhage 
≥ grade 3,7 cystic periventricular leukomalacia ≥ grade 2,8 ventricular dilatation ≥ 
97th percentile,9 porencephalic or parenchymal cysts, or other severe cerebral lesions 
associated with adverse neurological outcome.10 Neuroimaging was performed using 
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resonance imaging (MRI) was performed. Maternal educational level was recorded and 
divided into three levels. A score of 1 was given when the mother’s education was low 
(primary school), a score of 2 for an intermediate educational level (secondary school 
and intermediate vocational school), and a score of 3 for higher levels of education 
(higher vocational school and university). 
Follow-up assessments were performed by trained psychologists and pediatricians 
unaware of the treatment allocations. A follow-up visit was performed at age 2 years 
corrected for prematurity that is, 2 years after the estimated date of delivery, and 
included a physical and neurological examination and an assessment of cognitive and 
motor development using the Bayley scales of Infant and Toddler Development third 
edition (Bayley-III).11 The Bayley-III provides cognitive and motor composite scores 
with a normed mean of 100 and a standard deviation (SD) of 15. Cerebral palsy was 
defined according to the European CP Network and classified as spastic bilateral, spastic 
unilateral, dyskinetic (dystonic or choreo-athetotic), ataxic, or mixed.12 The functional 
severity was classified according to the Gross Motor Function Classification System 
(GMFCS) for Cerebral Palsy.13 
The primary outcome of this follow-up study was survival without neurodevelopmental 
impairment (NDI). Neurodevelopmental impairment was defined as the presence of at 
least one of the following: Cerebral Palsy (GMFCS II-V), a cognitive composite score 
of less than 85 (> -1 SD), a motor composite score of less than 85 (> -1 SD), bilateral 
blindness, or bilateral deafness requiring hearing aids. Severe NDI was defined as: 
Cerebral Palsy (GMFCS II-V), a cognitive composite score of less than 70 (> -2 SD), a 
motor composite score of less than 70 (> -2 SD), bilateral blindness, or bilateral deafness 
requiring hearing aids. 
Statistics
Data are reported as means with standard deviation (SD) or as medians with range, 
as appropriate. Baseline characteristics were compared using the t-test and Mann-
Whitney test for continuous variables. Chi-square test and Fisher exact test were used 
for categorical variables, as appropriate. All analyses per fetus, neonate or child were 
conducted using the generalized estimated equation module to account for the effect 
that observations between co-twins are not independent. A two-sided P-value of less 
than 0.05 was considered significant. Statistical data were analyzed using SPSS version 
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Results 
A total of 76 pregnancies, 152 fetuses, were treated with the Solomon and 77 
pregnancies, 154 fetuses, with the standard laser surgery technique for TTTS (Figure 1). 
Overall survival did not differ significantly between the Solomon (118/152, 78%) and 
the standard group (117/154, 76%) (P = .77). Cord occlusion of one of the twins was 
performed in four cases due to severe cerebral injury (Solomon group n=1, standard 
group n=1) or life-threatening condition of the co-twin (Solomon group n=1, standard 
group n=1). After treatment with Solomon laser surgery, one pregnancy was terminated 
following the diagnosis of trisomy 21. In both groups, neonatal death within 28 days of 
birth occurred in 6/124 (6%) of cases. In the standard group, intensive care treatment 
was withdrawn in three neonates due to severe cerebral injury. 
Five children were excluded from the analysis due to infantile Tay-Sachs disease (n=1; 
the co-twin was a fetal demise), Neurofibromatosis type I (n=2) and inherited moderate-
severe hearing loss (n=2). Long-term follow-up data were obtained from 221/235 
(94%) survivors. Fourteen children were lost to follow-up (n=4 declined consent, n=1 
mother unable to travel due to pregnancy, n=9 loss of contact information). Perinatal 
characteristics of the lost-to follow-up group were similar to the children included for 
follow-up (data not shown and available on request). Table 1 presents the baseline 
characteristics and Table 2 presents the neonatal characteristics of the children 
included for follow-up. The Solomon technique was associated with a reduced risk of 
TAPS or recurrent TTTS compared to the standard group, 4/107 (4%) versus 26/109 
(24%), respectively (P = .00). Antenatal treatment in the cases with post-laser TAPS or 
recurrent TTTS included intrauterine blood transfusion (n=14), cord occlusion (n=2), 
laser surgery re-intervention (n=6), induction of labor (n=2) or expectant management 
(n=20). Severe neonatal morbidity including severe cerebral injury did not differ 
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156 pregnancies, 312 fetuses 
randomly assigned 
78 pregnancies, 156 fetuses 
allocated to Solomon group 
152 fetuses received allocated 
intervention 
124 live-born neonates (82%) 
118 survivors eligible for follow-
up (78%) 
9 lost to follow-up 
2 exclusion 
107 children included for follow-
up (91%) 
NDI: 12/107 (11%) 
6 neonatal deaths 
24 fetal demise 
2 termination 
2 cord occlusion 
2 cord occlusion 
1 pregnancy did not meet  
inclusion criteria 
78 pregnancies, 156 fetuses 
allocated to Standard group 
154 fetuses received allocated 
intervention 
124 live-born neonates (81%) 
117 survivors eligible for follow-
up (76%) 
5 lost to follow-up 
3 exclusion 
109 children included for follow-
up (93%) 
NDI: 10/109 (9%) 
6 neonatal deaths 
1 death > 28 days 
28 fetal demise 
2 cord occlusion 
2 cord occlusion 
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Donor, n (%) 53 (50) 56 (51) .43
Mean gestational age at laser ± SD - weeks 19.4 ± 2.5 20.2 ± 2.8 .09
Median Quintero stage (range) 
Stage I, n (%) 
Stage II, n (%)
Stage III, n (%)
















Fetal demise co-twin, n (%) 9 (8) 12 (11) .54













TTTS, twin-twin transfusion syndrome, TAPS, twin anemia-polycythemia sequence





Female, n (%) 62 (58) 52 (48) .40
Mean gestational age at birth ± SD - weeks 32.8 ± 3.0 32.7 ± 3.1 .99
Mean birth weight ± SD - grams 1864.2 ± 568.2 1898.7 ± 561.2 .72









Intraventricular hemorrhage ≥ grade 3
Periventricular leukomalacia ≥ grade 2
Ventricular dilatation ≥ 97th percentile
Porencephalic or parenchymal cysts











































The primary outcome, survival without NDI, was detected in 95/141 (67%) in the 
Solomon group and in 99/146 (68%) in the standard group (P = .92). NDI in long-term 
survivors included for follow-up was detected in 12/107 (11%) in the Solomon and in 
10/109 (9%) in the standard group (P = .61). NDI was due to cerebral palsy in 1 (1%) 
case (spastic unilateral) in the Solomon group and in 2 (2%) cases (spastic unilateral 
and spastic bilateral) in the standard group (P = .58). Cognitive development < 85 was 
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the standard group (P = .23). Motor development < 85 occurred in 8/103 (8%) children 
in the Solomon group and 3/104 (3%) in the standard group (P = .23). Severe NDI was 
found in 3/107 (3%) in the Solomon group and in 6/109 (6%) in the standard group 
(P = .47). The long-term outcome of the children included for follow-up is presented in 
Table 3. Details on the combinations of findings detected in the children with NDI are 
presented in Table 4a and b.





Cerebral Palsy, n (%)
GMFCS ≥ grade II










Bilateral blindness or deafness requiring hearing aids, n (%) - - -
Mean cognitive composite score ± SD
Cognitive composite score > -1SD, n (%) 
Cognitive composite score > -2SD, n (%)
N=105










Mean motor composite score ± SD
Motor composite score > -1SD












Neurodevelopmental impairmenta, n (%) 12 (11) 10 (9) .61
Severe neurodevelopmental impairmentb, n (%) 3 (3) 6 (6) .47
GMFCS, Gross Motor Function Classification System; SD, standard deviation.
aNeurodevelopmental impairment: Cerebral Palsy (GMFCS II-V), cognitive development > -1SD, 
motor development > -1SD, bilateral blindness or deafness.
bSevere neurodevelopmental impairment: Cerebral Palsy (GMFCS II-V), cognitive development > 
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Table 4a Combination of abnormal findings in children with neurodevelopmental impairment in 
the Solomon group













1 donor 36 2160 - - 85 76
2 recipient 36 2400 - - 90 82
3 donor 37 2880 - - 95 82
4 recipient 37 2910 - - 95 76
5 donor 37 2500 - - 85 79 TAPS
6 recipient 37 2120 - - 85 82 TAPS
7 donor 29 1280 RDS - 95 82
8 donor 33 1940 - - 80 97
9 recipient 32 1649 - - 95 82
10 recipient 33 2520 - - 80 85
11 recipient 33 1740 Middle cerebral 
artery infarction
GMFCS IV 95 61
12 recipient 39 3260 - - 65 67 Fetal demise 
co-twin
GA, gestational age; RDS, Respiratory Distress Syndrome; TAPS, twin anemia-polycythemia 
sequence; GMFCS, Gross Motor Function Classification System
Table 4b Combination of abnormal findings in children with neurodevelopmental impairment in 
the Standard group













1 donor 33 2012 RDS - 80 88
2 recipient 33 2150 RDS - 75 76
3 donor 34 1675 - - 80 64
4 recipient 34 2230 - - 75 67
5 donor 37 2615 - - 75 82
6 recipient 37 2310 - - 75 82
7 donor 29 1565 - - 55 NA Speech language 
problems
8 recipient 29 1515 RDS, IVH-3, 
Ventricular 
dilatation > 97th
- 55 NA Speech language 
problems
9 donor 31 777 IVH-3 GMFCS II 59 64
10 recipient 32 1635 PVL-3 GMFCS II 100 85 TAPS
GA, gestational age; RDS, Respiratory Distress Syndrome; NA, not assessed; IVH, intraventricular 
hemorrhage; PVL, Periventricular leukomalacia; GMFCS, Gross Motor Function Classification 
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Comment
We found no difference in survival without NDI between the Solomon and standard 
laser technique. Overall, NDI was detected in 10% (22/206) of survivors included for 
follow-up that is, 11% in the Solomon group and 9% in the standard group. 
Our study shows that, although the Solomon laser technique strongly reduces the 
risk of short-term complications (TAPS and recurrent TTTS),1 the effect on the long-
term neurodevelopmental outcome appears negligible. Several explanations can be 
considered to explain the lack of difference between the two treatment groups in this 
follow-up study. First, the Solomon trial was primarily designed and powered to detect 
a difference in short-term outcome. Follow-up was only available from two of the five 
centers participating in the Solomon trial and results cannot be generalized to the total 
trial population. A second explanation for the lack of difference could be that timely 
detection and adequate management and treatment (intrauterine transfusion, laser 
surgery re-intervention) in patients with short-term complications (TAPS or recurrent 
TTTS) in the standard group reduced the risk for long-term impairment. In addition, 
the lack of difference in Bayley scores could also be related to early interventions for 
children with developmental impairment. However, no difference in the rate of early 
interventions including physical therapy (39% vs 41%, P = .89), speech-language 
therapy (9% vs 12%, P = .65) and psychological interventions (4% vs 7%, P = .54), was 
found between the Solomon and standard group, respectively. 
The primary outcome of our follow-up study was a composite of survival without NDI 
to exclude bias related to a positive correlation between high (fetal or neonatal) death 
rate and selective feticide or withdrawal of intensive care treatment in cases with 
severe cerebral injury. In the Eurofoetus trial, laser surgery was shown to be superior 
to amnioreduction in TTTS, but the long-term outcome was similar between the two 
treatment groups.14;15 However, the long-term evaluation did not take into account 
the fact that in a relatively large number of live-born neonates in the amnioreduction 
group, intensive care treatment was withdrawn due to severe cerebral injury. Had these 
children survived, the differences in long-term neurodevelopmental outcome between 
both groups could have been much more evident. In our study, cord occlusion was 
performed in one case with severe cerebral injury following the Solomon technique 
(n=1). In the standard group, cord occlusion was performed in one case and intensive 
care treatment was withdrawn from three neonates due to severe cerebral injury (n=4). 
Had these neonates with severe cerebral injury survived, long-term impairment would 
have increased from 11% (12/107) to 12% (13/107) in the Solomon group and from 
9% (10/109) to 13% (14/109) in the standard group.
Overall, NDI was detected in 10% (22/206) of children randomized for the Solomon 
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to 22%.15-20 Care must be taken when comparing the results of these studies, as this 
large discrepancy is due to different methodology, differences in (neonatal) death rates, 
considerable heterogeneity within the small case series and lack of uniform outcome 
criteria. In this study, NDI was clearly defined as the presence of cerebral palsy (GMFCS 
II-V), a Bayley-III cognitive and/or motor score below 85, bilateral blindness and/or 
deafness. We used a cut-off point of 85 (test scores < 1 SD) instead of 70 (test scores < 2 
SD) since studies report a significant underestimation of developmental delay using the 
Bayley-III compared to Bayley-II assessment, with differences up to 18 points in favor 
of Bayley-III assessment.21;22 In our study, severe NDI, defined as Bayley-III scores < 70, 
was detected in 3% in the Solomon group and in 6% in the standard group. We believe 
that these percentages underestimate the real incidence of impairment in the children 
treated with fetoscopic laser surgery for TTTS.
Although TTTS remains one of the most lethal conditions in perinatal medicine, 
the outcome (in terms of its most important parameter, survival without neuro-
developmental impairment) has significantly improved over time.23 In our study, the 
majority of children (90%) had no neurodevelopmental impairment at 2 years of age. 
Several factors may explain this improvement, including advancements in fetal and 
prenatal care strategies (monitoring and management options), increased awareness 
and knowledge of potential (treatable) complications in TTTS and learning curve effect 
associated with a highly technical procedure such as fetoscopic laser surgery.23
Our findings may be limited by several factors including the relatively small sample size 
and power, as discussed above. Another potential limitation is related to the limited 
predictive value of the Bayley scales for future cognitive and motor performance. 
An average Bayley-III score at age 2 years does not imply within average school 
performance at age twelve and vice versa. In addition, some developmental problems 
such as attention deficit- or speech-language problems become more apparent at a later 
age, especially at school age. Therefore follow-up until at least school age, preferably at 
age 2, 5 and 8 years, is highly recommended. We intend to perform long-term follow-up 
in all TTTS survivors at 5 and 8 years.
To date, this is the largest follow-up study of a randomized controlled trial in fetal 
therapy. We were able to follow-up 94% of survivors with individual and detailed 
follow-up assessments using standardized tests to evaluate neurological, cognitive and 
motor development. Follow-up assessments were performed by trained psychologists 
and pediatricians unaware of the treatment allocations minimizing potential bias. 
In conclusion, the results of the Solomon trial imply that the use of the Solomon 
technique reduces the risk of complications associated with TAPS and recurrent TTTS 
in monochorionic pregnancies treated with laser surgery for TTTS.1 The Solomon 
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of short-term complications and absence of increased adverse long-term effects, we 
recommend the use of the Solomon technique in the treatment of TTTS.
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Abstract
Objective
To evaluate the long-term neurodevelopmental outcome in children who developed twin 
anemia-polycythemia (TAPS) after laser surgery for twin-twin transfusion syndrome 
(TTTS). 
Methods
Neurological, motor and cognitive development was assessed in a consecutive cohort 
of TTTS survivors treated with laser between 2004 and 2011 and complicated by post-
laser TAPS. Primary outcome was neurodevelopmental impairment (NDI), a composite 
outcome including any of the following: cerebral palsy, bilateral deafness, blindness, 
severe motor and/or cognitive developmental delay (< -2 SD). A risk analysis on 
cognitive outcome was performed.
Results
During the study period, 33/306 (11%) monochorionic twin pairs developed TAPS after 
laser surgery for TTTS. Survival was 53/66 (80%). Long-term outcome was assessed in 
47/53 (89%) children. The incidence of NDI was 4/47 (9%), occurring in one donor 
(1/20, 5%) and three recipients (3/27, 11%) (P = .63). Risk factors for low cognitive 
scores are low gestational age at birth (P = 0.02) and low birth weight (P < = 0.01). 
Lowest cognitive scores were detected in the subgroup of TAPS survivors treated with 
intrauterine transfusion (median score: 82.5).
Conclusions
Neurodevelopmental impairment and cognitive delay was found in almost 1 in 5 children 
surviving post-laser TAPS. Better treatment and ideally prevention of this complication 
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Introduction
Twin anemia-polycythemia sequence (TAPS) is a chronic form of feto-fetal transfusion 
in monochorionic (MC) twins through small anastomoses at the placental surface.1 TAPS 
is characterized by large inter-twin hemoglobin (Hb) difference without signs of twin 
oligo-polyhydramnios sequence (TOPS). TAPS may occur spontaneous (spontaneous 
TAPS) or after twin-twin transfusion syndrome (TTTS) treated with laser (post-laser 
TAPS). The incidence varies between 1-5% in spontaneous TAPS and 1-16% in post-
laser TAPS.2-7 Antenatal diagnosis is based on Doppler ultrasound abnormalities 
showing an increased peak systolic velocity in the middle cerebral artery in the 
donor twin, suggestive of fetal anemia, and decreased velocities in the recipient twin, 
suggestive of polycythemia, without concomitant signs of TOPS. Postnatal diagnosis is 
based on inter-twin Hb difference ≥ 8.0 g/dL and at least one of the following criteria: 
reticulocyte count ratio ≥ 1.7 or small anastomoses (< 1 mm) at the placental surface. 
Perinatal mortality and morbidity rates in TAPS are not well known, and outcome may 
vary from two healthy neonates to severe neonatal morbidity, including severe cerebral 
injury, or neonatal death.2;7;8 
In TTTS treated with laser surgery, the risk of adverse long-term neurodevelopmental 
outcome is increased, ranging from 6% to 18%.9-11 Whether TTTS survivors who 
developed TAPS after laser surgery are also at increased risk of adverse long-term 
outcome is not known. The aim this study was to evaluate long-term neurodevelopmental 
outcome in post-laser TAPS survivors and to compare outcome between donors and 
recipients. 
Methods
All consecutive TTTS pregnancies treated with fetoscopic laser surgery at our center 
between 2004 and 2011 were eligible for this study. The Leiden University Medical 
Center is the national referral center for fetal therapy in the Netherlands, including 
laser surgery for TTTS. All TTTS cases complicated with TAPS after laser surgery (post-
laser TAPS), were included in this follow-up study. The study was approved by the 
Institutional review board at the Leiden University Medical Center and all parents gave 
written informed consent for their children. 
TAPS was identified using previously published criteria and staging system.2 In brief, 
antenatal TAPS was diagnosed when Doppler ultrasound examination revealed an 
increase in peak systolic velocity in the middle cerebral artery of > 1.5 Multiples of 
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in the co-twin, in the absence of TOPS. Postnatal TAPS diagnosis is based on inter-
twin hemoglobin (Hb) difference ≥ 8.0 g/dL and at least one of the following criteria: 
reticulocyte count ratio > 1.7 or small anastomoses (< 1 mm) at the placental surface.2 
Antenatal and postnatal TAPS is staged from stage 1 to 5 according to a previously 
published staging system.2 
The following antenatal and neonatal data were recorded: gestational age at laser 
treatment, Quintero stage of TTTS, fetal demise, age at detection of antenatal or 
postnatal TAPS, antenatal or postnatal TAPS stage, TAPS management in antenatally 
detected TAPS cases (expectant management, intrauterine transfusion, laser and cord 
coagulation), gestational age at birth, birth weight, severe neonatal morbidity including 
severe cerebral injury and neonatal death. Severe neonatal morbidity was defined as 
the presence of at least one of the following: respiratory distress syndrome (requiring 
medical ventilation and surfactant), patent ductus arteriosus (requiring medical therapy 
or surgical closure), necrotizing enterocolitis ≥ grade 2, retinopathy of prematurity ≥ 
stage III or severe cerebral injury. Severe cerebral injury was defined as at least one of 
the following: intraventricular hemorrhage (IVH) ≥ grade III,12 cystic periventricular 
leukomalacia (cPVL) ≥ grade II,13 ventricular dilatation ≥ 97th percentile,14 porencephalic 
cysts, arterial or venous infarction detected on cerebral imaging. 
A follow-up visit was performed at a minimum age of 24 months and included a 
neurologic examination and an assessment of cognitive and motor development using 
the Dutch version of the Bayley Scales of Infant and Toddler Development (BSID). Before 
2006, the second edition of the BSID was used (BSID-II), while the third edition (BSID-
III) was used from 2006 onwards.15;16 Children at the age ≥ 3 years were tested with the 
Wechsler Preschool and Primary Scale of Intelligence scale third edition (WPPSI-III).17 
These three tests (BSID-II, BSID-III and WPPSI-III) provide cognitive scores that follow 
a normal distribution with a mean of 100 and a standard deviation (SD) of 15. BSID-II 
and BSID-III also provide motor development scores. When each separate score was 
below 70, > 2 SD below the mean, this was indicative of a severe delay in either cognitive 
or motor development. Cerebral palsy (CP) was defined according to the European CP 
Network and classified as diplegia, hemiplegia, quadriplegia, dyskinetic, or mixed.18 
The primary outcome measure was a composite outcome termed neurodevelopmental 
impairment (NDI), including at least one of the following: CP, cognitive development 
score of less than 70 (< - 2 SD), motor development score of less than 70 (< - 2 SD), 
bilateral blindness, or bilateral deafness requiring amplification. The primary aim of 
our study was to assess the incidence of NDI in post-laser TAPS cases and to compare 
outcome between donors and recipients. Secondary outcome was estimation of risk 
factors associated with lower cognitive scores including gestational age at birth, birth 
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TAPS cases and severe neonatal morbidity (including severe cerebral injury). 
Data are reported as means with standard deviation (SD) or as medians with range, 
as appropriate. Statistical analysis was performed using the t-test and Mann-Whitney 
test for continuous variables. Chi-square test and Fisher’s exact test were used for 
categorical variables, as appropriate. Analysis for risk factors possibly contributing to 
cognitive outcome was conducted using univariate and multivariate regression methods. 
The potential risk factors for cognitive outcome were studied in a univariate logistic 
regression model. The multivariate logistic regression model included all variables 
that showed significant association in the univariate analysis. Analyses were conducted 
using the Generalized Estimated Equation (GEE) module to account for the effect that 
observations within twins are not independent. Results are expressed as P-values. A 
P-value of less than 0.05 was considered significant. All statistical data were analyzed 
using SPSS version 20.0 (IBM, Armonk, NY, USA).
Results
A total of 306 MC twin pregnancies were treated with fetoscopic laser surgery for TTTS 
between 2004 and 2011. A total of 33/306 (11%) of the MC twin pairs were diagnosed 
with TAPS after laser surgery for TTTS. Fetal death occurred in 7/66 (11%) cases, 
neonatal death in five cases (5/59, 8%) and in one case (1/59, 2%) sudden (unexplained) 
infant death occurred at the age of two months. Overall survival rate in the post-laser 
TAPS group was 53/66 (80%). Six children (6/53, 11%) were lost to follow-up due to 
declined consent or loss of contact information. Follow-up assessments were performed 
in 47/53 (89%) children. Baseline characteristics of the TAPS survivors included for 
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Table 1 Baseline characteristics of post-laser TAPS survivors for follow-up. 
N=47 children
TAPS donor 20 (43)
Gestational age at laser (weeks) 21 (15-27)
Quintero stage 2 (1-4)
























Gestational age at birth (weeks) 32 (26-41)
Birth weight (grams) 1635 (750-3667)
Female 22 (47)
Severe cerebral injuryc 2/46 (4)
Severe neonatal morbidityd 18/47 (38)
TAPS, twin-anemia polycythemia sequence; N, number. Data are presented as median (range) or 
n (%). 
aTAPS stage in the antenatal detected TAPS cases (n = 28)
bTAPS stage in de postnatal detected TAPS cases (n = 19)
cDenominator is the number of children who underwent cranial ultrasound.
dSevere neonatal morbidity was defined as any of the following characteristics: respiratory 
distress syndrome, patent ductus arteriosus, necrotizing enterocolitis≥ stage II or severe cerebral 
injury.
TAPS was detected antenatally in 28/47 (60%) cases and postnatally in the remaining 
19/47 (40%) cases. Median gestational age at birth in TAPS cases detected antenatally 
and postnatally was 32 (26-37) and 32.5 (26-41) completed weeks, respectively 
(P = 0.62). Of the 28 antenatally detected post-laser TAPS cases, 17 were managed 
expectantly, eight underwent IUT, two were treated with re-laser surgical intervention 
and in one case cord coagulation of the co-twin was performed. Intrauterine treatment 
was offered in all cases of TAPS stage 3 and 4. In TAPS stage 1 or 2, intrauterine treatment 
was offered only in case TAPS was rapidly progressing (within a couple of days), or 
when the fetus showed other signs of severe anemia not meeting criteria for stage 3, 
such as increasing heart size or prehydropic signs. In case of treatment, laser surgery 
was the first choice of treatment if this appeared technically feasible. Laser surgery in 
TAPS can be more challenging due to the absence of the oligo polyhydramnios sequence. 
Intrauterine transfusion was chosen in case laser was not perceived feasible. Cord 
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the ex TTTS recipient (new TAPS donor)19. Median gestational age at birth of the cases 
treated intrauterine (IUT, laser or cord coagulation) was 29 (26-33) weeks compared to 
33 (27-41) weeks in the cases treated expectantly (P = 0.07). 
Of the 47 children neonatal cranial ultrasound was performed in all but one case (46/47, 
98%). This child was born at term age in the referral hospital where cranial ultrasound 
was not part of standard procedure. Two children were diagnosed with severe cerebral 
injury. In one case, the TAPS donor (former TTTS recipient) was diagnosed with cystic 
PVL grade III. In the other case, a TAPS recipient (former TTTS recipient), cerebral 
imaging showed venous infarction and IVH grade II. 
Long-term neurodevelopmental outcome in the 47 children was assessed at a median 
age of 28 (24-96) months. Twenty-nine Children completed were assessed with the 
BSID tests using either the second edition (n = 9) or third edition (n=20). In three 
(3/29, 10%) children motor development could not be assessed due to child’s refusal. 
16 Children completed WPPSI-III. One twin pair was already tested elsewhere, due to 
behavioral difficulties, with the Snijders Oomen Non-Verbal Intelligence Scale (SON). 
Previous assessment with the WPPSI failed and the SON was used to obtain a reliable 
view of their capacities. One twin had mild-to-moderate cognitive delay and the co-twin 
scored within the normal range of intelligence.
The incidence of NDI in the studied cohort was 4/47 (9%), occurring in one donor 
(1/20, 5%) and three recipients (3/27, 11%) (P = 0.63). CP was diagnosed in one (1/47, 
2%) case. Severe cognitive delay was detected in two (2/47, 4%) children and severe 
motor delay, in one (1/47, 2%) child. The long-term outcome is reported in Table 2. 
Patient characteristics of the 4 children with NDI are presented in Table 3. 








Cerebral palsy 1/47 (2) 1/20 (5) 0/27 (0) 0.43
Cognitive score 95.3 ± 12.5 94.5 ± 11.3 95.8 ± 13.4 0.74
Cognitive development < -2 SD 2/47 (4) 0/20 (0) 2/27 (7) 0.50
Cognitive development < -1 SD 8/47 (17) 3/20 (15) 5/27 (19) 1.0
Motor scorea 93.9 ± 12.4 93.2 ± 7.8 94.4 ± 15.3 0.81
Motor development < -2 SDa 1/26 (4) 0/11 (0) 1/15 (7) 1.0
Motor development < -1 SDa 5/26 (19) 1/11 (9) 4/15 (27) 0.36
Bilateral blindness/deafness 0/47 (0) 0/20 (0) 0/27 (0) -
Neurodevelopmental impairmentb 4/47 (9) 1/20 (5) 3/27 (11) 0.63
SD, standard deviation; Data are expressed as n (%) or mean ± SD.
aTotal number of children with assessment of motor development with Bayley scales, 11 donors 
and 15 recipients.
bNeurodevelopmental impairment included any of the following: Cerebral Palsy, cognitive 
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We performed a subgroup analysis on cognitive outcome of the antenatal TAPS cases 
according to the prenatal management (Table 4). We found that the subgroup of TAPS 
survivors treated with intrauterine transfusions had the lowest mean cognitive score 
compared to the other subgroups (Table 4). 
We also performed univariate analysis of potential risk factors for cognitive outcome in 
the whole cohort. Risk factors for low cognitive scores are low gestational age at birth (P 
= 0.02) and low birth weight (P < 0.01). Since these two risk factors are highly correlated 
(r = 0.87, P < 0.01), no multivariate analysis was performed. In the antenatal TAPS cases 
(n = 28), intrauterine transfusion was a significant risk factor for low cognitive scores 
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Discussion
This is the first study evaluating long-term neurodevelopmental outcome in TTTS 
survivors who developed TAPS after laser surgery. NDI was detected in 9%, with no 
difference between donors and recipients. Our results suggest that impairment in post-
laser TAPS cases is frequent but is within the range of the incidence of NDI reported 
in case series of TTTS treated with laser (range 6% to 18%).9-11 Unfortunately due to 
logistic reasons we did not have the opportunity to perform follow-up in the years 2006-
2007. This is the reason why our cohort could not be compared with the whole cohort 
of TTTS treated with laser. Larger studies, possibly with a case-control study design, 
are needed to determine if post-laser TAPS leads to an increased risk of impairment 
compared to uncomplicated TTTS cases. 
The incidence of CP of 2% in our series was similar to previously published TTTS 
follow-up studies, ranging from 3 to 12%.9-11 In the general population, CP occurs 
in approximately 6% at 28 to 31 weeks, 0.7% at 32 to 36 weeks, and 0.1% in term 
infants.20 Severe cognitive delay (4%) and severe motor delay (2%) was in the lower 
range compared to outcomes after TTTS in general (0% to 25%).11 According to the 
normal distribution of intelligence, severe cognitive delay occurs at a 2.3% rate in the 
general population.
Cerebral injury and neurologic impairment in TAPS survivors can theoretically be 
due to several factors, including among others, hematologic disorders (anemia and 
polycythemia, leading to impaired cerebral oxygenation), morbidity related to TTTS, 
preterm delivery, or the type of antenatal TAPS treatment. In a univariate risk factor 
analysis on cognitive scores, we found that low gestational age and low birth weight 
were important risk factors for cognitive delay. Low gestational age at birth and 
low birth weight are known to be independently associated with increased risk for 
severe cerebral lesions21 and impaired neurodevelopmental outcome.22 In a subgroup 
analysis on antenatal detected/managed TAPS cases, we found that the TAPS subgroup 
treated with IUT had the lowest median cognitive score (82.5) compared to the other 
subgroups. A possible explanation for the low cognitive scores could be that these cases 
were born at a lower gestational age at birth of 29 weeks (IQR 27.5-33) due to induced 
labor or planned caesarean for severe anemia or polycythemia. IUT may temporarily 
improve the condition of the donor, allowing prolongation of the pregnancy. However, 
IUT may also worsen the polycythemia in the recipient twin and lead to possible 
severe complications such as severe cerebral injury.8 Additionally IUT is a symptomatic 
treatment, not a causal treatment for TAPS. 
One of the limitations of our study is the use of different developmental tests, that is 
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a significant underestimation of developmental delay using the BSID-III compared 
to BSID-II assessment.23;24 Of the 3 children with severe developmental delay, 2 were 
tested with BSID-III and one with BSID-II. Children at the age ≥ 3 years were tested 
with WPPSI. With advanced age a more reliable view of capacities can be obtained. 
Two children were already tested elsewhere with the Snijders Oomen Non-Verbal 
Intelligence Scale due to failure of previous WPPSI assessment. The most important 
limitation of this study was the relatively small sample size. Although this is the largest 
study to date reporting on neurodevelopmental outcome in post-laser TAPS our data 
should be interpreted with care. 
Since post-laser TAPS is caused by small residual anastomoses that might have been 
missed at initial laser treatment for TTTS, it is of high importance to reduce the amount 
of these residual anastomoses. A recent published randomized controlled trial showed 
a significant reduction of the incidence of post-laser TAPS without any identifiable 
adverse outcomes.25 To reduce the amount of residual anastomoses and the incidence 
of TAPS, we advise the use of the Solomon technique, where the whole vascular equator 
is coagulated, for laser treatment in TTTS. 
In conclusion, this is the first study reporting on neurodevelopmental outcome in post-
laser TAPS. We report a 9% incidence of NDI and 17% incidence of mild-to-moderate 
cognitive delay, without difference between donors and recipients. Risk factors for 
lower cognitive score are lower gestational age at birth and birth weight. Antenatal 
TAPS management consisting of IUT was a risk factor for lower cognitive scores. Larger 
studies are needed to reliably investigate long-term neurodevelopmental outcome and 
evaluate risk factors for adverse outcome. Since TAPS is a rare disease, collaboration 
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Abstract
Objective 
To estimate incidence and risk factors of severe cerebral injury in survivors from 
monochorionic pregnancies with selective intrauterine growth restriction (sIUGR) 
and/or birth weight discordance (BWD).
Methods 
Electronic databases were searched for studies describing perinatal and neurologic 
outcome in monochorionic twins with sIUGR and/or BWD. Exclusion criteria were 
twin–twin transfusion syndrome, twin anemia–polycythemia sequence, selective 
feticide or laser treatment.
Results
Eleven articles were included in the systematic review. Analysis was hampered by 
different methodology and definitions of cerebral injury. The incidence of severe 
cerebral injury varied from 0% to 33% (average 8%, 52/661), and was higher in studies 
including single intrauterine demise [odds ratio (OR) 2.92; 95% confidence interval 
(CI) 0.89- 9.56] and studies with a median gestational age at birth of ≤32 weeks (OR 
1.56; 95% CI 1.06–2.27). The risk of severe cerebral injury was higher in pregnancies 
with abnormal umbilical artery Doppler (13.5% vs 2.5%; OR 7.69; 95% CI 2.56–25.00) 
and in larger twins (9% vs 5%; OR 1.93; 95% CI 0.95–3.92).
Conclusion
The incidence of severe cerebral injury in monochorionic twins with sIUGR and/or 
BWD is approximately 8% and is associated with abnormal umbilical artery Doppler, 
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Introduction
Monochorionic (MC) twins are at increased risk of several complications including 
twin–twin transfusion syndrome (TTTS), twin anemia–polycythemia sequence (TAPS), 
selective intrauterine growth restriction (sIUGR) and/or birthweight discordance 
(BWD). Although most studies in the last decades focused primarily on TTTS, the 
attention is now gradually shifting to other complications, in particular MC twins with 
sIUGR and BWD. The incidence of sIUGR is reported to be higher than of TTTS and may 
occur in up to 25% of MC pregnancies.1–3 In contrast with TTTS, the optimal management 
in MC twins with sIUGR is not clear, and international consensus on the best treatment 
strategy is lacking. Treatment options include expectant management, elective preterm 
birth, fetoscopic laser coagulation of the vascular anastomoses and selective feticide.2;3 
The main cause of sIUGR and BWD is unequal placenta sharing. The growth restricted 
fetus often has a small placental share and a velamentous cord insertion. The clinical 
outcome however also depends on the presence of vascular anastomoses in the MC 
placenta.4–7 Superficial arterio-arterial or veno-venous anastomoses are known to allow 
bidirectional blood-flow with low resistance related to their large diameter.8 Because 
of these anastomoses, intrauterine fetal death (IUFD) of the growth-restricted twin 
may cause concomitant death or neurological damage in the normal co-twin because 
of acute exsanguination. In addition, even when both twins survive, the risk of adverse 
outcome appears to be increased.3;4;9 However, the short-term and long-term outcomes 
in MC twins with sIUGR remain unclear, and conflicting results on the risk of cerebral 
injury have been reported.1–3;6;9 We performed a systematic review, focusing on the 
neurological outcome in MC pregnancies with sIUGR and/or BWD following a natural 




To retrieve studies and articles for this review, online electronic databases were searched 
from inception until July 2012, with aid of a librarian from the Walaeus Medical Library 
of the Leiden University Medical Center. The databases included PubMed, Embase, Web 
of Science, COCHRANE, CINAHL, Academic Search Premier, ScienceDirect and MEDLINE. 
The following MESH terms or keywords were used with various spelling options: MC, 
sIUGR, BWD, fetal weight discordance and fetal growth retardation, intrauterine growth 
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lists of the primary articles was carried out to identify relevant articles not captured by 
the electronic searches. The search was limited to English language articles.
Study selection
The following inclusion criteria were applied: MC twins with sIUGR and/or BWD and 
assessment of perinatal outcome, including the presence of severe cerebral injury in 
live born infants on the basis of postnatal cranial ultrasound. sIUGR was defined as an 
estimated fetal weight (EFW) in one fetus <10th percentile.1;2;6;10–12 BWD was described 
as a difference in birth weight varying from ≥18% to ≥25%. The difference in birth 
weight was calculated as the difference between the fetal weight of the larger and the 
smaller twin, divided by the fetal weight of the larger twin ((in formula: body weight 
of larger twin - body weight of smaller twin)/body weight of larger twin × 100%).3;13–17 
Severe cerebral injury was defined as the presence of intraventricular hemorrhage (IVH) 
grades III and IV, periventricular leucomalacia (PVL) grade II or more, porencephalic 
cysts and/or ventricular dilatation (width of one or both lateral ventricles exceeded the 
97th percentile).1;3;7;10;18
We excluded MC twin pregnancies with TTTS or TAPS and MC twin pregnancies treated 
with selective feticide or laser treatment. Further exclusion criteria for this systematic 
review were as follows: case reports, reviews, conference abstracts, book chapters and 
guidelines. When multiple articles described (partly) the same cases, the articles with 
the largest study population were included. In case of lack of detailed information, no 
attempt was made to contact principal investigators to request details regarding their 
raw data.
The primary outcome was the incidence of severe cerebral injury. When the severity of 
the cerebral injury could not be determined in all cases (as a result of lack of detailed 
information), the lowest and highest limits of the incidence of severe cerebral injury are 
reported. When gestational age (GA) at birth and birth weight were reported separately 
for different subgroups, a weighted mean was calculated.
The following potential predictors for severe cerebral injury were studied: GA at birth 
(per study cohort), study cohorts with single IUFD (compared with cohorts without 
IUFD), abnormal umbilical artery (UA) Doppler measurements (compared with 
normal Doppler) and larger twin (compared with smaller twin). For the risk analysis, 
we calculated a mean incidence instead of a range. Type I sIUGR was classified as UA 
Doppler with positive end-diastolic flow, type II was defined as persistent absent or 
reversed end-diastolic flow (AREDF), and type III as intermittent AREDF. For this study, 
we divided the three types in two groups: normal UA Doppler (type I) and abnormal UA 
Doppler (types II and III). The results of the mixed effects logistic regression models 
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was considered to indicate statistical significance. Analysis was performed using SPSS 
20 (SPSS Inc., Chicago, IL).
For this literature review, no ethical committee approval was sought.
Results
We obtained 242 articles with the online electronic database search of which 13 articles 
met the inclusion criteria. As a result of overlapping study populations, three articles 
had to be excluded.1;5;13 Manual search of the reference lists provided one more relevant 
article, resulting in a total of 11 included articles. A flowchart of the derivation of the 
included studies is shown in Figure 1, and characteristics of the study designs are 
reported in Table 1. The number of infants included in the studies ranged from 24 to 
108. Inclusion criteria and definitions of sIUGR and/or BWD and cerebral injury varied 
considerably between the studies. The protocol for timing and frequency of cranial 
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Potential relevant articles 
from database search  
N=242 
Articles evaluated on full 
manuscript 
N=59 
Included articles from 
electronic database search 
N=10 
Articles included in 
systematic review 
N=11 
Included articles from 
manual search of 
reference list 
N=1 
Articles excluded  
N=49 
Other population: n=12 
Other outcome: n=20 
No original (raw) data: n=14 
Overlapping study population: n=3 
Articles excluded (did not 
meet selection criteria) 
N=183 
Figure 1 Flowchart showing the derivation of the included studies.
Detailed information on the incidence and type of severe cerebral injury in the 11 
studies is shown in Table 2. The incidence of severe cerebral injury varied from 0% 
up to 33% between the studies. The lowest and highest limits of the mean incidence of 
severe cerebral injury were 7% (45/661) and 9% (57/661), respectively, depending on 
the interpretation of the severity of the cerebral injury.
The first study, by Quintero et al.2;3 reported the outcome in 17 MC twin pregnancies 
with sIUGR (EFW <10th percentile in one twin), including eight pregnancies with IUFD 
(six single and two double IUFD). The incidence of severe cerebral injury in live-born 
infants was 4–13% (1–3/24). Two of the three cases with cerebral injury could not be 
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In 2004, Gratacos et al.9 published a prospective study of 84 MC twin pregnancies with 
IUGR in one fetus (EFW <5th percentile) together with a BWD of ≥25%. Six pregnancies 
with IUFD (three single and three double IUFDs) were included in the study, all with 
intermittent A/REDV. The median GA at birth in this group was low, 30.7 weeks. The 
incidence of severe cerebral injury was high, ranging from 12-17% (9-13/75). Four 
cases with IVH were not graded and could not be classified as mild or severe injury. 
To calculate this incidence, we added up the cases with IVH with the cases with 
parenchymal brain damage. No overlap between the cases was reported. The incidence 
of severe brain damage was particularly increased in infants with intermittent A/REDV 
and in larger twins.
Adegbite et al.19 considered twins discordant when (1) interpair difference in birth 
weight was ≥20% with normal amniotic fluid in the larger twin and (2) an abdominal 
circumference of ≤5th percentile with an abnormal UA Doppler in the smaller twin. 
They included a small population of 30 infants without IUFD that were prematurely 
delivered between 24 and 34 weeks’ gestation. The incidence of severe cerebral injury 
in this group was high, 27–33% (8–10/30). In two cases with IVH, it was not possible to 
determine whether the injury was mild or severe.
In 2005, Leduc et al.16 reported on 25 MC pregnancies complicated with a BWD of ≥25% 
in a prospective study. Pregnancies with IUFD were excluded. The incidence of IVH 
grade III or IV was 4% (2/50). No information was reported on the difference between 
normal versus abnormal UA Doppler and larger versus smaller twins.
Cordero et al.15 described a group of 54 MC infants with BWD of ≥20%. Cerebral 
ultrasounds were performed in 48/54 (89%) infants, and the incidence of severe 
cerebral injury was reported to range from 2% to 4% (1-2/48). PVL was not graded; 
therefore, it was not possible to classify one case as mild or severe. No information 
about the incidence related to UA Doppler and larger versus smaller twin was reported. 
There were no pregnancies with IUFD in this group. Alam Machado et al.17 reported 
the neurologic complications (defined asmulticystic leuko-encephalomalacia) in 12 
MC twin pregnancies with a BWD of ≥20%. Pregnancies with IUFD were excluded. The 
incidence of neurologic complications was 8% (2/24). The difference between normal 
versus abnormal UA Doppler and larger versus smaller twins was not reported.
In a prospective study, Chang et al.20 reported in 27 MC pregnancies with sIUGR (defined 
as EFW <10th percentile in one twin) resulting in two live born infants on the occurrence 
of severe cerebral injury. Of these 54 infants, only one (2%) child was diagnosed with 
severe cerebral injury. This was an appropriate for gestational age twin delivered at 
27+5 weeks with cystic PVL and ventriculomegaly, showing signs of cerebral palsy and 
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Ishii et al.6 described the outcome in a large group of 63 MC twin pregnancies with sIUGR 
(defined as EFW <10th percentile in one twin). There were 18 cases of IUFD, which 
left 108 surviving children. Besides IVH grades III and IV and cystic PVL, the definition 
of neurologic morbidity also included blindness and/or deafness and was recorded in 
an observational period up to six months of age. The overall incidence of neurological 
morbidity was 15% (16/108). This occurred mainly in the group with abnormal UA 
Doppler findings. The incidence was similar between larger and smaller twins.
In a prospective study, Weisz et al.7 reported the outcome in 37 MC twin pregnancies 
with sIUGR (defined as an EFW <10th percentile in one twin and a co-twin with an 
EFW>10th percentile). In 74 infants with sIUGR, the incidence of severe cerebral injury 
was 5% (4/74). All cases with severe cerebral injury occurred in pregnancies with an 
abnormal UA Doppler. The incidence of severe cerebral injury was higher in larger twins 
compared with smaller twins. There were no pregnancies with IUFD.
Breathnach et al.14 established a threshold for intertwin BWD of ≥18% in a prospective 
study. They included pregnancies with two live fetuses and intact membranes at 24 
weeks of gestation. In 82 discordant MC infants, the mean GA at birth was relatively 
high with almost 35 weeks. The range of severe cerebral injury was 0-4% (0-3/82). It 
was not possible to classify the injury as mild or severe because grades of IVH and PVL 
were not reported. The incidence of cerebral injury was similar between larger and 
smaller twins.
Recently, our group reported the outcome in 47 MC twin pregnancies with a BWD≥25%.3 
The majority of these pregnancies (94%, 44/47) were also classified as sIUGR (EFW<10th 
percentile) and staged on the basis of UA Doppler. Only pregnancies resulting in two live 
born twins were included. Cranial ultrasound scans were performed in 92/94 (98%). 
Cranial ultrasounds were not performed in two cases because of quick discharge from 
the hospital in good condition. The overall incidence of severe cerebral injury was 1% 
(1/92) and was similar between larger and smaller twins. The case with severe cerebral 
injury was the larger twin from an MC pregnancy with sIUGR type III born at a GA of 
28+6 weeks and diagnosed with PVL grade III at 2 weeks of age.
Risk analysis
Table 3 shows detailed information on the risk factors in the included studies. The 
median GA at birth in the reported cohorts ranged from 30.6 to 34.9 weeks, indicating 
that the timing of delivery varied substantially between the studies. Some studies 
included the surviving twin from sIUGR pregnancies with single IUFD, whereas other 
studies had no cases with IUFD or explicitly excluded these cases. The results of the risk 
analysis for potential risk factors (IUFD, abnormal UA Doppler, larger twin and low GA 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































152  |  Chapter 9
Table 4: Univariate analysis of potential risk factors for severe cerebral injury in MC twins with 
sIUGR and/or BWD
 OR (95% CI) P-value
Studies with IUFD versus studies without IUFD 2.92 (0.89-9.56) .076
Studies with median GA at birth of ≤32 wks versus >32 wks 1.56 (1.06-2.27) .022
Abnormal versus normal UA Dopplers 7.69 (2.56-25.00) <.001
Larger versus smaller twins 1.93 (0.95-3.92) .070
OD, odds ratio; CI, confidence interval; IUFD, intrauterine fetal death; GA, gestational age; UA, 
umbilical artery.
Intrauterine fetal demise:  Of the 11 studies included in our systematic review, 
three also included MC pregnancies with IUFD. The 
incidence of severe cerebral injury in these three 
studies was higher compared to studies without IUFD 
(OR 2.92; 95% CI 0.89–9.56).
Abnormal UA Doppler In 5 of the 11 studies, UA Doppler measurements
measurements: were reported in relation to the risk of cerebral 
injury. Risk analysis showed a significantly increased 
incidence of cerebral injury in the group with 
abnormal UA Doppler compared with the group with 
normal UA Doppler measurements (OR 7.69; 95% CI 
2.56–25.00).
Larger versus In 7 of the 11 studies, the risk of cerebral injury was 
smaller twin: reported in relation to the larger or the smaller twin. 
Risk analysis showed a slightly increased incidence of 
cerebral injury in larger twins compared with smaller 
twins (OR 1.93; 95% CI 0.95–3.92).
Low GA at birth:  We studied the association between the median GA 
at birth reported for each cohort and the incidence 
of severe cerebral injury. In Table 4, this relation is 
shown for studies with a median GA at birth of ≤32 
weeks versus >32weeks of gestation. The risk of 
cerebral injury was significantly increased in studies 
with a lower GA at birth (OR 1.56, 95% CI 1.06–2.27). 
Furthermore, we performed a logistic regression 
analysis where we included random effects to account 
for heterogeneity between studies. We found that the 
log odds for cerebral injury decreased by 0.44 (P = 












































Figure 2 Incidence of severe cerebral injury in relation with median gestational age at birth in 11 studies of 
MC twins with sIUGR and/or BWD.   
 




This systematic review shows that the incidence of severe cerebral injury in MC twins 
with sIUGR and/or BWD varies greatly between the studies, from 0% up to 33%, with 
an average of approximately 7-9% (45-57/661). The incidence appears to be similar 
compared with the risk of severe cerebral injury reported in dichorionic twins (8%) 
and lower compared with MC twins having TTTS (range: 9% to 38%).21–23 
In addition, we found that the highest incidence of severe cerebral injury was reported 
in cohorts with lower median GA at birth and in studies including cases with IUFD. 
Furthermore, the risk for cerebral injury appears to be higher in pregnancies with 
abnormal UA Doppler findings. These three risk factors are likely to be 
Figure 2 Incidence of severe cerebral injury in relation with median gestational age at birth in 11 
studies of MC twins with sIUGR and/or BWD. 
Logistic regression of severe cerebral injury and gestational age at birth (P = 0.02). 
The circles reflect study size.
Discussion
This systema ic eview shows th t the incidence of severe cerebral injury in MC twins 
with sIUGR and/or BWD varies greatly between the studies, from 0% up to 33%, with 
an average of approximately 7-9% (45-57/661). The incidence appears to be similar 
compared with the isk of seve e cerebral injury reported in dic orionic twins (8%) 
and lower compared with MC twins having TTTS (range: 9% to 38%).21–23
In addition, we found that the highest incidence of severe cerebral injury was reported 
in cohorts with lower median GA at birth and in studies including cases with IUFD. 
Furthermore, the risk for cerebral injury appears to be higher in pregnancies with 
abnormal UA Doppler findings. These three risk factors are likely to be interdependent. 
Which of these factors independently contributes the most to the increased risk of 
cerebral injury could not be determined in this study because we could not perform an 
individual patient meta-analysis.
Interestingly, the risk of cerebral injury is approximately doubled in the larger twin 
compared to the smaller twin. Two different theories could explain this finding. 
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having the most elevated risk of IUFD of the smaller twin and neurological damage in 
the larger twin.
Theoretically, this group may be more prone to in utero fetofetal blood transfusions 
through the large arterio-arterial anastomoses resulting in hypoxic injury, particularly 
in the larger twin.4;11 The increased risk of cerebral injury in the group with abnormal 
Doppler found in this study may be in agreement with this theory. An alternative theory, 
recently postulated by our group, suggests that cerebral injury in the larger baby does 
not primarily develop in utero, but rather after birth as a result of (iatrogenic) premature 
delivery and subsequent brain immaturity. Detailed analysis of the timing of detection 
of severe cerebral injury is required to determine whether the injury is mainly due to 
antenatal factors (such as abnormal UA Doppler and impaired cerebral perfusion of 
the fetal brain) or postnatal factors due to (extreme) prematurity. Detection of cerebral 
injury early after birth (within 1-2 weeks) suggests an antenatal etiology, whereas late 
detection (≥ 2 weeks after delivery) suggests a postnatal etiology.
Low GA at birth, particularly extreme prematurity, is a well-defined risk factor for 
cerebral injury. Because preterm delivery occurs more frequently in MC twins with 
sIUGR and/or BWD compared with the general population, the development of cerebral 
injury is bound to be correlated with this factor. As shown in Figure 2, the highest 
incidence of cerebral injury was reported in studies with the lowest GA at birth. The 
cause of the wide variation in GA at birth between the studies is not clear. The optimal 
timing of delivery in MC twins with sIUGR and/or BWD is not known and may vary 
between centers. Some centers may be more prone to induce delivery or perform a 
cesarean delivery at an earlier age to decrease the risk of fetal demise. In case of IUFD 
of one twin, concomitant death or neurological damage in the co-twin may occur as a 
result of acute exsanguination through the vascular anastomoses. As emphasized by 
previous studies, the risk of abnormal postnatal cranial imaging in the surviving MC 
cotwin may be as high as 34%.24 In agreement with these findings, the data in our meta-
analysis confirm that the risk of cerebral injury in three studies including cases with 
IUFD is increased (Table 4).
However, the strategy of ‘early delivery’ in MC twin pregnancies with sIUGR and/or 
BWD may theoretically not only decrease the risk of fetal demise but also increase the 
risk of cerebral injury related to prematurity. How to balance the benefit of prolonging 
the pregnancy in preventing prematurity-related cerebral injury against the harm of 
risking single IUFD and concomitant damage of the co-twin is a true clinical challenge 
and urgently warrants more study.
Besides expectant management and elective preterm birth, other management 
options in MC twins with sIUGR include fetoscopic laser coagulation of the vascular 
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both fetal circulations and therefore prevent acute exsanguination from one fetus into 
the other. However, the invasiveness of both methods is associated with complications 
such as premature rupture of membranes, chorioamnionitis and preterm delivery.25 In 
addition, fetoscopic laser coagulation of the vascular anastomoses is technically more 
challenging in sIUGR pregnancies compared with TTTS pregnancies, because of the 
absence of a polyhydramnios.5
Our results should be interpreted with care due to the uncertainty related to a high 
degree of heterogeneity between the studies as well as their retrospective nature and 
inclusion of relative small cohorts. All studies applied different inclusion criteria and 
various definitions of sIUGR and BWD and different outcome measures. A distinction 
between types of sIUGR was often not made. Furthermore, detailed information on the 
timing of fetal demise and cerebral imaging was rarely reported. Because of a lack of 
detailed information, we could not determine the severity of all cases with cerebral 
injury. Comparison between the selected studies was therefore difficult to perform, 
and knowledge on the incidence and risk factors of severe cerebral injury in this group 
remains limited Another potential limitation of our study is the inclusion of only studies 
reported in English. Imposing language restrictions may result in bias.
Identification of the true risk factors for cerebral injury in MC twins with sIUGR 
and/or BWD can only be assessed through meta-analysis of published cohorts using 
an individual patient analysis or large prospective studies. Whether fetal surgery or 
obstetrical interventions may improve the outcome in this risk group remains to be 
elucidated and outcome studies assessing the natural history are urgently required. 
Finally, although the predictive value of cerebral imaging techniques is increasing, its 
predictive accuracy remains subject of debate.23 Presence of clinically relevant, long-
term impairment can only reliably be ascertained by accurate and standardized long-
term follow-up until at least childhood.
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What’s already known about this topic?
• sIUGR may occur in up to 25% of monochorionic twin pregnancies.
• The main cause of sIUGR is related to unequal placenta sharing, in which the growth 
restricted fetus often has a small placental share and a velamentous cord insertion.
• The optimal management in monochorionic twins with sIUGR is not clear and 
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What does this study add?
• The average incidence of severe cerebral injury in monochorionic twins with sIUGR 
is approximately 8%, but varies greatly between the studies from 0% up to 33%.
• Severe cerebral injury in monochorionic twins with sIUGR is associated with 
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Abstract
Objective
To evaluate the incidence, type and severity of cerebral injury in the surviving 
monochorionic (MC) co-twin after single fetal demise. 
Methods
All MC pregnancies with single fetal demise that were evaluated at the Leiden University 
Medical Center between 2002 and 2013 were included. Perinatal characteristics, 
neonatal outcome and the presence of cerebral injury, observed on neuroimaging, were 
recorded for all co-twin survivors.
Results
A total of 49 MC pregnancies with single fetal demise, including one MC pair from a 
dichorionic triplet, were included in the study (n = 50 co-twins). The median gestational 
age at the occurrence of single fetal demise was 25 weeks and the median interval 
between single fetal demise and live birth was 61 days, with a median gestational 
age at birth of 36 weeks. Severe cerebral injury was diagnosed in 13 (26%) of the 50 
co-twins and was detected antenatally in 4/50 (8%) and postnatally in 9/50 (18%) 
cases. Cerebral injury was mostly due to hypoxic-ischemic injury resulting in cystic 
periventricular leukomalacia, middle cerebral artery infarction or injury to basal 
ganglia, thalamus and/or cortex. Risk factors associated with severe cerebral injury 
were advanced gestational age at the occurrence of single fetal demise (odds ratio (OR), 
1.14 for each week of gestation; 95% CI, 1.01-1.29; P = 0.03), twin–twin transfusion 
syndrome, developing prior to single fetal demise, (OR, 5.0; 95% CI, 1.30-19.13; P = 0.02) 
and a lower gestational age at birth (OR, 0.83 for each week of gestation; 95% CI, 0.69-
0.99; P = 0.04). 
Conclusions
Single fetal demise in MC pregnancies is associated with severe cerebral injury occurring 
in 1 in 4 surviving co-twins. Routine antenatal and postnatal neuroimaging, followed by 








































Cerebral injury after single fetal demise in monochorionic pregnancies  |  161
Introduction
Monochorionic (MC) pregnancies are at an increased risk for complications, including 
twin–twin transfusion syndrome (TTTS), twin anemia–polycythemia sequence and 
selective intrauterine growth restriction (sIUGR). In the case of single fetal demise 
in a MC pregnancy, severe complications may arise. Several reports have shown that 
the co-twin is at an increased risk of fetal demise or severe morbidity due to injury 
to the brain, gastrointestinal tract or kidneys.1 These complications are thought to be 
caused by acute fetal exsanguination into the low-pressure circulation of the demised 
fetus through the placental vascular anastomoses. Acute hypovolemia, hypotension and 
anemia may subsequently result in hypoxic-ischemic multi-organ damage, particularly 
to the brain, and even double fetal death.2 In a meta-analysis, Hillman et al. reported a 
rate of abnormal postnatal cranial imaging and neurodevelopmental impairment after 
single fetal demise of 34% and 26%, respectively.3 However, this meta-analysis was 
based on a few small series and case reports, which may have introduced selection or 
publication bias, hampering accurate estimation of the incidence. In addition, little is 
known on the type, severity and risk factors of cerebral injury after single fetal demise. 
The aim of this study was to determine the incidence and characteristics of severe 
cerebral lesions in the surviving co-twin of a large case series of MC pregnancies after 
single fetal demise.
Methods
In this retrospective analysis of collected data, we included all consecutive MC 
pregnancies with single fetal demise diagnosed at or referred to the Leiden University 
Medical Center (LUMC), between June 2002 and November 2013. The LUMC is the 
national referral center in The Netherlands for fetal therapy. Ethical approval from the 
parents is not required for this type of retrospective study with anonymized data in 
The Netherlands. We excluded MC pregnancies with fetal demise occurring after laser 
treatment for TTTS, selective feticide, cases with double fetal demise occurring on 
the same day, and cases with single fetal demise occurring during the first trimester. 
Dichorionic (DC) triplets were included if the fetal demise occurred in one of the MC 
twins. In such cases, the outcomes of the MC co-twin were analyzed only. 
We recorded the presence and characteristics of fetal and/or neonatal cerebral injury 
detected on antenatal and/or postnatal neuroimaging examination. Neuroimaging was 
performed using either fetal or neonatal ultrasound or magnetic resonance imaging 
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Best, The Netherlands) and included T2 turbo spin echo sequences in three directions 
and T2* fast field echo. The neonatal MRI was performed using a 3-T MRI system (Achieva 
3T; Philips Medical Systems, Best, The Netherlands) and included a 3D T1 turbo field-
echo, T2 turbo spin echo, T2* fast field echo, and diffusion weighted sequences. We 
recorded the neuroimaging data obtained within the first year of life. Cerebral injury was 
categorized as follows: intraventricular hemorrhage (IVH), parenchymal hemorrhage, 
cystic periventricular leukomalacia (cPVL), porencephalic cyst, ventricular dilation, 
arterial or venous infarction, and hypoxic-ischemic injury of basal ganglia, thalamus 
and/or cortex. Severe cerebral injury was defined as at least one of the following: IVH ≥ 
Grade III4, cPVL ≥ Grade II,5 ventricular dilatation ≥ 97th percentile,6 porencephalic cyst, 
arterial or venous infarction, basal ganglia, thalamic and/or cortical injury, or other 
severe cerebral lesions associated with an adverse neurological outcome.7
The following obstetric parameters were recorded: amnionicity, sIUGR (defined as an 
estimated fetal weight of the growth-restricted fetus < 10th centile), TTTS (including 
Quintero stage and management),8 congenital anomalies, gestational age at detection 
of fetal demise, cause of fetal demise, fetal middle cerebral arterial (MCA) peak systolic 
velocity (PSV) Doppler measurement, presence of fetal cerebral injury and gestational 
age at detection, time between fetal demise and delivery, and mode of delivery. In the 
surviving co-twins that were treated with intrauterine blood transfusion (IUT) for 
anemia, we recorded the hemoglobin level prior to the transfusion.
The following neonatal parameters were recorded: gestational age at birth, birth 
weight, gender, occurrence of perinatal asphyxia, neonatal death, presence of 
respiratory distress syndrome, patent ductus arteriosus, hemoglobin level at birth and 
need for a blood transfusion, and need for inotropic support. Perinatal asphyxia was 
defined as the presence of three or more of the following five criteria: non-reassuring 
cardiotocogram patterns, umbilical cord arterial pH < 7.10 and base excess ≥ 16mmol/L 
or lactate > 10mmol/L, an Apgar score < 5 at 5 minutes after birth, failure of spontaneous 
breathing at 5 minutes after birth, and onset of multiple organ failure.
Statistical data were analyzed using SPSS version 20.0 (IBM, Armonk, NY, USA) and 
reported as n (%), mean ± SD or median (interquartile range (IQR)). Statistical analysis 
was performed using the t-test and Mann–Whitney U-test for continuous variables. The 
chi-squared test and Fisher’s exact test were used for categorical variables. Risk factors 
possibly contributing to severe cerebral injury were studied in a univariable regression 
model. The multivariable model included all variables that showed a significant 
association in the univariable analysis. Results are expressed as odds ratio (OR) with 
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Results
A total of 49 MC pregnancies, including one MC triplet and two DC pregnancies with a 
MC component, fulfilled our inclusion criteria and were included in the study (n = 50 
fetuses). The median gestational age at the diagnosis of single fetal demise was 25 (20–
29.3) weeks’ gestation. In 35/49 (71%) pregnancies, a likely cause of single fetal demise 
could be identified: monoamnionicity (5/49, 10%), sIUGR (13/49, 27%) or TTTS 
(17/49, 35%). In all monoamniotic twin pregnancies, umbilical cord entanglement 
was present. In one monoamniotic pregnancy, fetal co-twin demise was detected at 42 
days after single fetal demise. In the sIUGR pregnancies, single fetal demise occurred 
most often in the growth-restricted fetus (11/13, 85%). In the TTTS pregnancies, single 
fetal demise occurred mostly in the donors (14/17, 82%). Two pregnancies with sIUGR 
were also complicated by congenital anomalies in the demised twin (Potter syndrome, 
transposition of the great arteries and esophageal atresia). MCA-PSV Doppler 
measurements were performed in 47/50 (94%) cases after single fetal demise. In three 
cases, MCA-PSV measurements were not performed due to imminent delivery of the 
surviving co-twin. Treatment with IUT due to signs of severe acute anemia shortly after 
the demise of the co-twin was performed in 6/50 (12%) cases. The median interval 
between fetal demise and delivery was 58 (9.5–106) days. Figure 1 presents a flow chart 
showing the derivation of the study population. Details of the antenatal characteristics 
of the study group are reported in Table 1. 
Table 1 Antenatal characteristics of the 49 monochorionic (MC) pregnancies after single fetal 
demise
Characteristic MC pregnancies
Female fetus 25 (50)
Twin–twin transfusion syndrome 17 (35)
Amnioreduction                     4/17 (24)
Selective IUGR 13 (27)
Monoamniotic twin 5 (10)
GA at single fetal demise (weeks) 25 (20–29.3)
Interval between fetal demise and delivery (days) 58 (9.5–106)
IUT after single fetal demise 6 (12)
Hb level at transfusion (g/dL)                      5 (3–5.9)
Cerebral injury 4 (8) 
GA at detection (weeks) 26.5 (22.3–30.8)
Data are given as n (%), n/N (%) or median (interquartile range). 
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MC co-twins after single fetal 
demise  
N=50 
Live-born co-twins  
N=47 
Long-term survivors  
N=42 
Cerebral injury at 1 year:  
1/42 (2) 
MRI 1/42 (2) 
Cerebral injury, overall  
13/50 (26) 
Postnatal cerebral injury:  
8/47 (17) 
US 28/47 (60) 
MRI 11/47 (23) NND n=5 (cerebral 
 injury/ asphyxia) 
Antenatal cerebral injury : 
4/50 (8) 
US 36/50 (72) 
MRI 16/50 (32) TOP n=2 (cerebral injury) 
FD n=1 (cord entanglement) 
Figure 1 Derivation of the study population.
MC, monochorionic; US, ultrasound; MRI, magnetic resonance imaging; TOP, termination of 
pregnancy; FD, fetal demise; NND, neonatal death.
Serial fetal cranial ultrasound after single fetal demise was performed in 36/50 (72%) 
fetuses, of which, 16/36 (44%) also underwent fetal MRI. In 4/36 (11%) fetuses, severe 
cerebral injury was detected at a median gestational age of 26.5 (22.3–30.8) weeks. 
Among these were two pregnancies complicated with TTTS, of which, single fetal 
demise of the donor twin occurred at 19 and 23 weeks’ gestation. Fetal MRI at 21 and 
26 weeks, respectively, revealed infarction of the MCA in the recipient co-twin. In both 
cases, the parents opted for termination of the pregnancy after extensive counseling. 
In the third case of severe cerebral injury, occurring in a DC triplet pregnancy, single 
fetal demise of the growth-restricted MC co-twin was detected at 25 weeks’ gestation. 
Fetal MRI performed at 27 weeks displayed multicystic encephalopathy in the surviving 
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of the donor twin was detected at 28 weeks’ gestation and fetal MRI at 32 weeks 
showed cerebral atrophy, diffuse white matter loss and abnormalities of the thalamus 
and internal capsula in the recipient co-twin. Postnatal MRI confirmed the cerebral 
abnormalities detected with a fetal MRI in both the surviving co-twins.
The median interval between the occurrence of single fetal demise and delivery of the 
47 live-born co-twins was 61 (9–114) days, with a median gestational age at live-birth 
of 36 (33–38) weeks. Perinatal asphyxia was detected in 6/47 (13%) neonates and 
three (3/47; 6%) neonates were diagnosed with persistent pulmonary hypertension, of 
which, one required extracorporeal membrane oxygenation. This child was diagnosed 
with severe renal failure and died at 2 years of age after a renal transplant9. Eight 
(8/47; 17%) neonates were treated with blood transfusion, of which five also required 
inotropic medication at birth. These children were born shortly after the demise of 
their co-twin (range, 0–2 days). One (2%) child presented with an unexpected limb 
reduction at birth. Neonatal death occurred in 5/47 (11%) co-twins, due to asphyxia 
and/or severe cerebral injury. Detailed information on neonatal outcome is presented 
in Table 2. 
Table 2 Neonatal outcome of live-born co-twins after single fetal demise
Outcome Co-twins (n = 47) 
GA at birth (weeks) 36 (33–38)
Birth weight (g) 2622.5 (1816.3–2985)
Perinatal asphyxia 6 (13)
Respiratory distress syndrome 10 (21)
Patent ductus arteriosus 4 (9)
Renal failure 1 (2)
Hb level at birth (g/dL)* 15 (9.4–18.1)
Blood transfusion at birth 8 (17)
Neonatal death 5 (11)
Age at death (days)                      6 (3.5–19)
Data are given as n (%) or median (interquartile range). *n = 23. GA, gestational age; Hb, 
hemoglobin.
Postnatal ultrasound was performed, within the first days of life, in 28/47 (60%) 
neonates, of which, 11/28 (39%) also underwent MRI. Severe cerebral injury 
was detected on postnatal imaging in 8/28 (29%). Overall, antenatal or postnatal 
neuroimaging at birth was performed in all but one case (49/50, 98%). This child was 
born at 37 weeks gestational age in another hospital where cranial ultrasound was not 
part of standard procedure. However, the child presented with severe developmental 
delay at almost 1 year of age and subsequent MRI showed severe cerebral injury. In 
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demise. Of these 13 co-twins, eight (62%) were diagnosed with TTTS prior to single 
fetal demise. The median gestational age at single fetal demise was 27 (24–33) weeks, 
compared to 23.5 (19–28.75) weeks in co-twins without severe cerebral injury 
(P = 0.03). The median gestational age at live birth was 35 (28–37) and 37 (34–38) 
weeks, respectively (P = 0.04). Details on characteristics and outcome of the 13 co-twins 
with severe cerebral injury after single fetal demise are presented in Table 3. Figure 2 
shows T2-weighted MRI scans of four children with different types of severe cerebral 
injury. 
Figure 2 (a) T2-weighted fetal magnetic resonance image (MRI) obtained at 26 weeks’ gestation, 
3 weeks after single fetal demise in a monochorionic pregnancy, showing bilateral middle 
cerebral artery infarction (arrows). (b) T2-weighted MRI in a 3-day-old neonate who was born 
asphyxiated at 36 weeks’ gestation, one day after single fetal demise, showing diffuse cortical 
necrosis, white matter injury and severe basal ganglia/thalamic injury (arrows). (c) T2-weighted 
postnatal MRI in a 2-day-old neonate who was born at 37 weeks’ gestation, 63 days after single 
fetal demise, showing bilateral severe cerebral atrophy and cystic parenchymal destruction of 
right posterior cerebral hemisphere (arrow). (d) T2-weighted MRI in a 12-week-old neonate 
who was born at 28 weeks’ gestation, 10 days after single fetal demise, in whom neonatal cranial 
ultrasound showed Grade II unilateral intraventricular hemorrhage and infarction in the right 
caudate nucleus (not shown). A cystic lesion in the right caudate nucleus (arrow) can be seen, 
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Univariable and multivariable analysis of the potential risk factors contributing to 
severe cerebral injury was performed (Table 4). The associated risk factors were 
advanced gestational age at occurrence of single fetal demise (OR, 1.14 for each week; 
95% CI, 1.01-1.29; P = 0.03), diagnosis of TTTS prior to single fetal demise (OR, 5.0; 95% 
CI, 1.30-19.13; P = 0.02) and gestational age at live birth (OR, 0.83 for each week; 95% 
CI, 0.69-0.99; P = 0.04).
Table 4 Analysis of potential risk factors for severe cerebral injury in the surviving co-twin after 









P Multivariable OR 
(95% CI)






0.03 1.14 (1.01-1.29) 0.01 1.34 (1.06-1.69)
TTTS 8/13 (62) 9/37 (24) 0.02 5.0 (1.30-19.13) 0.02 19.2 (1.65-223.69)
sIUGR 2/13 (15) 11/37 (30) 0.32 0.43 (0.08-2.27)
Monoamniotic 
pregnancy
1/13 (8) 4/37 (11) 0.75 0.69 (0.07-6.78) 






0.04 0.83 (0.69-0.99) 0.05 0.77 (0.59-1.00) 
Data are presented as median (interquartile range) or n/N (%).
OR, odds ratio; CI, confidence interval; GA, gestational age; TTTS, twin-twin transfusion syndrome; 
sIUGR, selective intrauterine growth restriction.
Discussion
This study shows that the incidence of severe cerebral injury in MC pregnancies after 
single fetal demise is high (13/50, 26%) and is mostly due to hypoxic-ischemic injury 
resulting in cystic PVL, MCA infarction, or injury to basal ganglia, thalamus and/or 
cortex. The exact mechanisms leading to these different types of cerebral injury are 
still unclear. In the past, co-twin morbidity after single fetal demise was thought to 
result from transfusion of thromboembolic material from the demised fetus into the 
circulation of its co-twin. At present, most experts think that co-twin morbidity results 
from acute exsanguination from the surviving co-twin into the low-pressure circulation 
of the demised co-twin. Acute exsanguination results in acute hemodynamic changes 
(hypovolemia and anemia) leading to hypoxic-ischemic injury and multi-organ failure.2 
In a previous study, we showed that perinatal asphyxia in MC twins, in contrast to DC 
twins, is strongly associated with acute exsanguination and anemia at birth.10 However, 
alternative explanations can be considered to explain the observed cerebral injury. In 
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with the presence of TTTS (diagnosed prior to single fetal demise), higher gestational age 
at the time of single fetal demise and lower gestational age at birth. In two pregnancies 
complicated by TTTS, MCA infarction in the recipient twin was detected antenatally. 
Whether the cerebral lesions in the TTTS cases occurred before or after single fetal 
demise is not clear. As shown in previous studies, TTTS is known to be associated with 
the development of antenatal cerebral injury, including arterial infarctions in recipient 
twins.11 The combination of TTTS and single fetal demise may increase the risk of 
cerebral injury. Similarly, a lower gestational age at birth is a well-known risk factor for 
cerebral injury; prematurity may have accounted for the cases with severe IVH in our 
series. The explanation for the association between a higher gestational age at single 
fetal demise and the presence of cerebral injury is not clear. Since the size of placental 
vascular anastomoses increases with gestational age, we hypothesize that the severity 
of acute exsanguination may also increase with gestational age, with reduced vascular 
resistance through the larger vascular anastomoses. However, care should be taken 
when interpreting these results and speculating on possible explanations due to the 
relatively small sample size. In order to reliably investigate risk factors contributing 
to the development of severe cerebral injury in co-twins following single fetal demise, 
larger studies are needed.
The incidence of severe cerebral injury reported in this study (26%) is slightly lower 
than the 34% (95% CI, 28.8–46.1%) risk reported in the recent meta-analysis of Hillman 
et al.3 Methodological differences and heterogeneity between the studies included in 
this meta-analysis could have led to an overestimation of the true risk. Our study, the 
largest single-center series to date, with antenatal and postnatal imaging in the majority 
of cases, still has limited numbers. 
In our study, all but one fetus underwent routine antenatal or postnatal cerebral imaging 
after single fetal demise. In two cases, severe cerebral injury was detected antenatally 
and had important clinical implications which led to termination of the pregnancy in 
both cases. In the majority of cases, severe cerebral injury was detected postnatally, and 
led to either neonatal death or subsequent neurological symptoms related to perinatal 
asphyxia. In one case, cerebral imaging was not performed at birth but neurological 
symptoms became apparent several months later. Given the important clinical and 
prognostic implications, we recommend routine ante- and postnatal imaging in all MC 
co-twins after single fetal demise, to enable appropriate ante- and postnatal intervention 
and timely counseling.
The intriguing question remains as to why the majority (37/50; 74%) of surviving 
co-twins do not suffer from cerebral injury. We speculate that the type and size of 
the anastomoses may play an important role in the pathogenesis of cerebral injury. 
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allow a more rapid and massive exsanguination due to the low resistance of these 
anastomoses. However, this relation is not easy to establish, since the interval between 
fetal demise and birth is often more than 1 week, after which, placental anastomoses 
cannot be evaluated due to maceration of the placental share of the demised co-twin.
Severe injury on cerebral imaging does not equal long-term developmental delay. 
Outcome can vary from healthy development to mild impairment on multiple 
domains to severe developmental delay. The presence of clinically relevant, long-term 
impairment can only reliably be ascertained by standardized long-term follow-up of 
these children until at least school age.11;12 Hillman et al. found a rate of long-term 
neurodevelopmental impairment after single fetal demise in MC co-twins of 26%.3 
Neurodevelopmental impairment was only defined broadly as cerebral palsy or ‘minor 
delay’ in motor development and standardized developmental tests were not employed. 
In addition, the timing of follow-up was often unclear. As such, the true rate of long-
term impairment in MC co-twins after single fetal demise is still unknown. We intend 
to perform long-term follow-up in the surviving MC co-twins after single fetal demise 
using standardized developmental tests.
Our findings should be interpreted with care due to the retrospective nature of this 
study and the relatively small number of cases. In addition, the combination of either 
pre- and/or postnatal imaging is an important limitation. We recommend stringent 
and precise ante- and postnatal imaging protocols to evaluate accurately the incidence 
of antenatal cerebral injury and investigate the correlation between antenatal and 
postnatal imaging findings. Given the extreme rarity of these events, more accurate 
estimations of the incidence of severe cerebral injury, and other complications such 
as gastrointestinal or renal lesions, can only be obtained through an international 
multicenter registry of MC pregnancies with single fetal demise. Nevertheless, this is 
the largest cohort thus far, showing clearly that single fetal demise in MC pregnancies is 
associated with an increased risk of severe cerebral injury for the surviving co-twin. We 
would strongly advocate careful follow-up with antenatal and postnatal neuroimaging 
investigations as well as long-term neurodevelopmental follow-up in all MC pregnancies 
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Abstract
Objective
To evaluate the incidence and risk factors of adverse perinatal outcome in complicated 
monochorionic twin pregnancies treated with selective feticide.
Methods
This was a retrospective analysis of prospectively collected data from a consecutive, 
national cohort. All monochorionic twin pregnancies treated with selective feticide 
at Leiden University Medical Center between June 2000 and November 2011 were 
included. Obstetric and neonatal data were recorded. The primary outcome measure 
was adverse perinatal outcome, including fetal or neonatal demise or severe neonatal 
morbidity.
Results
Data on perinatal outcome were obtained in all cases (n=131).Overall perinatal survival 
rate was 67.2% (88/131). Median gestational age at delivery was 34 (interquartile 
range, 23–38) weeks. Neonatal mortality and morbidity rate in liveborn children was 
4.3% (4/92) and 12.0 % (11/92), respectively. Severe cerebral injury was detected in 
three children. The overall incidence of adverse perinatal outcome was 41.2% (54/131). 
Median gestational age at occurrence of preterm prelabor rupture of membranes 
(PPROM) was 19.0 weeks and 32.0 weeks in cases with and without adverse perinatal 
outcome, respectively (P = 0.017). Liveborn children with adverse perinatal outcome 
were born at a lower median gestational age (29.0 weeks) than were children without 
adverse perinatal outcome (38.0 weeks) (P < 0.001).
Conclusions
The risk of adverse perinatal outcome after selective feticide is high and associated with 
low gestational age at occurrence of PPROM and low gestational age at delivery. Long-
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Introduction
The incidence of complications and perinatal mortality is higher in monochorionic (MC) 
twin pregnancies than in dichorionic (DC) twin pregnancies, owing to the presence 
of placental vascular anastomoses. These vascular connections can lead to specific 
complications including twin–twin transfusion syndrome (TTTS),1 twin anemia–
polycythemia sequence,2 and twin reversed arterial perfusion (TRAP).3;4 In addition, 
selective intrauterine growth restriction (sIUGR) occurs more frequently in MC 
pregnancies and is associated with an increased risk of morbidity and mortality. When 
intrauterine death of one fetus occurs, the risk of death or cerebral damage in the cotwin 
is increased, owing to acute exsanguination through the placental anastomoses.5–7
Several indications have been described for selective feticide in MC twin pregnancies, 
including TTTS, TRAP, sIUGR, severe congenital anomalies and higher-order multiple 
pregnancies.5;8;9 Reported methods for selective feticide include fetoscopic laser 
coagulation, bipolar cord coagulation, radiofrequency ablation (RFA), cord occlusion 
by ligation or photocoagulation and interstitial laser coagulation.5;6;10;11 Associated 
complications are premature rupture of membranes in up to 30% of cases and preterm 
delivery.5;12 Perinatal survival rates vary between 65 and 92%, depending on technique 
and indication.5 However, data on the risk of neonatal complications and long-term 
neurodevelopmental outcome in surviving twins are limited.6;13
The primary objective of this study was to evaluate the incidence of perinatal mortality 
and neonatal morbidity in a series of MC twin pregnancies treated with selective feticide 
in a large national cohort. Our secondary objective was to assess possible risk factors 
for adverse outcome in order to find ways to improve care.
Methods
All MC pregnancies treated with selective feticide at our center between June 2000 and 
November 2011 were included in this consecutive cohort study. The Leiden University 
Medical Center is a tertiary medical center and is the national referral center for fetal 
therapy (including selective feticide) in The Netherlands.1 MC triplets (or higher order 
pregnancies) were excluded from the study.
The following obstetric data were recorded: indication for selective feticide and 
technique used, gestational age at intervention, preterm prelabor rupture of 
membranes (PPROM) before 37 weeks, gestational age at delivery and mode of delivery. 
The techniques used comprised fetoscopic laser coagulation, bipolar cord coagulation, 
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18 weeks, an embryoscope was used with a diameter of 1.0 mm. For cord coagulation 
after 18 weeks, a 1.3-mm fetoscope was used through an 8-F introduction sheath. 
Criteria for intervention in TRAP were signs of cardiac compromise in the pump twin 
based on abnormal ductus venosus flow.
The following neonatal data were recorded: gender, birth weight, presence of respiratory 
distress syndrome (RDS), chronic lung disease, patent ductus arteriosus, necrotizing 
enterocolitis (NEC) ≥ Stage II,14 neonatal sepsis (defined as a clinically ill neonate with 
positive bacterial culture), renal failure and severe cerebral injury on cranial ultrasound 
examination. Severe cerebral injury was defined as the presence of at least one of the 
following findings on ultrasound scan: Intraventricular hemorrhage (IVH) ≥ Grade III,15 
periventricular leukomalacia ≥ Grade II,16 ventricular dilatation, arterial or venous 
infarct or other cerebral anomalies associated with adverse neurological outcome.
The primary outcome measure was a composite outcome termed ‘adverse perinatal 
outcome’, which included intrauterine fetal death (IUFD), neonatal death (NND), 
termination of pregnancy (TOP) or severe neonatal morbidity. NND was defined as the 
death of a liveborn child delivered after 23 weeks’ gestation. Severe neonatal morbidity 
was defined as the presence of any of the following: RDS, NEC, neonatal sepsis, renal 
failure or severe cerebral injury. The incidence of adverse perinatal outcome was 
described by technique employed. Following analyses in recent studies,5 we evaluated 
the outcome in the groups treated with selective feticide at ≤ 18 weeks’ gestation and 
> 18 weeks’ gestation.
Categorical variables were compared using Fisher’s exact test or the chi-square test, 
as appropriate. Continuous variables were compared using unpaired Student’s t-test, 
median test or the Mann-Whitney U-test. Statistical analysis was performed with SPSS 
version 20.0 (SPSS Inc., Chicago, IL, USA).
Results
A total of 131 MC twin pregnancies were treated with selective feticide during the study 
period. In cases of DC triplets with an MC component (n=7), only the MC cotwin pair 
was analyzed. Figure 1 shows mortality within the study population. Information on 















































Neonatal death, n=4 (3.1%) 
Intrauterine fetal demise, n=32 
(24.4%) 
Termination of pregnancy, n=7 
(5.3%) 
Figure 1 Flowchart showing mortality in study population of 131 monochorionic twin 
pregnancies that underwent selective feticide.
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IUFD occurred in 32 cases, and in seven cases the pregnancy was terminated after 
selective feticide. In the 32 IUFD cases, fetal death occurred on average 1.67 (range, 
0.0–9.0) weeks after the operation (median gestational age at therapy 16.0 weeks, 
median gestational age at delivery 17.5 weeks). Reasons for TOP were persistent 
severe fetal hydrops (n=1), chromosomal abnormality (n=2) and PPROM (n=4). Four 
liveborn neonates died during the neonatal period because of complications related 
to prematurity, Potter sequence or severe brain injury. Overall perinatal survival rate 
was 67.2% (88/131). Perinatal survival rate was higher in the group treated after 18 
weeks’ gestation than in the group treated before 18 weeks, at 80% (64/80) and 47.1% 
(24/51), respectively (P < 0.001).
Perinatal outcome by technique is given in Table 2. Feticide was performed successfully 
in all but one pregnancy. In this case, fetoscopic laser coagulation was discontinued 
because of complex entanglement of the umbilical cords in a monoamniotic twin, 
with too high a risk of damaging the cord of the healthy twin. This pregnancy was 
subsequently completely terminated because of mosaicism for trisomy 18.
The reasons for selective feticide in the TTTS group included technical issues (n=9), 
anterior placenta location (n=5), severe fetal malformation (n=11), severe sIUGR (n=6), 
severe cerebral injury (n=3), reversal of TTTS (n=2) and parental choice (n=4). Quintero 
stage at time of intervention was Stage 1 (n=5), Stage 2 (n=6), Stage 3 (n=21) and Stage 
4 (n=8). Higher Quintero stage at intervention was not associated with increased risk of 
adverse perinatal outcome (P = 0.29).
PPROM occurred in 26 (19.8%) cases at a median gestational age of 25.5 weeks, 
of which 15 (57.7%) occurred before 28 weeks, three (11.5%) between 28 and 32 
weeks and eight (30.8%) between 32 and 37 weeks. Four of these pregnancies were 
terminated because of anhydramnios, in two cases IUFD occurred and one child died in 
the neonatal period. Median gestational age at therapy was comparable between cases 
with and without PPROM, at 17.0 and 17.5 weeks, respectively (P = 0.490). Median 
gestational age at delivery in the subgroups with and without PPROM was 30.0 weeks 
and 35.0 weeks, respectively (P = 0.047).
Median gestational age at delivery in the 92 liveborn children was 37 (range, 33-39) 
weeks. Twenty-five neonates (27.2%) were born between 32 and 37 weeks’ gestation, 
15 (16.3%) between 28 and 32 weeks and five (5.4%) were born extremely prematurely 
(before 28 weeks). Detailed information on neonatal morbidity in one case was not 
available because the mother moved to another country shortly after the operation. She 
delivered in a foreign hospital at 26 weeks’ gestation and the premature neonate died 
subsequently. Gender and birth weight are unknown.
Severe neonatal morbidity occurred in 15 neonates (16.3%). A total of 27 (29.3%) 
neonates required admission to the neonatal intensive care unit (NICU) and four of 
them died in the neonatal period (Figure 1). Detailed information on the cases with 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Overall, the rate of adverse perinatal outcome (including perinatal mortality and severe 
neonatal morbidity) was 41.2% (54/131). The rates of PPROM in cases with and without 
adverse perinatal outcome were 24.1% (13/54) and 16.9% (13/77), respectively (P = 
0.275). However, the median gestational age at occurrence of PPROM was significantly 
lower in cases with than in those without adverse perinatal outcome, at 19.0 weeks 
and 32.0 weeks, respectively (P = 0.017). In addition, liveborn children with adverse 
perinatal outcome were born at a lower median gestational age (29.0 weeks) than were 
children without adverse perinatal outcome (38.0 weeks; P < 0.001).
Detailed information on brain imaging was obtained in 28/92 neonates (30.4%). Severe 
cerebral injury was detected on ultrasound scan in three neonates, including IVH Grade 
IV (n=2) and vein of Galen malformation (n=1). The case of the child with vein of Galen 
malformation has been reported previously.17 Two children with severe cerebral injury 
died in the neonatal period. In the majority of neonates (64/92), routine ultrasound 
scans were not performed. Most of these children were in good clinical condition and 
were discharged from the hospital shortly after birth.
Other neonatal complications in the group of liveborn infants were nine cases of RDS 
(9.8%), two of chronic lung disease (2.2%), six of patent ductus arteriosus (6.5%), four 
of neonatal sepsis (4.3%) and one of NEC (1.1%).
Discussion
In this study we evaluated the perinatal outcome after selective feticide in a large 
cohort (n=131) of MC twin pregnancies and report an overall perinatal survival rate 
of 67.2%. Survival rates of 65–92% have been reported in the literature.5 Rossi and 
D’Addario5 reported an overall survival rate of 79% in a systematic review. However, 
care should be taken when comparing results of different studies, as overall perinatal 
outcome depends on various factors including indication for, and technique and timing 
of, the selective feticide procedure. Analysis of our results after stratification by type 
of surgical technique shows that interstitial laser coagulation and RFA are associated 
with the lowest survival rates, at 46.7% and 63.6%, respectively. Rossi and D’Addario5 
in contrast found the highest survival in the RFA group (86%). Nevertheless, important 
methodological issues (primarily related to the small number of patients included) 
prevent accurate comparison between the various reports. Larger studies are urgently 
needed to reach reliable conclusions on outcome after RFA and interstitial laser 
coagulation.
Our study also shows that perinatal survival is higher (86.3%) when intervention is 
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(47.1%). Our findings are in accordance with those of Rossi and D’Addario.5 who also 
found a higher survival rate (89%) when the procedure was performed after 18 weeks 
than when it was performed earlier (69%), irrespective of the indication for selective 
feticide. In support of the hypothesis that gestational age at therapy is associated with 
adverse perinatal outcome, Lanna et al.18 found an incidence of miscarriage of 3% when 
bipolar cord coagulation was performed after 19 weeks’ gestation, compared with 45% 
when performed before 19 weeks. Overall survival rate in this large study (n=118) was 
71%, which is comparable with our results. The findings in our study and other reports 
suggest that intervention should be postponed until after 18weeks’ gestation, when 
possible.5;18
The reported rate of neonatal morbidity and mortality (16.3%; 15/92) in our study 
was higher than the reported rate of 7.0% (19/273) in the systematic review of Rossi 
and D’Addario.5 Discrepancies in the results may be due to methodological differences 
such as under-reporting of neonatal morbidity and/or the use of different definitions of 
morbidity in the papers included in the review. In addition, most studies included in the 
systematic review of Rossi and D’Addario had a relatively high rate of loss to- follow-up, 
whereas we were able to report the perinatal and neonatal outcomes in all cases.
Our study confirms PPROM as one of the major risk factors for adverse perinatal 
outcome after invasive fetal interventions. In our cohort, in all but one case, neonatal 
mortality and morbidity occurred in neonates delivered at a gestational age of ≤30 
weeks. Our data are in agreement with a recent study by Bebbington et al.19 of 146 cases 
treated with selective feticide. The authors report a similar increased rate of PPROM and 
premature delivery and a clear association with adverse outcome. However, neonatal 
morbidity was not evaluated or reported.
In two small studies with six and 13 survivors, no neonatal morbidity was detected,6;20 
whereas in another small study, by Tsao et al.21, one out of 13 children died from 
complications of prematurity. Lewi et al.13 found a survival rate of 83% in a group of 
80 pregnancies treated with fetoscopic laser and/or bipolar cord coagulation. These 
authors only described neonatal morbidity (asphyxia and NEC) in the subgroup with 
neonatal death and cerebral injury only in children who had developmental delay in 
long-term follow up. Robyr et al.22 reported 8.7% prematurity-related deaths (4/46) 
after bipolar cord coagulation, without further describing neonatal morbidity in 
survivors. Paramasivam et al.23 reported brain abnormalities in two cases in a group 
of 32 survivors after treatment with RFA, however other neonatal problems were not 
discussed. Ilagan et al.24 reported that 48% of neonates required admission to the 
NICU after bipolar cord coagulation because of various neonatal morbidities. Perinatal 
mortality was 3/27 (11.1%). Their conclusions were unfortunately marred owing to 
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Care should be taken when interpreting our results because of the limitations associated 
with the retrospective nature of this study. In our cohort, different techniques were used 
depending on various clinical factors and the operator’s preference, and the indications 
for selective feticide varied. The population was therefore inhomogeneous and difficult 
to compare with those of other studies. A risk-factor analysis comparing different 
techniques or indications was envisaged but considered inappropriate owing to small 
sample size per technique.
Although only a few cases with severe cerebral injury were found, it is possible that 
some were missed since cranial ultrasound scans were not routinely performed. More 
research is needed to determine the value of routine ultrasound scans in all liveborn 
survivors after selective feticide, or in fact after all fetal interventions. Also, because 
it is difficult to predict long-term outcome based on findings on cranial ultrasound 
scan, long-term follow-up should be performed to determine quality of life and 
neurodevelopmental outcome of survivors.
Few studies describe neurodevelopmental outcome in children treated with selective 
feticide. Moise et al.6 reported that all of the six survivors in a study of RFA in nine 
patients were doing well based on telephone follow-up at a mean neonatal age of 4 
months. Lewi et al.13 described long-term follow up in 67 survivors, of whom five had 
some form of developmental delay. Robyr et al.22 found one child with developmental 
delay at age 18 months, although without any abnormalities on brain imaging. Large 
long-term follow-up studies in survivors after selective feticide are urgently required in 
order to acquire the knowledge necessary to counsel parents reliably.
In conclusion, selective feticide is associated with a high risk of adverse perinatal 
outcome. Further research is warranted to find ways to minimize the risks of selective 
feticide, by optimizing indications, timing and methods used. Outcome studies should 
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Abstract
Objective 
To assess the incidence and risk factors for adverse long-term neurodevelopmental 
outcome in complicated monochorionic pregnancies treated with selective feticide at 




National referral center for fetal therapy (Leiden University Medical Center, the 
Netherlands).
Population 
Neurodevelopmental outcome was assessed in 74 long-term survivors.
Methods 
Children, at least two years of age, underwent an assessment of neurologic, motor 
and cognitive development using standardized psychometric tests and the parents 
completed a behavioral questionnaire. 
Main outcome measures 
A composite outcome termed neurodevelopmental impairment including cerebral palsy 
(GMFCS II-V), cognitive and/or motor test score of less than 70, bilateral blindness, or 
bilateral deafness requiring amplification.
Results 
A total of 131 monochorionic pregnancies were treated with selective feticide at the 
Leiden University Medical Center. Overall survival rate was 88/131 (67%). Long-term 
outcome was assessed in 74/88 (84%). Neurodevelopmental impairment was detected 
in 5/74 (6.8%, 95%CI 1.1 to 12.5) of survivors. Overall adverse outcome, including 
perinatal mortality or neurodevelopmental impairment was 48/131 (36.6%). In 
multivariate analysis, parental educational level was associated with cognitive test 
scores (regression coefficient B 3.9, 95% confidence interval 1.8 to 6.0). Behavioral 
problems were reported in 10/69 (14.5%).
Conclusions 
Adverse long-term outcome in survivor twins of complicated monochorionic 
pregnancies treated with selective feticide appears to be more prevalent than in the 
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Introduction
Monochorionic (MC) pregnancies are associated with increased risks of complications 
and perinatal mortality. Due to the presence of placental vascular anastomoses, specific 
complications can arise including twin-twin transfusion syndrome (TTTS), twin anemia 
polycythemia sequence (TAPS), twin reversed arterial perfusion (TRAP), and selective 
intrauterine growth restriction (sIUGR). In addition, severe discordant congenital 
anomalies occur more frequently in MC pregnancies and are associated with increased 
risk of morbidity and mortality.1 
In case of spontaneous intrauterine demise of one fetus, its co-twin may subsequently 
die (15%) or suffer from severe cerebral injury (34%) due to acute exsanguination 
into the circulation of the demised twin through the placental vascular anastomoses.2;3 
Selective feticide may be an option for the management of abovementioned severe 
complications, with the aim to optimize the chances for healthy survival of the co-twin.4 
Reported methods for selective feticide include fetoscopic laser coagulation, bipolar cord 
coagulation, radiofrequency ablation, cord occlusion by ligation or photocoagulation 
and interstitial laser coagulation.5-10 Perinatal survival rates following selective feticide 
vary between 65% and 92%, depending on indication and technique.6
Reliable data on the long-term neurodevelopmental outcome in surviving twins is scarce. 
Developmental delay is reported in 0-12%.7;10-13 However, in these studies standardized 
developmental tests and detailed specification of delays were often lacking. In addition, 
apart from evident impairments such as cerebral palsy or severe cognitive delay, more 
subtle impairments including behavioral problems require evaluation in order to obtain 
an integrated picture of the long-term outcome in surviving twins. 
The primary objective of this study was to assess the incidence and risk factors 
for adverse long-term neurodevelopmental outcome and behavioral problems in a 
consecutive series of MC pregnancies treated with selective feticide in a large national 
cohort.
Methods
The Leiden University Medical Center (LUMC) is the national referral center for fetal 
therapy in the Netherlands. We previously reported on the perinatal outcome of 131 MC 
twin pregnancies treated with selective feticide at our center between June 2000 and 
November 2011.14 All surviving co-twins were invited to participate in this long-term 
follow-up study. The institutional review board of the LUMC approved the study and all 
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The following obstetrical data were recorded: indication and technique for selective 
feticide, gestational age at intervention, fetal demise, termination of pregnancy (TOP) 
and preterm prelabor rupture of membranes. Following the procedure, patients were 
discharged after 24 hours with detailed ultrasound of the survivor twin. At 4 to 6 weeks 
after the procedure, either at our center or at the referring hospital, an ultrasound 
was performed and in case of suspected cerebral injury, a fetal MRI was performed. 
Expectant management with routine obstetric care were part of prenatal follow-up until 
delivery. The following neonatal data were recorded: gender, gestational age at birth in 
completed weeks, birth weight, neonatal death and severe neonatal morbidity (defined 
as any of the following: respiratory distress syndrome, necrotizing enterocolitis ≥ stage 
II,15 neonatal sepsis, renal failure or severe cerebral injury). Severe cerebral injury was 
defined as the presence of at least one of the following findings on cranial imaging: 
intraventricular hemorrhage ≥ grade III,16 periventricular leukomalacia ≥ grade II,17 
(progressive and non-progressive) ventricular dilatation ≥ 97th percentile,18 arterial 
or venous infarct or other cerebral anomalies associated with adverse neurological 
outcome. Socio-economic status (SES) of the parents was registered as high, average 
or low according to the Dutch Sociaal en Cultureel Planbureau.19 Parental education 
was determined by the level of education of each parent individually. A score of one 
was given when the parent’s education was low (primary school), a score of two for 
an intermediate educational level (secondary school and intermediate vocational 
school), and a score of three for higher levels of education (higher vocational school and 
university). Scores of both parents were then added (range: 2-6).
A follow-up visit was performed at a minimum age of 24 months corrected for 
prematurity and included a neurologic examination and an assessment of cognitive and 
motor development using the Bayley Scales of Infant and Toddler Development third 
edition (Bayley-III) in children at 2 years of age.20 Bayley-III scores provide cognitive 
and motor composite scores. Cognitive development of children between 3 and 7 years 
of age was tested with the Wechsler Preschool Primary Scale of Intelligence third edition 
(WPPSI-III).21;22 Children at the age ≥ 7 years were tested with the Wechsler Intelligence 
Scale for Children third edition (WISC-III).23 Both the WPPSI and WISC provide a Total 
IQ (TIQ) score including a Verbal IQ (VIQ) and a Performance IQ (PIQ). Bayley-III, WPPSI 
and WISC scores follow a normal distribution curve with a mean of 100 and a standard 
deviation (SD) of 15. A cognitive test score that is, a Bayley-III cognitive composite score, 
WPPSI TIQ- or WISC TIQ score, below 70 (< -2 SD) indicates severe cognitive delay and 
scores below 85 (< -1 SD) indicate mild-to-moderate cognitive delay . Cerebral palsy 
was defined according to the European CP Network and classified as spastic bilateral, 
spastic unilateral, dyskinetic (dystonic or choreo-athetotic), ataxic , or mixed.24 Severity 
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for Cerebral Palsy.25 Behavioral problems were assessed using the Achenbach’s Child 
Behavior Checklist (CBCL) versions 1½-5 and 6-18 years.26;27 These questionnaires 
measure the occurrence of problem-behavior as reported by parents. For the purpose of 
this study the Total problem scale, and the two broadband syndrome scales Internalizing 
(withdrawn, somatic complaints, anxious/depressed) and Externalizing (delinquent or 
rule-breaking, aggressive) behavior problems were used. T scores were computed from 
raw scores with higher scores on the syndrome scales indicating greater severity of 
problems. T scores of the normative sample have a mean of 50 ± SD 10. A clinical score 
in 10% of the children for the Total, Internalizing and Externalizing behavior problem 
scales (T score ≥ 64) served as cut-off points for comparison with Dutch normative 
data.27
The primary outcome measure was a composite outcome termed neurodevelopmental 
impairment (NDI) including cerebral palsy (GMFCS II-V), cognitive and/or motor test 
score of less than 70, bilateral blindness, or bilateral deafness requiring amplification. 
In addition, an ‘overall adverse outcome’ was calculated including perinatal mortality or 
neurodevelopmental impairment. Secondary outcome was an estimation of risk factors 
associated with cognitive test scores including indication and technique for selective 
feticide, gestational age at intervention, preterm prelabor rupture of membranes, 
gestational age at birth, birth weight, severe neonatal morbidity, age of the children and 
parental educational level. Third, we assessed behavioral problem scores.
Statistical analysis
All statistical analyses were conducted using SPSS version 20.0 (IBM, Armonk, NY, USA). 
Data are presented as number and percentage (%), medians with range or as means with 
SD, as appropriate. Statistical analysis was performed using t-test and Mann-Whitney 
test for continuous variables. Chi-square test and Fisher’s exact test were used for 
categorical variables, as appropriate. The percentages of children with a clinical CBCL 
score (T score ≥ 64) were compared with normative percentages (10% with clinical 
score) using a binomial test. Analysis for risk factors contributing to cognitive test scores 
was conducted using univariate and multivariate regression methods. The potential 
risk factors for cognitive outcome were studied in a univariate linear regression model. 
The multivariate linear regression model included all variables that showed significant 
association in the univariate analysis. Results are expressed as regression coefficients 
(B) with 95% confidence intervals (95%CI). The level of statistical significance for all 
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Results
A total of 131 MC twin pregnancies were treated with selective feticide during the study 
period. Figure 1 represents the derivation of the study population. No differences in 
perinatal and neonatal characteristics and SES were found between the included and 
lost-to-follow-up group. Baseline characteristics of the children included for follow-up 








Lost to follow-up n=14 (16%) 
Declined consent n=9 
Loss of contact information n=5 
Follow-up n=74 (84%) 
Median age 54.5 (range: 25-
144) months 
Neonatal death n=4 (3.1%) 
Intrauterine fetal demise n=32 
(24.4%) 
Termination of pregnancy n=7 
(5.3%) 
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Table 1 Baseline characteristics of 74 monochorionic co-twins included for follow-up
Characteristics Children 
n = 74
Indication for selective feticide
TTTS, n (%)









Selective feticide technique used
Fetoscopic laser cord coagulation, n (%)
Bipolar cord coagulation, n (%)
Interstitial laser coagulation, n (%)





Gestational age at intervention, weeks 18 (13-30)
PPROM, n (%) 15 (20)
Gestational age at birth, weeks 37 (25-41)
Birth weight, grams 2675 (800-4740)
Female, n (%) 38 (51)
Neonatal morbidity**, n (%) 8 (11)





















Data are presented as median (range). 
*High risk pregnancy due to history of preterm delivery and conisation of the cervix.
**Neonatal morbidity is defined as any of the following: respiratory stress syndrome, necrotizing 
enterocolitis, neonatal sepsis, renal failure or severe cerebral injury.
TTTS, Twin-Twin Transfusion Syndrome; TRAP, Twin Reversed Arterial Perfusion; SIUGR, 
Selective Intrauterine Growth Restriction; PPROM, Preterm Prelabor Rupture of Membranes.
The incidence of neurodevelopmental impairment in survivor twins of monochorionic 
pregnancies treated with selective feticide was 5/74 (6.8%, 95%CI 1.1 to 12.5) Overall 
adverse outcome, including perinatal mortality or long-term neurodevelopmental 
impairment, was 48/131 (36.6%). All 74 long-term survivors underwent physical 
examination, five of them did not participate in psychometric testing since parents 
declined consent. Median cognitive score of the children was 100 (range: 95-125), 105 
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III (n = 43) and WISC-III (n = 17), respectively. Overall, median cognitive score was 
104 (range: 62-131). The long-term outcome of the 74 children included for follow-
up is reported in Table 2. Details on prenatal and neonatal characteristics and the 
combination of impairments in the five children with neurodevelopmental impairment 
are presented in Table 3. In one child with deafness and severe cognitive delay, congenital 
cytomegalovirus (CMV) infection was diagnosed.
Table 2 Long-term neurodevelopmental outcome in the 74 children included for follow-up
Characteristics Children
n = 74
Age at follow-up, months 54.5 (25-144)
Neurodevelopmental impairment*, n (%) 5 (6.8)
Cerebral Palsy, n (%) 2 (2.7)
Cognitive development <-2 SD, n (%) 4 (5.4)
Motor development <-2 SD, n (%) 1 (1.4)
Bilateral deafness, n (%) 1 (1.4)
Cognitive score
Bayley-III (n = 8)
Cognitive development score
Motor development score
























Data are presented as median (range) 
*Neurodevelopmental impairment is defined as any of the following: Cerebral Palsy (GMFCS II-V), 
cognitive development <2 SD, motor development <2 SD, bilateral blindness or deafness.
Bayley-III, Bayley Scales of Infant and Toddler Development third edition; WPPSI-III, Wechsler 
Preschool Primary Scale of Intelligence third edition; WISC-III, Wechsler Intelligence Scale for 
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Univariate analysis of potential risk factors associated with cognitive test scores was 
performed (Table S1). Gestational age at birth (B 1.0, 95%CI 0.2 to 1.9), birth weight (B 
0.4, 95%CI 0.1 to 0.8), neonatal morbidity (B -15.8, 95%CI -27.2 to -4.4) and parental 
education (B 4.4, 95%CI 2.2 to 6.5) were significantly associated with cognitive test 
scores. Since gestational age at birth was strongly correlated with birth weight (Pearson 
correlation 0.9; P < .01) multivariate analysis was performed including gestational age 
at birth, neonatal morbidity and parental education (Table S1). We found that only 
parental education was still significantly associated with cognitive test scores (B 3.9, 
95%CI 1.8 to 6.0). 
Complete behavioral questionnaires were obtained from the parents of 69/74 (93%) 
children. According to the CBCL 1½-5, mean total problem score was 44.2 ± 11.0. 
Mean internalizing and externalizing problem scores were 44.5 ± 11.0 and 45.1 ± 11.4, 
respectively. According to the CBCL 6-18, mean scores were 51.1 ± 13.0, 52.6 ± 12.8 
and 48.2 ± 10.4, respectively. T scores of the normative sample have a mean of 50 ± 10. 
Overall, behavioral problems within the clinical range were reported in 10/69 (14.5%) 
cases, with internalizing problems in 10/69 (14.5%) and externalizing problems 
in 3/69 (4.3%) cases (Table 2). Compared with normative percentages (10% with 
clinical score), significantly more total and internalizing problems (P < .01) and less 
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Discussion
Main findings
In the present study, we evaluated the long-term neurodevelopmental outcome 
in survivors following selective feticide in MC pregnancies. Neurodevelopmental 
impairment was detected in 6.8% (95%CI 1.1 to 12.5). Overall adverse outcome, 
including perinatal mortality or long-term impairment was 48/131 (36.6%). One of 
the children included for long-term follow-up was diagnosed with congenital CMV 
infection. At five years of age this child had bilateral deafness, severe cognitive delay 
and behavioral problems. Neurodevelopmental impairment in this case was therefore 
likely due to the CMV infection. Excluding this case, the rate of impairment was 5.5%. 
Importantly, one pregnancy was terminated following selective feticide due to severe 
cerebral injury in the fetus. In addition, intensive care treatment was withdrawn from 
two neonates due to severe cerebral injury. Had these three children survived, the rate 
of impairment could have been higher (8/77; 10.4%).
Strengths and limitations
One of the limitations of this study is the lack of a control group. Another important 
limitation of long-term follow-up studies including ours is the inability to obtain 100% 
inclusion. We were not able to track 6% of families. Another 10% percent of parents 
declined consent largely due to emotional reasons. It is possible that parents who 
have not come to terms with their highly stressful medical history may tend to avoid 
situations where these difficulties are highlighted.28 Although no differences in perinatal 
characteristics and socio-economic status were found between the included and lost-to-
follow-up group, losses in follow-up studies are mostly unrelated to prenatal, perinatal, 
or neonatal medical conditions.29 However, parents with low educational levels and 
those with children with severe developmental delay are most likely to drop out of 
follow-up programs.29;30 Parental educational level could not be assessed in the lost-to 
follow-up group. In addition, a high percentage of parents were highly educated in our 
study. Therefore, the rate of long-term impairment could have been underestimated 
compared to more general populations. While it is not possible to compel families to 
participate in follow-up studies, it is possible to hypothesize the impact that might be 
seen if the outcome of interest occurred in none or all of those who were unwilling to 
participate (n=9). In our study, the range of impairment in those who survived would 
be 6.0% (5/83) up to 16.9% (14/83). Including the 3 cases with cerebral injury that did 
not survive, the range would be 9.3% (8/86) up to 19.8% (17/86).
Care should be taken when interpreting our results due to these limitations. In our 
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indications for selective feticide varied. The population was therefore inhomogeneous 
and difficult to compare to other studies.14 Also, different tests assessing cognitive 
and motor development were used due to a relative large age range (2-12 years). 
Ideally, standardized follow-up after fetal therapy should be performed in all children 
at 2 years, 5 and 8 years to obtain a reliable view of long-term child development. In 
addition we suggest that routine cerebral imaging should be performed in all survivors 
after selective feticide to rule out severe cerebral injury and determine the etiology and 
timing of injury. Unfortunately, in our cohort, routine cerebral imaging was performed 
only a minority of cases.
Interpretation 
The rate of cerebral palsy (2/74; 2.7%) in our study group was higher compared to the 
general population (0.2%).24,;31 However, twins in general are estimated to have a 5- to 
10-fold increased risk of cerebral palsy because of the higher prevalence of preterm 
birth and low birth weight.32 In MC twin pregnancies, the risk of cerebral palsy may 
be further increased by potential antenatal cerebral injury as a result of transfusion 
imbalances across placental vascular anastomoses.32 Although mean cognitive scores 
were within the normal range, the incidence of severe cognitive delay was 5%. According 
to the normal distribution of intelligence, severe cognitive delay occurs at a 2.3% rate 
in the general population. Compared with normative percentages (10%), significantly 
more behavioral problems (14.5%) were reported.27;33 It is possible that, besides the 
obvious impairments such as cerebral palsy, subtle difficulties including behavioral 
problems are even more frequent. A large proportion of survivor twins (33/74; 45%) 
was born below 37 weeks. Children born late preterm are reported to be at increased 
risk of behavioral problems.34 In addition to fetal- disease and therapy, premature birth 
and related complications could increase the risk of adverse long-term outcome. At 
present, there are no published studies on behavioral functioning in survivor twins 
after selective feticide of the MC co-twin.
Our rate of long-term impairment is in line with the rate reported in literature ranging 
from 0-12%.7;10-13 In a series of 36 children, Robyr et al reported one case with ‘some 
form of developmental delay’ at 18 months.11 Follow-up was obtained from a clinical 
evaluation by the referring pediatrician, a specification of delay was not described 
and developmental tests were lacking. We employed standardized tests in all 
children performed by certified child psychologists. Lewi et al reported some form of 
developmental delay in 5/67 (7.5%) survivors after selective feticide of the co-twin.12 
Four children were diagnosed with minor cognitive or motor delay with Bayley scales 
(2nd edition) and one child had severe cognitive delay according to a pediatrician. In 
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four months.7 Follow-up was based on a telephone interview with parents. In a large 
single-center study from Lanna et al, severe neurologic morbidity was detected in 2/84 
(2.4%) children with follow-up ranging from 1 to 9 years.10 Delebaere et al reported 
developmental delay in 3/26 (12%) children at a mean age of five years according to 
their medical records or phone calls with the parents.13 A specification of delay as well 
as standardized tests were lacking.
In univariate analysis we found that gestational age at birth, birth weight, neonatal 
morbidity and parental educational level were risk factors for long-term cognitive 
outcome. In multivariate analysis we found that only parental educational was 
associated with cognitive test scores. Low gestational age at birth, low birth weight, 
and often related severe neonatal morbidity, are known risk factors for long-term 
impairment. In addition, parental educational level is a well-documented and strong 
determinant of child cognitive development.35 Due to the small number of cases, we 
could not determine whether the clinical situation leading to the decision to perform 
feticide as well as the type of fetal intervention may have had an impact on the long-
term outcome. Furthermore, it is not clear whether fetoscopic coagulation of placental 
vascular anastomoses in addition to cord coagulation may improve outcome by further 
reducing the risk of intertwin blood flow. At our center we do not perform this procedure 
after cord coagulation. We assume that cord coagulation guarantees complete cessation 
of blood flow, also through still patent placental vascular anastomoses. 
Conclusion 
The present study represents the first study evaluating cognitive, motor and behavioral 
development using standardized tests in the largest consecutive cohort so far. We found 
that long-term neurodevelopmental impairment in survivors of MC pregnancies treated 
with selective feticide appears slightly more prevalent compared to general populations. 
Long-term cognitive test scores were associated with the level of education of the 
parents. Large multi-center long-term follow-up studies in survivors after selective 
feticide are required to counsel future parents reliably. We recommend standardized 
pre- and postnatal cerebral imaging in all survivor twins after selective feticide along 
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General Discussion
Intrauterine transfusion in fetal anemia
Alloimmune hemolytic disease
Despite the use of intravascular IUTs for fetal anemia for over three decades, knowledge 
on the long-term neurodevelopmental outcome of children treated with IUT, especially 
in certain subgroups, is limited. The long-term outcome in children treated with IUT for 
alloimmune anemia is now considered favorable with long-term impairment ranging 
from 4.8% in recent studies to 12% in older ones.1 In a large follow-up study performed 
at our center, including 291 children, we found a 4.8% of long-term neurodevelopmental 
impairment (NDI) after IUT for alloimmune hemolytic disease (Chapter 2). Significant 
risk factors for long-term impairment were severe fetal hydrops, the number of IUTs 
performed, severe neonatal morbidity including severe cerebral injury as well as 
the educational level of the parents. Nevertheless, even in children without obvious 
impairments such as cerebral palsy, subtle problems may occur including health-
related quality of life (HRQOL) issues or increased behavioral difficulties.2 In our study 
on HRQOL and behavioral functioning after IUT for alloimmune anemia we found that, 
according to parents, the children had more difficulties with cognitive functioning 
compared to healthy Dutch references (Chapter 2). In addition, behavioral problems 
were more prevalent and were associated with the level of education of the mother. 
These results suggest that, besides assessment of neurological disorders, other 
important and perhaps more subtle aspects of children’s well-being require detailed 
evaluation. 
In our follow-up study of a randomized controlled trial (RCT)3, we found that the 
neurodevelopmental outcome in children treated postnatally with intravenous 
immunoglobulins (IVIg) for hemolytic disease of the fetus/newborn was not different 
from children treated with placebo (Chapter 3). After stratification for treatment with or 
without IUT, similar results were obtained. According to our RCT analyses, prophylactic 
IVIg does not reduce the need for exchange transfusion nor the rate of other adverse 
neonatal outcomes. In addition, IVIg does not appear to have a beneficial effect on the 
long-term outcome. Standardized follow-up studies with large enough cases series and 
sufficient power are needed to replicate these findings.
Other indications for intrauterine transfusions
The long-term outcome of survivors of IUT for other indications such as congenital 
Parvovirus B19 infection and fetomaternal hemorrhage (FMT) is not well known. Up 
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with IUT for Parvovirus B19 infection have been performed with severe long-term 
impairment in up to 12.5% of children.4-6 The underlying cause for a potential increased 
rate of adverse neurodevelopmental outcome in parvovirus B19 infection is not yet 
fully understood.7 Adverse outcome may be directly related to cerebral injury caused by 
the viral infection itself or the compromised condition of the fetus with severe anemia 
and hydrops. Our knowledge on the long-term outcome after FMH is confined to case 
reports and small series of cases without intrauterine treatment.7 Since the occurrence 
of Parvovirus B19- and FMH induced fetal anemia is rare, international multicenter 
studies are required to determine long-term outcome in these subgroups.
Fetoscopic laser surgery in monochorionic twin pregnancies
Twin-twin transfusion syndrome
The preferred treatment for TTTS is fetoscopic laser coagulation of the placental vascular 
anastomoses. Before the introduction of this technique, TTTS was managed with serial 
amnioreduction of excessive amniotic fluid in the amniotic sac of the recipient twin. 
It is now general knowledge that twins treated with amnioreduction are less likely to 
survive compared to twins treated with laser surgery.8;9 In our meta-analysis we found 
a 7-fold higher risk of severe cerebral injury in twins treated with amnioreduction 
compared to twins treated with laser surgery (Chapter 5). Since amnioreduction is 
only a symptomatic intervention, twins remain exposed to TTTS for a longer period 
of time compared to twins treated with laser surgery. In addition, twins treated with 
amnioreduction are born on average at 29 weeks’ gestation. In comparison, twins 
treated with laser surgery are born on average almost one month later at 32-33 weeks. 
Prematurity is a well-known risk factor for neonatal morbidity and adverse long-term 
neurodevelopmental outcome.10
Since the introduction of fetoscopic laser surgery in the Netherlands, overall survival 
rate has improved from 70% to 80% with a significant reduction in (double) 
fetal demise (Chapter 6). This significant increase in survival is associated with a 
concomitant decrease in the incidence of long-term neurodevelopmental impairment 
(NDI) from 18% in the first years of the laser surgery program to 6% in more recent 
years (> 2008) (Chapter 6). In 2008 the Solomon trial was initiated, introducing a 
modified laser technique, the Solomon technique, in the treatment of TTTS.11 The 
Solomon technique, in which the whole vascular equator is coagulated, is associated 
with a significant reduction in short-term complications that is, TAPS and recurrent 
TTTS, when compared to the standard laser surgery technique. We compared the 
neurodevelopmental outcome in surviving children included in the trial and treated 
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We found no difference in our primary outcome that is, survival without NDI, between 
the two groups. Overall, NDI was detected in 11% of survivors in the Solomon and 9% 
in the standard group. The lack of difference between the two treatment groups could 
be that timely detection and adequate management and treatment (IUT, laser surgery 
re-intervention) in pregnancies with short-term complications in the standard group 
reduced the risk for long-term impairment. In addition, the Solomon trial was designed 
and powered to detect a difference in short-term perinatal outcome instead of long-
term outcome. In view of the reduction of short-term complications and the absence of 
increased adverse long-term effects, we recommend the use of the Solomon technique 
in the treatment of TTTS. 
Our follow-up studies in TTTS survivors identified several risk factors for adverse 
long-term outcome including advanced gestational age at laser surgery (and related 
Quintero stage), low gestational age at birth (and related low birth weight), severe 
neonatal morbidity including severe cerebral injury as well as the educational level of 
the parent(s). 
Although TTTS remains one of the most lethal conditions in perinatal medicine, the 
outcome in terms of its most important parameter that is, survival without NDI, has 
significantly improved in the last decade.
Twin anemia-polycythemia sequence
Twin anemia-polycythemia sequence (TAPS) may occur spontaneously in up to 5% 
of MC pregnancies or after TTTS treated with laser surgery (post-laser TAPS) in up to 
16%.12 Data on the neurodevelopmental outcome in TTTS survivors who developed 
TAPS after laser surgery is confined to one recent study in 47 long-term survivors 
(Chapter 8). NDI was detected in 9%, with no difference between TAPS-donors and 
-recipients. Mild-to-moderate cognitive delay was detected in 17%. Low gestational age 
at birth and related low birth weight were significant risk factors for cognitive delay. 
These results are within the range of the incidence of NDI in TTTS case series treated 
with laser (range: 6% to 18%). However, larger case-controlled studies are needed to 
determine if post-laser TAPS leads to an increased risk of impairment compared with 
uncomplicated TTTS cases. Knowledge on neonatal morbidity in spontaneous TAPS is 
scarce and long-term outcome studies in survivors have not been published yet. A TAPS 
registry website has been set up, an international collaboration of maternal and fetal 
medicine centers to gain knowledge on TAPS in order to improve treatment for this 
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Specific complications in monochorionic pregnancies
Selective intrauterine growth restriction in monochorionic twin pregnancies
Selective intrauterine growth restriction (sIUGR) or selective fetal growth restriction 
may occur in up to 25% of MC twin pregnancies and is related to unequal placental 
sharing in which the growth restricted fetus has a small placental share and a 
velamentous cord insertion.15;16 Our systematic review shows that the incidence of 
severe cerebral injury in MC twins with sIUGR varies greatly from 0% to 33%, with an 
estimated average of 8% (Chapter 10). The highest incidence of cerebral injury was 
reported in studies including pregnancies with single fetal demise, in pregnancies with 
abnormal umbilical artery Doppler findings and in cohorts with lower gestational age 
at birth. Results should however be interpreted with care due to the large heterogeneity 
between studies as well as their retrospective nature and the inclusion of relative small 
cohorts. Studies applied different inclusion criteria, various definitions of sIUGR and 
different outcome measures. The optimal management in MC twins with sIUGR is not 
clear and international consensus on the best treatment strategy is lacking. Whether 
fetal surgery (fetoscopic laser coagulation of vascular anastomoses or selective 
feticide) or obstetrical interventions (elective preterm birth) may improve the (long-
term) outcome remains to be determined. How to balance the benefit from prolonging 
pregnancy in preventing prematurity-related cerebral injury against the harm or 
risking single fetal demise and concomitant damage to the co-twin is a clinical challenge 
and warrants further study (Chapter 10). On the other hand, the invasiveness of fetal 
therapy is associated with complications such as premature rupture of membranes 
(PPROM) and preterm delivery. Outcome studies assessing the natural history of MC 
pregnancies with sIUGR are therefore urgently required.
Single fetal demise in monochorionic pregnancies
In case of single fetal demise in a MC pregnancy, severe complications may arise 
resulting from acute exsanguination from the surviving co-twin into the low-pressure 
circulation of the demised co-twin. Acute hypovolemia, hypotension and anemia may 
result in hypoxic-ischemic multi-organ damage, particularly to the developing brain, 
and even double fetal demise.13 Abnormal postnatal cranial imaging and NDI after 
single fetal demise are reported in 34% and 26% respectively.14 In our cohort of 49 
MC pregnancies, severe cerebral injury was detected in 26% and was mostly due to 
hypoxic-ischemic injury resulting in cystic periventricular leukomalacia, middle 
cerebral artery infarction or injury tot basal ganglia, thalamus and/or cortex (Chapter 
8). Risk factors associated with cerebral injury included advanced gestational age at 
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Nonetheless, abnormal postnatal cranial imaging does not necessarily imply long-term 
NDI. Outcome can vary from healthy development to mild impairments in multiple 
domains to severe cognitive delay or cerebral palsy. Stringent antenatal and postnatal 
neuroimaging protocols to accurately evaluate the incidence of antenatal cerebral injury 
and to investigate the correlation between antenatal and postnatal imaging findings are 
strongly recommended. The clinical relevance of these findings should subsequently be 
determined using long-term neurodevelopmental outcome data of all MC pregnancies 
with single fetal demise.
Selective feticide in complicated monochorionic pregnancies 
In specific complicated MC pregnancies, selective feticide can be offered as an alternative 
management option with the aim to optimize the chances of healthy survival of the 
co-twin. Indications include, among others, twin reversed arterial perfusion (TRAP) 
sequence, sIUGR, monoamniotic twin pregnancies or severe discordant congenital 
anomalies. We evaluated the perinatal and long-term neurodevelopmental outcome in 
a large consecutive cohort of 131 MC pregnancies treated between 2000 and 2011 at 
our center (Chapters 11 and 12). We found an overall perinatal survival rate of 67%, 
with higher survival (86%) when intervention was performed after 18 weeks’ gestation 
compared to interventions before 18 weeks (47%) (Chapter 11). Adverse perinatal 
outcome, including mortality or severe neonatal morbidity, was reported in 41% and 
was associated with low gestational age at PPROM and low gestational age at birth. 
Long-term NDI was detected in 7% of survivors (Chapter 12). Our rate of long-term 
impairment is in line with the reported rate in literature ranging from 0% to 12%.17-
21 However, in these studies standardized developmental tests, a clear definition and/
or a detailed specification of developmental delay were lacking. In our study, overall 
adverse outcome, including perinatal mortality and long-term impairment, was 37%. 
Compared with normative percentages (10%), significant more behavioral problems 
were reported by parents. Gestational age at birth, birth weight, neonatal morbidity 
including severe cerebral injury and parental educational level were significantly 
associated with cognitive test scores. Due to the relative small number of cases, we 
could not determine whether the clinical situation leading to the decision to perform 
feticide as well as the type of fetal intervention may have had an impact on the long-
term outcome. Again, multi-center efforts are of paramount importance to entangle 
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Future research perspectives 
Although an increasing number of children are being born alive after fetal therapy, 
knowledge on long-term child development is still limited, especially on potential 
risk factors for adverse outcome. The majority of follow-up studies available are 
observational, cross-sectional in design and do not allow for examination of child 
development over time. The studies are generally limited by small sample size and power 
and do not include matched controls. In addition, standardized neurodevelopmental 
testing and clearly specified criteria for impairment are lacking. 
The importance of long-term follow-up studies lies in both the necessity of evaluating 
fetal therapy as well as in evidence-based counselling of future parents. In addition, 
when a center decides to treat fetuses in utero, with the knowledge that a proportion 
will develop long-term morbidity, this center also has the responsibility to ensure that 
survivors will eventually receive the care they need. Long-term follow-up should be an 
integrated component of fetal therapy. Unfortunately, long-term neurodevelopmental 
studies are costly and difficult to perform and, consequently, hard to realize. Challenges 
include, among others, tracking families, motivate families to participate (in order 
to maintain a lost-to follow-up rate <10-20%), organizing follow-up assessments 
with trained pediatricians and child psychologists using standardized measures of 
well documented psychometric quality, as well as complete data acquisition and 
analysis. In countries where parents have to travel long distances to the follow-up 
clinic, assessments using (web-based) questionnaires such as the Ages and Stages 
Questionnaire (ASQ) could be more feasible. Structured long-term follow-up programs 
of children treated with fetal therapy require a dedicated follow-up team including fetal 
medicine specialists, neonatologists, child psychologists and research nurses. 
This chapter focuses on future perspectives and proposals for future research on the 
long-term neurodevelopmental outcome in all children treated with fetal therapy.
Intrauterine transfusion in fetal anemia
Alloimmune hemolytic disease
The majority of children treated with IUT for alloimmune hemolytic disease have a 
normal neurodevelopmental outcome, but some children are at increased risk for 
adverse long-term outcome. Important risk factors include fetal hydrops, severe 
neonatal morbidity and low parental education. We suggest routine standardized 
evaluations at age 2 using questionnaires such as the ASQ. Additionally, questionnaires 
on school performance, HRQOL and behavioral functioning at age 5 and 8 should be 
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outcome since these more subtle impairments may already have a significant impact on 
care requirements.
Other indications for intrauterine transfusions
Since the occurrence of Parvovirus B19- and FMH induced fetal anemia is rare, 
international collaboration of fetal medicine centers regarding long-term follow-up 
is mandatory. In Parvovirus B19, adverse outcome may be directly related to cerebral 
injury caused by the viral infection itself or the compromised condition of the fetus with 
severe anemia and hydrops. Standardized ante- and postnatal neuroimaging protocols 
to accurately evaluate the timing and nature of cerebral injury and to investigate the 
correlation between imaging findings and long-term outcome is strongly recommended. 
Whether the outcome of cases with FMH- induced anemia is improved with IUT needs 
further study. An international registration of cases with FMH, treated with or without 
IUT, is required to study the natural history, perinatal and neonatal outcome as well as 
the potential risk factors for adverse long-term outcome. 
Fetoscopic laser surgery in monochorionic twin pregnancies
Twin-twin transfusion syndrome
To date, three randomized controlled trials have been performed to determine optimal 
management and treatment of TTTS.11;22;23 Another trial, the TTTS stage I trail, is 
ongoing. These trials were however designed and powered to detect a difference in 
short-term outcome. Future trials should also be powered to detect a difference in long-
term outcome that is, survival without NDI. The sample size in studies including long-
term outcome is larger, therefore international multicenter collaboration is required. 
Long-term follow-up in TTTS survivors, at least at age 2, 5 and 8, should be an integrated 
component of the fetoscopic laser surgery program in each fetal therapy center. A 
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Table 1 Follow-up assessment according to age in years. 
Fetus Neonate 2 5  8 12 16 years
Brain development: cerebral imaging
Senses: hearing test, vision test
Cognitive: Bayley scales/ Ages and Stages Questionnaire, Wechsler scales
Physical: Neurological Examination, Cerebral Palsy (GMFCS)
Academic: special education, number of grades below age-
appropriate level
Neuropsychological: learning, language, executive 
functioning, attention, visual spatial abilities, memory, fine 
motor development
Psychosocial and behavior: internalizing and 
externalizing behavior, Quality of Life, Achenbach System, 
Vineland Adaptive Behavioral Scales
Developmental problems: attention deficit, hyperactivity, 
autism spectrum.
Post-laser TAPS and spontaneous TAPS
TAPS is a newly described disease and long-term neurodevelopmental outcome 
has not yet been described, except for a small subgroup of post-laser TAPS children. 
Adequately powered, prospective studies, ideally using a randomized controlled design 
including long-term follow-up, are urgently needed to determine best management in 
MC pregnancies complicated by TAPS. The web-based TAPS registry (www.tapsregistry.
org) now enables a prospective evaluation of the management of TAPS in all 
participating fetal medicine centers to further improve our knowledge on this relative 
new complication. At present, we are setting up a prospective, case-controlled follow-
up study to investigate if post-laser TAPS leads to an increased risk of impairment 
compared with uncomplicated TTTS cases. In addition, we will assess the short- and 
long-term outcome of all pregnancies complicated by spontaneous TAPS and managed 
at our center.
Specific complications in monochorionic pregnancies
Selective intrauterine growth restriction
The optimal management in MC twins with sIUGR is not clear and international 
consensus on the best treatment strategy is lacking. Studies on the natural history are 
required to improve our knowledge in order to design a multi-center RCT and determine 
whether fetal surgery (fetoscopic laser surgery of placental vascular anastomoses) or 
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term neurodevelopmental outcome in all survivors from sIUGR pregnancies diagnosed 
at or referred to our center and managed either expectantly or with fetal therapy 
between 2002 and 2013. The objective is to explore the natural history of MC twin 
pregnancies diagnosed with sIUGR and to determine potential risk factors for adverse 
long-term outcome.
Single fetal demise in monochorionic pregnancies
Single fetal demise in MC pregnancies with patent vascular anastomoses poses a high 
risk for severe cerebral injury in the surviving co-twin. Information on long-term 
outcome in this subgroup of survivors is missing. A (inter)national database should be 
developed to register all cases with single fetal demise in order to study the natural 
history and possible risk factors for adverse long-term outcome. Stringent neuroimaging 
protocols to accurately evaluate the incidence and nature of antenatal cerebral injury 
and to investigate the correlation between antenatal and postnatal imaging findings 
are strongly recommended. The clinical relevance of these findings can be determined 
using long-term neurodevelopmental outcome data of all MC pregnancies with single 
fetal demise. 
Selective feticide in complicated monochorionic pregnancies 
Routine cerebral imaging should be performed in all survivors of selective feticide to 
rule out severe cerebral injury and determine etiology and timing of possible injury. 
Following selective feticide, the majority of MC pregnancies are however discharged 
to the referring hospital. Information at discharge regarding the management of these 
pregnancies should therefore include ante- and postnatal cerebral imaging in the 
surviving co-twin. Currently a multi-center RCT (TRAP Intervention Study, TRAPIST) is 
being set up comparing early (12-14 weeks) versus late intervention (16-18 weeks) in 
TRAP sequence. Primary outcome is pump-twin neonatal survival at or after 32 weeks. 
Secondary outcome includes 2-year neurodevelopmental outcome using ASQ in all 
survivors in the participating centers. 
Monoamniotic twins
Since monoamniotic twinning occurs in approximately 1 in 10.000 pregnancies,24 a 
multicenter study including Utrecht University Medical Center, Zwolle Isala clinics and 
LUMC has been set up to gain knowledge on short and long-term outcome of these 
pregnancies in the Netherlands. The aim of this study is to gain more insight in risk 
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Other indications for fetal therapy
Other indications of fetal therapy that require further study include lower urinary 
tract obstruction (LUTO) and congenital lung lesions including congenital cystic 
adenomatoid malformation (CCAM) and bronchopulmonary sequestration (BPS). Fetal 
interventions include (vesicoamniotic or thoracoamniotic) shunting, laser treatment 
and/or needle drainage. Research suggest that increased perinatal survival with the 
use of fetal interventions is associated with a significant risk of neonatal morbidity.25 We 
are currently investigating the neonatal and long-term outcome of all survivors referred 
to and treated for abovementioned complications at our center. Potential risk factors for 
adverse outcome should be studied combining neonatal and long-term data from other 
fetal therapy centers. 
In conclusion, multicenter efforts are of utmost importance to study the natural history 
in complicated pregnancies with fetal disorders treated with or without fetal therapy, to 
determine optimal management (timing and type of intervention). Ideal study designs 
to evaluate new interventions in fetal therapy should be RCTs using ‘survival without 
NDI’ as primary outcome. Long-term follow-up, at a minimum of 2 years of age, should 
be an integrated component of fetal therapy in all fetal medicine centers around the 
world. In addition, worldwide registries (in analogy with www.tapsregistry.org) to 
record and evaluate the outcome in large groups of children (treated with and without 
fetal therapy) are of paramount importance to increase current knowledge in specific 
subgroups. It is crucial to continuously assess child development including formal 
psychological testing and standardized measures of well documented psychometric 
quality, with increasing reliability of results with increasing age of surviving children 
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Summary
An increasing number of fetal diseases are being detected prior to birth due to major 
improvements in prenatal ultrasound examinations and the wide implementation of 
screening programs.26 For various diseases, fetal therapy is a life-saving option or an 
alternative to postnatal treatment, to prevent permanent organ damage. 
A major breakthrough in fetal therapy was the introduction of intrauterine transfusion 
(IUT) for severe fetal anemia in the early 1960s. Since then, fetal therapy has gradually 
evolved resulting in a dramatic increase in overall survival in several fetal diseases. 
In the Netherlands, fetal surgical interventions are concentrated in one center, the 
Leiden University Medical Center (LUMC), a tertiary medical center which serves as the 
national referral center for fetal therapy. 
Although an increasing number of children are being born alive after fetal therapy, 
reliable data on the long-term neurodevelopmental outcome remain scarce. Long-
term follow-up studies are of paramount importance to increase our knowledge on the 
quality of survival and to identify potential risk factors for adverse long-term outcome. 
Detailed and adequate information on long-term outcome is required to improve both 
fetal management and the quality of antenatal parental counseling. In addition, long-
term follow-up studies are essential for conducting future randomized controlled trials 
(RCT) in all fields of fetal therapy, in order to implement new or modified techniques. 
In this thesis, several studies on the long-term neurodevelopmental outcome after 
fetal therapy for various fetal diseases are presented, including IUT for fetal anemia, 
fetoscopic laser surgery for twin-twin transfusion syndrome (TTTS) and selective 
feticide in complicated monochorionic (MC) pregnancies. 
Intrauterine transfusion in fetal anemia
In Chapter 1 an overview of the literature on the long-term neurodevelopmental 
outcome after IUT for fetal anemia is presented. The review discusses the latest findings 
on the long-term outcome, possible risk factors for long-term impairment and provides 
recommendations for future research.
In Chapter 2 we assessed health-related quality of life (HRQOL) and behavioral 
functioning in 285 children and adolescents treated before birth with IUT for alloimmune 
anemia. Significantly lower HRQOL-scores were reported by parents of children 
6-11 years compared with Dutch norms on 3 scales: cognitive-, social functioning 
and positive emotions (P < .00, P = .02, P = .04). In children aged 8-11 the cognitive 
functioning scale score was significantly lower compared with Dutch norms (P = .01). 
The children aged 12-15 reported higher scores on the negative emotions scale (P = 
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scale remained significant (P < .001). Regarding the HRQOL scores of adolescents ≥ 
16 years, no differences were detected. Overall, behavioral difficulties were reported 
in 37/246 (15%) children 3-16 years, and were associated with maternal educational 
levels (P < .001). Our findings suggest that, for the majority of survivors after IUT for 
alloimmune anemia, HRQOL and long-term behavioral functioning appears favorable. 
The clinical significance of our findings should however be validated by further study, 
as assessment of HRQOL and socioeconomic status in adulthood will provide a clearer 
representation of the long-term functional outcomes following IUT.
The objective of the study described in Chapter 3 was to assess the long-term 
neurodevelopmental outcome in children included in a RCT and treated with either 
intravenous immunoglobulin (IVIg) or placebo. Sixty-six of the 80 children (82.5%) 
who were recruited in the initial trial participated in this follow-up study. Children were 
assessed at a median age of 4 years (range: 2-7 years). The median cognitive score in the 
IVIg group was 96 (range: 68-118) and 97 (range: 66-118) in the placebo group (P = .79). 
There was no difference in the rate of neurodevelopmental impairment (NDI) between 
the IVIg and placebo groups (3% (1/34) versus 3% (1/32), P = 1.00). In conclusion, 
long-term neurodevelopmental outcome in children treated with IVIg was not different 
from children treated with placebo neither after stratification for treatment with or 
without IUT. Standardized long-term follow-up studies with large enough case series 
and sufficient power are needed to replicate these findings. 
Fetoscopic laser surgery in monochorionic twin pregnancies
Chapter 4 presents an overview of the literature on the long-term neurodevelopmental 
outcome after 1) serial amnioreduction in TTTS, 2) fetoscopic laser surgery for TTTS 
and 3) selective feticide in MC pregnancies due to TTTS, twin-reversed arterial perfusion 
(TRAP), selective intrauterine growth restriction (sIUGR) or congenital anomalies. 
The review discusses the latest findings on the long-term outcome, risk factors for 
long-term impairment and provides recommendations for future research. Overall, 
amnioreduction was associated with an increased risk of long-term impairments 
compared to fetoscopic laser surgery. Important risk factors for long-term impairment 
included advanced gestational age at intervention, advanced Quintero stage and low 
gestational age at birth (and related low birth weight). Unfortunately, accurate and 
large long-term-follow-up studies on the long-term outcome following selective feticide 
are limited. All in all, regardless of antenatal treatment, survivors are at risk for NDI and 
require long-term follow-up. 
Chapter 5 reports a systematic review and meta-analysis of studies on cerebral injury 
and long-term impairment after amnioreduction versus laser surgery for TTTS. The 
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twins treated with amnioreduction versus laser surgery. We found an ample seven-fold 
higher risk of severe cerebral injury in live-born children treated with amnioreduction 
compared to laser (Odds Ratio (OR) 7.69, 95% Confidence Interval (CI) 2.78-20.0, P 
= .00). In children surviving the neonatal period, the odds were three-times higher 
following amnioreduction (OR 3.23, 95% CI 1.45-7.14, P = .00). Although not significant, 
MC twins treated with amnioreduction had higher odds of periventricular leukomalacia 
and intraventricular hemorrhage (OR 2.08, 95% CI .86-5.00, P = .10 and OR 3.56, 95% 
CI .82-14.29, P = .09). Unfortunately, there was insufficient long-term outcome data 
available to assess the odds of NDI. In conclusion, amnioreduction is associated with an 
increased risk of severe cerebral injury compared to laser surgery in TTTS. This study 
highlights a crucial lack of studies focusing on long-term neurodevelopmental outcome. 
Follow-up into childhood is indispensable to determine outcome in terms of cerebral 
palsy, cognitive and socio-emotional development. 
In Chapter 6 we compared the neurodevelopmental outcome between the first 
consecutive cohort of TTTS pregnancies treated with laser surgery from 2000 to 
2005, with a cohort treated between 2008 and 2010. Neurological, cognitive and 
motor development was evaluated using Bayley scales at 2 years of age corrected for 
prematurity. Overall survival increased from 70% (158/226) to 80% (170/212) (P = 
.014). The incidence of NDI decreased from 18% (28/152) to 6% (10/155) (P < .01). In 
multivariate analysis, severe cerebral injury at birth was independently associated with 
long-term NDI (OR 34.86, 95% CI 11.83-102.75, P < .01). These findings suggest that 
overall survival in TTTS has improved over time, with a concomitant reduction in the 
incidence of NDI. Research focused on prevention of cerebral injury is needed to further 
improve outcomes of these complicated twin pregnancies.
The objective of the study described in Chapter 7 was to compare the long-term 
neurodevelopmental outcome in surviving children with TTTS included in the Solomon 
randomized trial and treated with either the Solomon technique or standard laser 
surgery technique. Routine standardized follow-up in survivors, at least 2 years after 
the estimated date of delivery, was performed at two of the five centers participating 
in the Solomon trial, Buzzi Hospital Milan (Italy) and Leiden University Medical Center 
(The Netherlands). The primary outcome, survival without long-term NDI, was detected 
in 95/141 (67%) in the Solomon group and in 99/146 (68%) in the standard group (P = 
.92). NDI in long-term survivors included for follow-up was detected in 12/107 (11%) 
in the Solomon and in 10/109 (9%) in the standard group (P = .61) and was due to: 
cerebral palsy in 1 (1%) case (spastic unilateral) in the Solomon group and in 2 (2%) 
cases (spastic unilateral and spastic bilateral) in the standard group (P = .58). Cognitive 
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6/106 (6%) children in the standard group (P = .23). Motor development < 85 occurred 
in 8/103 (8%) children in the Solomon group and 3/104 (3%) in the standard group 
(P = .23). In conclusion, we found no difference in our primary outcome between the 
Solomon and standard laser technique for TTTS. In view of the reduction of short-term 
complications and absence of increased adverse long-term effects, these data support 
the use of the Solomon technique in the treatment of TTTS.
Chapter 8 presents the first study evaluating long-term neurodevelopmental outcome 
in twin-anemia polycythemia sequence (TAPS) after laser surgery for TTTS. Long-
term outcome was assessed in 47/53 (89%) children. The incidence of long-term 
impairment was 4/47 (9%), occurring in one donor (1/20, 5%) and three recipients 
(3/27, 11%) (P = .63). Risk factors for low cognitive scores were low gestational age 
at birth (P = .02) and low birth weight (P = .01). Lowest cognitive scores were detected 
in the subgroup of TAPS survivors treated with IUT (median score: 82.5). Our results 
suggest that impairment in post-laser TAPS is frequent, but is within the range of NDI 
reported in case-series of TTTS treated with laser (range: 6-18%). Consensus on best 
treatment strategy and ideally prevention of this complication after laser for TTTS is 
urgently warranted.
Specific complications in monochorionic pregnancies
The objective of the systematic review presented in Chapter 9 was to estimate the 
incidence of and risk factors for severe cerebral injury in survivors from MC pregnancies 
with sIUGR. Eleven articles were included in the systematic review. Analysis was however 
hampered by different methodology and definitions of cerebral injury. The incidence of 
severe cerebral injury varied from 0% to 33% (average 8%, 52/661), and was higher 
in studies including single fetal demise [OR 2.92; 95% CI 0.89- 9.56] and studies with 
a median gestational age at birth of ≤32 weeks (OR 1.56; 95% CI 1.06–2.27). The risk 
of severe cerebral injury was higher in pregnancies with abnormal umbilical artery 
Doppler (13.5% vs 2.5%; OR 7.69; 95% CI 2.56–25.00) and in larger twins (9% vs 5%; 
OR 1.93; 95% CI 0.95–3.92). In conclusion, the incidence of severe cerebral injury in MC 
twins with sIUGR is approximately 8% and is associated with abnormal umbilical artery 
Doppler, larger twins, single fetal demise and low gestational age at birth.
In Chapter 10 we evaluated the incidence, type and severity of cerebral injury in the 
surviving MC co-twin after single fetal demise. A total of 49 MC pregnancies with single 
fetal demise, including one MC pair from a dichorionic triplet, were included in the 
study (n = 50 co-twins). The median gestational age at single fetal demise of the co-twin 
was 25 weeks and the median interval between single fetal demise and live birth was 
61 days, with a median gestational age at birth of 36 weeks. Severe cerebral injury was 
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postnatally in 9/50 (18%) cases. Cerebral injury was mostly due to hypoxic-ischemic 
injury resulting in cystic periventricular leukomalacia, middle cerebral artery infarction 
or injury to basal ganglia, thalamus and/or cortex. Risk factors associated with severe 
cerebral injury were advanced gestational age at the occurrence of single fetal demise 
(OR 1.14 for each week of gestation; 95% CI, 1.01-1.29; P = .03), TTTS diagnosed prior 
to single fetal demise, (OR 5.0; 95% CI, 1.30-19.13; P = .02) and gestational age at birth 
(OR 0.83 for each week of gestation; 95% CI, 0.69-0.99; P = .04). This study shows that 
the incidence of severe cerebral injury in MC pregnancies after single fetal demise is 
high that is, 1 in 4 surviving co-twins. Routine antenatal and postnatal neuroimaging, 
followed by standardized long-term follow-up, is mandatory. 
Chapter 11 presents a retrospective analysis of the perinatal outcome of complicated 
MC pregnancies treated with selective feticide at the LUMC between June 2000 and 
November 2011. Overall perinatal survival rate was 67.2% (88/131). Median gestational 
age at delivery was 34 (interquartile range, 23–38) weeks. Neonatal mortality and 
morbidity rate in live-born children was 4.3% (4/92) and 12.0 % (11/92), respectively. 
Severe cerebral injury was detected in three children. The overall incidence of adverse 
perinatal outcome (fetal demise, neonatal death, termination of pregnancy or severe 
neonatal morbidity) was 41.2% (54/131). Median gestational age at occurrence of 
preterm prelabor rupture of membranes (PPROM) was 19.0 weeks and 32.0 weeks in 
cases with and without adverse perinatal outcome, respectively (P = .017). Live-born 
children with adverse perinatal outcome were born at a lower median gestational age 
(29.0 weeks) than were children without adverse perinatal outcome (38.0 weeks) (P < 
.001). In conclusion, selective feticide is associated with a high risk of adverse perinatal 
outcome. Further research is warranted to find ways to minimize the risks of selective 
feticide, by optimizing indications, timing and methods used. Outcome studies should 
include long-term follow-up to assess neurodevelopmental outcome in survivors.
The objective of the study described in Chapter 12 was to assess the incidence and 
risk factors for adverse long-term neurodevelopmental outcome in complicated MC 
pregnancies treated with selective feticide at our center between 2000 and 2011. 
Children, at least two years of age, underwent an assessment of neurologic, motor 
and cognitive development using standardized psychometric tests and the parents 
completed a behavioral questionnaire. Long-term outcome was assessed in 74/88 
(84%) survivors. NDI was detected in 5/74 (6.8%, 95%CI 1.1 to 12.5). Overall adverse 
outcome, including perinatal mortality or NDI was 48/131 (36.6%). In multivariate 
analysis, parental educational level was associated with cognitive test scores (regression 
coefficient B 3.9; 95% CI 1.8 to 6.0). Behavioral problems were reported in 10/69 
(14.5%). Our results suggest that long-term NDI in survivors of MC pregnancies treated 
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Long-term cognitive test scores were associated with the level of education of the 
parents. Multi-center efforts are required to entangle those factors leading to adverse 
perinatal and long-term outcome.
In conclusion, we believe long-term follow-up should be an integral component of fetal 
therapy in all fetal medicine centers around the world. Although fetal therapy resulted 
in an impressive increase in overall survival after various fetal diseases, perinatal 
morbidity and long-term neurodevelopmental impairment in surviving children are 
still significant. More research and new developments are required to improve short- 
and long-term outcome after fetal therapy. International collaboration between fetal 
medicine centers around the world is necessary to reliably investigate outcome and, in 
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Nederlandse samenvatting
Een toenemend aantal foetale aandoeningen wordt al voor de geboorte gediagnosticeerd 
dankzij belangrijke verbeteringen in prenataal echoscopisch onderzoek en de brede 
implementatie van screeningsprogramma’s.26 Voor verschillende ziekten is foetale 
therapie een levensreddende optie of een alternatief voor postnatale behandeling om 
permanente orgaanschade (inclusief het zich ontwikkelende foetale brein) te kunnen 
voorkomen. Een grote doorbraak in de foetale therapie was de introductie van de intra-
uteriene bloedtransfusie (IUT) ter behandeling van ernstige foetale bloedarmoede 
(anemie). Deze interventie werd voor het eerst beschreven in de vroege jaren ’60 
door Sir William Liley in Nieuw Zeeland.27 Sindsdien heeft de foetale therapie zich 
geleidelijk doorontwikkeld met als resultaat een significante toename in de overleving 
na uiteenlopende foetale aandoeningen. Wereldwijd werden gespecialiseerde foetale 
therapie centra opgezet en een nieuwe medische discipline deed zijn intrede. 
In Nederland, is de foetale therapie geconcentreerd in één centrum, het Leids Universitair 
Medisch Centrum (LUMC). Het LUMC is een tertiair medisch centrum en het nationale 
kennis-en verwijscentrum voor invasieve behandeling van het ongeboren kind. 
Intra-uteriene bloedtransfusie bij foetale anemie
Intra-uteriene bloedtransfusie kan sterfte voorkomen bij foetale anemie.28 De bekendste 
oorzaak van deze aandoening is de hemolytische ziekte door maternale alloimmunisatie 
tegen rode bloedcelantigenen (zoals Rhesus immunisatie). Bij alloimmunisatie 
tijdens de zwangerschap maakt de moeder afweerstoffen tegen een bloedgroepeiwit, 
dat niet op haar eigen bloedcellen aanwezig is. Deze antistoffen kunnen de placenta 
passeren, in de bloedsomloop van de foetus terecht komen, en foetale rode bloedcellen 
afbreken (hemolyse). Progressieve hemolyse kan, indien niet behandeld, leiden tot 
ernstige foetale anemie, hydrops en perinatale sterfte.29 Andere oorzaken van foetale 
anemie kunnen zijn een infectie met humaan Parvovirus B19 of (chronische of acute) 
foetomaternale transfusie. 
In Nederland werd in 1986 de eerste intravasculaire IUT toegepast. Sinds 2000 is 
het overlevingspercentage na een IUT als behandeling voor foetale anemie vanwege 
alloimmunisatie gestegen tot > 95%.28 In het LUMC worden jaarlijks ongeveer 30 
foetussen behandeld met een IUT. Gemiddeld blijkt 3 maal een transfusie nodig 
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Foetoscopische laserbehandeling bij monochoriale tweelingen
Een andere, belangrijke interventie in de foetale therapie betreft de foetale behandeling 
van eeneiige of monochoriale (MC) tweelingen. MC tweelingen hebben een zogenaamde 
gezamenlijke placenta die vrijwel altijd vaatverbindingen bevat, waardoor de 
bloedsomlopen van beide foetussen met elkaar verbonden zijn. Ten gevolge van deze 
vaatverbindingen kan in 15% van de MC tweelingen het tweelingtransfusie syndroom 
(TTS) ontstaan. Door de vaatverbindingen stroomt bloed van de ene foetus (de donor) 
naar de andere foetus (de ontvanger of recipiënt) en de donor krijgt hiervoor maar 
weinig bloed terug. Bij de donor ontstaat een tekort aan bloed, waardoor hij minder 
en, in een later stadium, helemaal niet meer plast en uiteindelijk geen vruchtwater 
meer heeft (oligohydramnion). De ontvanger krijgt juist te veel bloed en gaat steeds 
meer plassen. De recipiënt krijgt daardoor te veel vruchtwater in zijn vruchtzak 
(polyhydramnion). Dit kan leiden tot een acute toename van de buikomvang van de 
moeder en tot vroegtijdige weeën en vroeggeboorte. Indien niet behandeld kan TTS 
leiden tot een sterfte 73-100%.30 De beste behandeling voor TTS is de foetoscopische 
laserbehandeling waarbij de bloedvatverbindingen op de gezamenlijke placenta 
worden dicht gebrand (gecoaguleerd).23 
Sinds 2000 wordt de foetoscopische laserbehandeling in het LUMC toegepast. Jaarlijks 
worden ongeveer 60 MC zwangerschappen behandeld, met een overlevingspercentage 
>74%.11 In een recent beschreven complicatie bij MC tweelingen, tweeling anemie-
polycythemie sequentie (TAPS), kunnen verschillende foetale interventies worden 
overwogen zoals de IUT en de foetoscopische laserbehandeling. De beste therapeutische 
optie voor TAPS dient nog te worden bepaald. 
Als bij een MC tweeling één foetus een ernstige afwijking heeft, kan dit de gezonde 
foetus bedreigen.28 Soms wordt dan gekozen voor selectieve reductie door middel van 
navelstrengcoagulatie. Indicaties voor selectieve reductie kunnen zijn een ernstige 
selectieve intra-uteriene groeirestrictie (sIUGR), twin reversed arterial perfusion 
(TRAP) en/of een ernstige congenitale afwijking. Het overlevingspercentage voor de 
gezonde foetus betreft 65-92% afhankelijk van de indicatie en de techniek die wordt 
toegepast.31
Lange termijn uitkomsten na foetale therapie
Met een toenemend aantal kinderen dat overleefd na behandeling met een foetale 
therapie, verschuift de aandacht van de korte termijn uitkomst naar de ontwikkeling 
van de kinderen op de lange termijn. Echter, betrouwbare informatie over de lange 
termijn uitkomst van kinderen behandeld met een foetale therapie is nog altijd schaars. 
Vervolgstudies zijn kostbaar, niet gemakkelijk uitvoerbaar (planning en organisatie) 
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grote vervolgstudies wordt belemmerd door de relatieve zeldzaamheid van foetale 
ziekten. Desalniettemin zijn vervolgstudies naar de ontwikkeling van kinderen na 
foetale therapie van groot belang voor het optimaliseren van foetale behandeling als 
ook kwaliteitsborging. Onderzoek naar de ontwikkelingsuitkomsten van kinderen 
behandeld met een foetale therapie is cruciaal; op deze manier kunnen risicofactoren 
voor een suboptimale ontwikkeling van het kind worden achterhaald en zo de foetale 
therapie verder worden verbeterd. Daarnaast is gedetailleerde en adequate informatie 
over de lange termijn uitkomst nodig om toekomstige ouders van betrouwbare 
informatie te kunnen voorzien tijdens antenatale en postnatale counseling. Tenslotte 
kunnen ouder en (het vaak prematuur geboren) kind aan de hand van deze informatie 
tijdig van gepaste ondersteuning worden voorzien.
Vervolgstudies met aandacht voor de motorische, cognitieve en sociaal-emotionele 
ontwikkeling van het kind zijn essentieel voor het opzetten van gerandomiseerde 
trials (RCT) in de foetale therapie, met als doel nieuwe of aangepaste technieken te 
kunnen introduceren. Dit vereist samenwerking tussen gynaecologen-perinatologen, 
neonatologen, kinderpsychologen en andere experts in de (vroege) ontwikkeling 
van het kind om verder te kijken dan perinatale overleving. Daarbij is samenwerking 
tussen internationale foetale therapie centra geboden om betrouwbaar data te 
kunnen verzamelen aan de hand van voldoende grote case series. Dit stelt ons in staat 
om potentiële risicofactoren voor ontwikkelingsproblemen op de lange termijn te 
achterhalen. 
Voortgaand onderzoek naar de lange termijn ontwikkeling van kinderen behandeld 
met een foetale therapie is noodzakelijk. Daarbij dient gebruikt te worden gemaakt van 
formele, gestandaardiseerde tests van voldoende psychometrische kwaliteit. Hierbij is 
het belangrijk om op te merken dat de betrouwbaarheid van de verkregen testresultaten 
toeneemt naarmate de kinderen ouder worden. Om de klinische significantie van de 
verkregen resultaten te kunnen valideren, dient vervolgonderzoek plaats te hebben tot 
tenminste de schoolleeftijd en bij voorkeur tot en met de volwassen leeftijd aangezien 
het evalueren van de kwaliteit van leven en de verworven socio-economische status 
op de volwassen leeftijd een duidelijker representatie geven van de functionele lange-
termijn uitkomst na foetale therapie. 
Het doel van onderhavig proefschrift is om de kennis over de lange termijn ontwikkeling 
van kinderen behandeld met een foetale therapie te vergroten alsmede potentiele risico 
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Intra-uteriene bloedtransfusie bij foetale anemie
Hoofdstuk 1 bevat een samenvatting van de literatuur betreffende de lange termijn 
uitkomst na IUT vanwege foetale anemie. Mogelijke risicofactoren voor ernstige 
neurologische, motorische en cognitieve ontwikkelingsproblemen op de lange termijn 
worden beschreven als ook aanbevelingen voor toekomstig vervolgonderzoek. Uit het 
literatuuroverzicht komt naar voren dat de meerderheid van de kinderen behandeld 
met IUT vanwege foetale alloimmuun anemie een gunstige lange-termijn ontwikkeling 
laat zien. Risicofactoren voor ontwikkelingsproblemen blijken: ernstige foetale hydrops, 
het aantal IUTs verricht, ernstige neonatale morbiditeit en het opleidingsniveau van de 
ouders. De studie toont aan dat er dringend behoefte is aan lange termijn studies na 
foetale behandeling van Parvovirus B19 infectie en foetomaternale transfusie. 
In Hoofdstuk 2 hebben we de gezondheidsgerelateerde kwaliteit van leven (KvL) en de 
gedragsuitkomsten onderzocht van 285 kinderen en adolescenten behandeld met IUT 
vanwege foetale alloimmuun anemie. In vergelijking met een Nederlandse norm-groep 
werden significant lagere KvL-scores gerapporteerd door de ouders van kinderen 6-11 
jaar op 3 van de 7 schalen: cognitief functioneren, sociaal functioneren en positieve 
emoties (P < .00, P = .02, P = .04). De kinderen van 8-11 jaar rapporteerden eveneens 
lagere scores op de schaal cognitief functioneren vergeleken met de Nederlandse 
norm-groep (P = .01). De kinderen van 12-15 jaar rapporteerden hogere scores op 
de schaal negatieve emoties (P = .02). Na correctie voor het aantal testen dat werd 
uitgevoerd (Bonferroni correctie), bleek alleen de verschilscore op de schaal cognitief 
functioneren zoals gerapporteerd door de ouders nog significant (P < .001). Er werden 
geen verschillen gevonden tussen de KvL-scores van de adolescenten ≥ 16 jaar en de 
Nederlandse norm-groep. Gedragsproblemen werden gerapporteerd bij 37/246 (15%) 
kinderen 3-16 jaar. Een laag opleidingsniveau van de moeder bleek geassocieerd 
met meer gedragsproblemen (P < .001). Over het geheel genomen, tonen deze 
bevindingen aan dat de lange-termijn uitkomst (de gezondheidsgerelateerde KvL en de 
gedragsuitkomsten) gunstig lijkt voor de meerderheid van de kinderen en adolescenten 
behandeld met IUT vanwege foetale alloimmuun anemie.
In Hoofdstuk 3 hebben we de motorische en cognitieve ontwikkeling van kinderen, 
geïncludeerd in een gerandomiseerde studie en behandeld met intraveneuze 
immunoglobuline (IVIg) of placebo vanwege hemolytische ziekte van de foetus 
en pasgeborene (HZFP), onderzocht. Primaire uitkomstmaat was een ernstig 
ontwikkelingsprobleem of ‘neurodevelopmental impairment’ (NDI), een samengestelde 
uitkomstmaat gedefiniëerd als de aanwezigheid van één of meer van de volgende 
uitkomsten: cerebrale parese, blindheid, doofheid, een ernstige motorische en/of 
cognitieve ontwikkelingsachterstand. De kinderen (66/80, 83%) werden onderzocht 
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De mediane cognitieve score van de kinderen in de IVIg groep was 96 (uitersten: 68-
118) en 97 (uitersten: 66-118) in de placebo groep (P = .79). Er bleek geen verschil 
in het voorkomen van een ernstig ontwikkelingsprobleem (NDI) tussen de IVIg- en 
placebo groep (3% (1/34) versus 3% (1/32), P = 1.00). De lange termijn uitkomst 
van de kinderen behandeld met IVIg bleek dan ook niet te verschillen van de kinderen 
behandeld met placebo. Behandeling met IVIg bij HZFP lijkt geen positief (noch een 
negatief) effect te hebben op de lange termijn uitkomst. Deze bevindingen dienen 
echter gerepliceerd te worden aan de hand van gestandaardiseerde vervolgstudies met 
een voldoende grote onderzoeksgroep. 
Foetoscopische laserbehandeling bij monochoriale tweelingen
Hoofdstuk 4 bevat een literatuuroverzicht betreffende de lange termijn uitkomst 
na 1) amniodrainage voor TTS, 2) de foetoscopische laserbehandeling voor TTS 3) 
selectieve reductie bij gecompliceerde MC zwangerschappen (ernstige sIUGR, TRAP 
en/of een ernstige congenitale afwijking). Mogelijke risicofactoren voor ernstige 
neurologische, motorische en cognitieve ontwikkelingsproblemen op de lange termijn 
worden beschreven als ook aanbevelingen voor toekomstig vervolgonderzoek. Uit het 
literatuuroverzicht blijkt dat amniodrainage geassocieerd wordt met een verhoogd 
risico op ernstige ontwikkelingsproblemen op de lange termijn in vergelijking 
met de foetoscopische laserbehandeling voor TTS. Belangrijke risicofactoren voor 
ontwikkelingsproblemen zijn: Quintero stadium (hoe verder gevorderd het stadium 
hoe hoger de kans op beperkingen op de lange termijn) en een lage zwangerschapsduur 
bij geboorte. Onderzoek naar de lange termijn uitkomst na selectieve reductie blijkt 
schaars; Adequaat opgezette en voldoende grote vervolgstudies worden dan ook 
dringend geadviseerd.
Hoofdstuk 5 betreft een samenvatting en meta-analyse van studies naar het voorkomen 
van cerebrale schade en ernstige ontwikkelingsproblemen in TTS tweelingen na 
behandeling met amniodrainage versus foetoscopische laserbehandeling. De kans 
op ernstige cerebrale schade bij levendgeboren kinderen bleek na behandeling met 
amniodrainage significant hoger dan na laserbehandeling (Odds Ratio (OR) 7.69, 
95% betrouwbaarheidsinterval 2.78-20.0, P = .00). Zo ook de kans op cerebrale 
schade bij kinderen die de neonatale periode hadden overleefd (OR 3.23, 95% 
betrouwbaarheidsinterval 1.45-7.14, P = .00). Helaas bleek er onvoldoende lange-
termijn data beschikbaar om het risico op een ernstig ontwikkelingsprobleem in TTS 
tweelingen na behandeling met amniodrainage versus foetoscopische laserbehandeling 
betrouwbaar te kunnen onderzoeken. De conclusie is dan ook dat de behandeling van 
TTS met amniodrainage geassocieerd is met een verhoogd risico op het ontwikkelen 
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De studie onderstreept een belangrijk gebrek aan gedegen studies naar de lange termijn 
uitkomst van TTS tweelingen. Gestandaardiseerd vervolgonderzoek tot tenminste 
de schoolleeftijd is noodzakelijk om de lange termijn uitkomst in termen van de 
neurologische, motorische, cognitieve en sociaal emotionele ontwikkeling betrouwbaar 
in kaart te kunnen brengen.
In Hoofdstuk 6 hebben we de ontwikkelingsuitkomsten van TTS tweelingen behandeld 
met foetoscopische laser sinds de start van het laserprogramma in 2000 tot en met 
2005 vergeleken met een recent cohort TTS tweelingen behandeld tussen 2008 en 
2010. De neurologische, motorische en cognitive ontwikkeling werd onderzocht op de 
leeftijd van 2 jaar. Het overlevingspercentage bleek toegenomen van 70% (158/226) 
in de periode 2000-2005 naar 80% (170/212) in de periode 2008-2010 (P = .014). 
Het voorkomen van een ernstig ontwikkelingsprobleem bleek daarentegen afgenomen 
van 18% (28/152) naar 6% (10/155) in 2008-2010 (P < .01). In een multivariate 
analyse, bleek ernstige cerebrale schade bij geboorte geassocieerd met een ernstig 
ontwikkelingsprobleem op de lange termijn (OR 34.86, 95% betrouwbaarheidsinterval 
11.83-102.75, P < .01). Deze bevindingen suggereren dat de kans op overleving zonder 
een ernstig ontwikkelingsprobleem significant is toegenomen sinds de introductie 
van het foetoscopische laserprogramma in het LUMC. Onderzoek naar preventie van 
cerebrale schade is noodzakelijk om de uitkomst van TTS tweelingen nog verder te 
kunnen verbeteren. 
In Hoofdstuk 7 hebben we de lange termijn uitkomst van TTS tweelingen, geïncludeerd 
in de Solomon RCT en behandeld met de Solomon of de standaard laserbehandeling, 
beschreven. Gestandaardiseerd ontwikkelingsonderzoek op de leeftijd van 2 jaar 
werd systematisch uitgevoerd in 2 van de 5 deelnemende centra te weten, V Buzzi 
Children’s Hospital Milaan (Italië) en het LUMC. De primaire uitkomst, overleving 
zonder een ernstig ontwikkelingsprobleem (NDI), werd vastgesteld bij 95/141 (67%) 
in de Solomon groep en bij 99/146 (68%) in de standaard groep (P = .92) Een ernstig 
ontwikkelingsprobleem werd gediagnosticeerd bij 12/107 kinderen (11%) in de 
Solomon en bij 10/109 kinderen (9%) in de standaard groep (P = .61) en was gebaseerd 
op: cerebrale parese (n=1 in de Solomon versus n=2 in de standaard groep (P = .58)), 
cognitieve ontwikkeling < 85 (n=2 in de Solomon versus n=6 in de standaard groep (P = 
.23)) en motorische ontwikkeling < 85 (n=8 in de Solomon versus n=3 in de standaard 
groep (P = .23)). De conclusie is dan ook dat er geen verschil in primaire uitkomst 
werd gevonden tussen de Solomon en standaard laserbehandeling. Met het oog op de 
significante reductie in complicaties op de korte termijn en de afwezigheid van een 
verhoogd risico op ernstige ontwikkelingsproblemen op de lange termijn, ondersteunen 
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De eerste studie naar de lange termijn uitkomst van post-laser TAPS kinderen wordt 
beschreven in Hoofdstuk 8. In totaal werden 47/53 (89%) kinderen teruggezien 
voor ontwikkelingsonderzoek. Een ernstig ontwikkelingsprobleem werd vastgesteld 
bij 4/47 kinderen (9%), daarbij werd geen verschil gezien tussen donoren en 
recipiënten (1/20 (5%) versus 3/27 (11%), P = .63). Het voorkomen van een ernstig 
ontwikkelingsprobleem bij post-laser TAPS kinderen lijkt vergelijkbaar met het 
voorkomen bij post-laser TTS kinderen (6-18%). In een univariate risico-analyse bleek 
een lage zwangerschapsduur bij geboorte (P = .02) als ook een laag geboortegewicht 
(P < .01) geassocieerd met lagere cognitieve scores. In een subgroep analyse waarbij 
TAPS voor de geboorte ontdekt en behandeld was, werd in de gevallen behandeld 
met IUT, een lagere mediane cognitieve testscore (82.5) gezien in vergelijking met 
de andere subgroepen (afwachtend beleid, laserbehandeling en selectieve reductie). 
Een mogelijke verklaring voor de lagere testscores kan zijn dat deze kinderen bij een 
lagere zwangerschapsduur worden geboren, omdat de behandelaar beslist om de 
kinderen geboren te laten worden vanwege de ernst van de anemie en polycythemie. De 
resultaten suggereren dat een ontwikkelingsprobleem niet ongewoon is bij tweelingen 
die TAPS ontwikkelen na laserbehandeling voor TTS, maar vergelijkbaar lijkt met het 
voorkomen bij TTS tweelingen behandeld met laser. Studies met grote aantallen zijn 
nodig om risicofactoren voor ernstige ontwikkelingsproblemen op de lange termijn 
betrouwbaar te kunnen onderzoeken. Er is dringende behoefte aan overeenstemming 
voor wat betreft de best beschikbare therapeutische optie voor TAPS en, idealiter, 
preventie van deze complicatie na laserbehandeling voor TTS.
Specifieke complicaties bij monochoriale zwangerschappen
Het doel van het systematische literatuuroverzicht beschreven in Hoofdstuk 9 was 
om het voorkomen van en de risicofactoren voor ernstige cerebrale schade bij MC 
zwangerschappen met sIUGR te onderzoeken. Hiertoe werden elf studies geïncludeerd. 
De data-analyse werd echter belemmerd door grote verschillen in methodologie als ook 
in de definitie van ernstige cerebrale schade. Het voorkomen van ernstige cerebrale 
schade varieerde van 0% tot 33% (gemiddelde 8%, 52/661), en bleek hoger in studies 
met zwangerschappen waarbij één van de tweeling intra-uterien was overleden 
(OR 2.92; 95% betrouwbaarheidsinterval 0.89- 9.56) en in studies met een mediane 
zwangerschapsduur ≤ 32 weken (OR 1.56; 95% betrouwbaarheidsinterval 1.06–2.27). 
Het risico op ernstige cerebrale schade bleek hoger in zwangerschappen met afwijkende 
echo Doppler bevindingen (14% vs 3%; OR 7.69; 95% betrouwbaarheidsinterval 
2.56–25.00) en bij het ‘grote’ kind (9% vs 5%; OR 1.93; 95% betrouwbaarheidsinterval 
0.95–3.92). Samenvattend, het voorkomen van ernstige cerebrale schade bij MC 
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met intra-uterien overlijden van één van de tweeling, een lage zwangerschapsduur 
bij geboorte, afwijkende echo Doppler bevindingen en het ‘grote’ kind. De optimale 
benadeling van MC zwangerschappen gecompliceerd door sIUGR is nog onbekend 
en internationale overeenstemming over de best beschikbare therapeutische optie 
ontbreekt. 
In Hoofdstuk 10 hebben we het voorkomen, type en de ernst van cerebrale schade 
onderzocht bij de overlevende tweeling na plotseling intra-uterien overlijden van de 
co-tweeling. In totaal werden 49 MC zwangerschappen, inclusief een MC tweeling 
deel uitmakend van een dichoriale drieling zwangerschap, geïncludeerd (n = 50 co-
tweelingen). De mediane zwangerschapsduur ten tijde van intra-uterien overlijden van 
de co-tweeling was 25 weken met een mediaan interval tussen overlijden en het levend 
geboren worden van de co-tweeling van 61 dagen (mediane zwangerschapsduur 
bij geboorte 36 weken). Ernstige cerebrale schade werd vastgesteld bij 13/50 co-
tweelingen (26%); antenataal bij 4/50 (8%) and postnataal bij 9/50 (18%) kinderen. 
Cerebrale schade bleek met name gebaseerd op hypoxisch-ischemische schade 
resulterend in periventriculaire leucomalacie met cystevorming, een arterieel infarct 
en/of schade aan de basale ganglia, de thalamus en cortex. Risicofactoren geassocieerd 
met ernstige cerebrale schade bleken een gevorderde zwangerschapsduur bij intra-
uterien overlijden van één van de tweeling (OR, 1.14; 95% betrouwbaarheidsinterval, 
1.01-1.29; P = .03), TTS gediagnosticeerd alvorens het intra-uterien overlijden van 
één van de tweeling (OR, 5.0; 95% betrouwbaarheidsinterval, 1.30-19.13; P = .02) en 
de zwangerschapsduur bij geboorte van de overlevende co-tweeling (OR, 0.83; 95% 
betrouwbaarheidsinterval, 0.69-0.99; P = .04). Gezien de hoge incidentie van ernstige 
cerebrale schade na het plotseling intra-uterien overlijden van één van de tweeling 
adviseren wij om routinematig antenataal en postnataal echografisch onderzoek van 
de hersenen (en indien nodig MRI) te laten verrichten gevolgd door gestandaardiseerd 
vervolgonderzoek naar de ontwikkeling van deze kinderen. 
Hoofdstuk 11 betreft een retrospectieve analyse van de perinatale uitkomst van 
gecompliceerde MC zwangerschappen behandeld met selectieve reductie tussen 
Juni 2000 en November 2011 in het LUMC. Het perinatale overlevingspercentage 
bleek 67.2% (88/131). De mediane zwangerschapsduur bij geboorte was 34 weken. 
Neonatale mortaliteit en morbiditeit in levend geboren kinderen was, respectievelijk, 
4% (4/92) en 12 % (11/92). Ernstige cerebrale schade werd gedetecteerd bij drie 
kinderen. Het voorkomen van een slechte perinatale uitkomst (gedefiniëerd als intra-
uterien overlijden, neonataal overlijden, zwangerschapsafbreking of ernstige neonatale 
morbiditeit) was 41% (54/131). De kinderen met een slechte perinatale uitkomst 
bleken geboren bij een lagere mediane zwangerschapsduur (29 weken) dan de kinderen 
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reductie geassocieerd is met een hoog risico op een slechte perinatale uitkomst. Nader 
onderzoek naar mogelijkheden om de risico’s van selectieve reductie te minimaliseren 
is geboden, door het optimaliseren van indicaties, timing en procedures. 
In Hoofdstuk 12 hebben wij het voorkomen van en de risicofactoren voor een 
ernstig ontwikkelingsprobleem onderzocht bij MC tweelingen behandeld met 
selectieve reductie tussen 2000 en 2011 in het LUMC. De neurologische, motorische 
en cognitieve ontwikkeling van 74/88 (84%) kinderen werd onderzocht met 
gestandaardiseerde testen en de ouders van de kinderen vulden een gedragsvragenlijst 
in. Een ernstig ontwikkelingsprobleem werd gedetecteerd bij 5/74 kinderen (7%, 
95% betrouwbaarheidsinterval 1.1 - 12.5). Een slechte uitkomst in het algemeen, te 
weten perinataal overlijden of een ernstig ontwikkelingsprobleem, werd vastgesteld in 
48/131 (37%). In een multivariate analyse, bleek het opleidingsniveau van de ouder 
geassocieerd met de cognitieve test scores van het kind (regressie coëfficiënt B 3.9, 
95% betrouwbaarheidsinterval 1.8 - 6.0). Gedragsproblemen werden gerapporteerd bij 
10/69 kinderen (15%). Deze bevindingen suggereren dat ontwikkelingsproblemen bij 
tweelingen behandeld met selectieve reductie vaker voor lijken te komen in vergelijking 
met de algemene bevolking. Studies met grotere aantallen, bij voorkeur in internationaal 
samenwerkingsverband, zijn nodig om risicofactoren voor ontwikkelingsproblemen 
betrouwbaar te kunnen onderzoeken. Wij adviseren gestandaardiseerd pre- en 
postnataal echografisch onderzoek van de hersenen (en indien nodig MRI) bij 
alle overlevende kinderen na selectieve reductie van de co-tweeling gevolgd door 
gestandaardiseerd vervolgonderzoek naar de ontwikkeling van deze kinderen op de 
lange termijn. 
Samenvattend kunnen we stellen dat, hoewel foetale therapie voor verschillende ziekten 
een levensreddende optie betreft met een toenemend aantal overlevende kinderen, 
de lange termijn uitkomsten voor verschillende foetale therapieën nog onvoldoende 
in kaart zijn gebracht. Internationale samenwerking is vereist om aan de hand van 
voldoende grote groepen patiënten betrouwbaar de ontwikkelingsuitkomsten te 
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